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ABSTRACT OF DISSERTATION 
 
 
DOXORUBICIN-INDUCED, TNF-α -MEDIATED BRAIN OXIDATIVE STRESS, 
NEUROCHEMICAL ALTERATIONS, AND COGNITIVE DECLINE: INSIGHTS 
INTO MECHANISMS OF CHEMOTHERAPY INDUCED COGNITIVE 
IMPAIRMENT AND ITS PREVENTION 
 
 
The works presented in this dissertation provide insights into the mechanisms of 
chemotherapy-induced cognitive impairment (CICI or “ChemoBrain”) and take 
steps toward outlining a preventive strategy. CICI is now widely recognized as a 
complication of cancer chemotherapy experienced by a large percentage of 
cancer survivors. Approximately fifty percent of existing FDA-approved anti-
cancer drugs generate reactive oxygen species (ROS). Doxorubicin (Dox), a 
prototypical ROS-generating chemotherapeutic agent, produces the reactive 
superoxide radical anion (O2-•) in vivo. Dox treatment results in oxidation of 
plasma proteins, including ApoA-I, leading to TNF-α-mediated oxidative stress in 
plasma and brain. TNF-α elevation in brain leads to further central nervous 
system toxicity including mitochondrial dysfunction, neuronal death, and cognitive 
impairment. Co-administration of the antioxidant drug, 2-mercaptoethane 
sulfonate sodium (MESNA), prevents Dox-induced protein oxidation and 
subsequent TNF-α elevation in plasma without interfering with the cancer-killing 
ability of Dox.  
 
In studies presented in this dissertation, we measured oxidative stress in both 
brain and plasma of Dox-treated mice both with and without MESNA. MESNA 
ameliorated Dox-induced oxidative protein damage in plasma, confirming our 
prior studies, and in a new finding led to decreased oxidative stress in brain. 
Using novel object recognition (NOR), we demonstrated the Dox administration 
resulted in memory deficits. Using hydrogen magnetic resonance imaging 
spectroscopy (H1-MRS) techniques, we demonstrated that Dox administration led 
to a dramatic decrease in choline(phosphocholine)/creatine (Cho/Cr) ratios in 
mouse hippocampus. The activities of both phosphatidylcholine-specific 
phospholipase C (PC-PLC) and phospholipase D(PLD) were severely diminished 
following Dox administration. The activity of PC-PLC was preserved when 
MESNA was co-administered with Dox. In the absence of TNF-α, MRS-indexed 
Cho/Cr ratio, PLD activity, and mitochondrial oxygen consumption are preserved 
in brain, and markers of oxidative stress are reduced.  
 
Together with results from our previous studies, these results provide strong 
evidence that TNF-α is strongly associated, if not responsible for CICI. We also 
tested the notion that O2-• is responsible for Dox-induced plasma protein 
oxidation and TNF-α release. O2-• resulted in increased oxidative damage to 
proteins when added to plasma and increased levels of TNF-α in macrophage 
culture, providing strong evidence that O2-• is responsible for these Dox-induced 
toxicities. 
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CHAPTER 1 
INTRODUCTION 
 
The studies presented in this manuscript were conducted to examine the 
mechanisms likely underlying chemotherapy-induced cognitive impairment (CICI) 
and to outline potential preventative interventions thereby improving potential 
outcomes and quality of life for the increasing number of cancer survivors. We 
investigate the potential involvement of reactive oxygen species (ROS)-
producing chemotherapy drugs in the cause and progression of CICI. Briefly, 
oxidative stress is widely viewed as an imbalance in the physiological levels of 
oxidants over antioxidants. This imbalance can be due to increased oxidant 
production or exposure, decrease anti-oxidant capacity, or both. Damage to 
biomolecules and changes in levels and function can occur as a result. 
 
Doxorubicin (Dox), a representative chemotherapeutic agent used in these 
studies, is used to treat various solid tumors, often as part of a multi-drug 
chemotherapy regimen. Dox is known to produce reactive oxygen species (ROS) 
due to redox cycling of the quinone moiety within its structure.  Oxidative damage 
of plasma proteins are observed following Dox treatment. Prior studies by the 
Butterfield laboratory have shown that oxidative protein damage, mitochondrial 
dysfunction, and apoptosis are also observed in brain following Dox treatment, 
even though this agent does not cross the blood-brain barrier (BBB) (Joshi et al. 
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2005; Tangpong et al. 2006; Joshi et al. 2007; Tangpong et al. 2007; Tangpong 
et al. 2008; Joshi et al. 2010). This plasma protein oxidative leads to plasma 
elevation of the inflammatory cytokine, tumor necrosis factor alpha (TNF-α). This 
cytokine crosses the BBB leading to mitochondrial damage and dysfunction, 
which, we hypothesize, can lead to a series of biochemical alterations ultimately 
resulting in cognitive dysfunction and memory impairment, a condition patients 
describe as “chemobrain” or “chemofog.”   
 
In addition, samples from patients treated with Dox but not simultaneously 
treated with sodium-2-mercaptoethane sulfonate (MESNA) showed statistically 
significant increases markers of protein oxidation and lipid peroxidation.  
However, plasma samples from patients coincidentally treated with MESNA as 
part of their chemotherapy regimen did not exhibit the same levels of damage, 
suggesting that MESNA prevented Dox-induced oxidative stress.  Our group 
demonstrated in mouse models that MESNA suppresses the Dox-induced 
increase in plasma oxidative stress evidenced by protein carbonyl and protein-
bound HNE levels, suppressed oxidation of apolipoprotein A-I (ApoA-I), and 
suppressed the associated Dox-induced increase in peripheral TNF-α  levels. 
Since MESNA is negatively charged, this agent does not penetrate cells and, 
consequently, is known not to interfere with chemotherapy.   
 
The results of the current studies suggest that MESNA could reduce the systemic 
and neurotixic side effects of Dox.  A NCI-funded human clinical trial involving 
3 
 
Dox and MESNA is ongoing to test this hypothesis.  Our results presented here 
provide strong evidence in support of a plausible mechanism for Dox-initiated, 
TNF-α -mediated cognitive dysfunction that leads to CICI, and our results are 
consistent with a plausible means to prevent these harmful effects without 
interference with chemotherapy, thereby increasing the quality of life of cancer 
survivors. Given that about 50 percent of FDA-approved chemotherapeutic 
agents are associated with ROS, the conclusions of this present study 
conceivably might have widespread applicability. Studies to test this notion are 
ongoing in our laboratories.  
This dissertation research was conducted test the following hypotheses: 
1.) Co-administration of MESNA would prevent Dox-induced oxidation in 
brain.  
2.) Co-administration of MESNA would prevent Dox-related cognitive decline.  
3.) Dox-administration would alter the neurochemical profile indexed by 
proton MRS. 
4.) Dox-induced mitochondrial dysfunction would be prevented in brain of 
TNF-α knockout mice. 
5.) Dox-induced oxidative protein damage would be prevented in brain of 
TNF-α knockout mice. 
6.) Superoxide produces oxidative damage to plasma proteins and TNF- α 
elevation in macrophages similar to that seen following Dox 
administration. 
Copyright © Jeriel T. R. Keeney 2013  
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CHAPTER 2 
BACKGROUND 
 
2.1 Cancer: Incidence, mortality, and treatments 
People everywhere get cancer. Few people could say that their lives have not 
been touched either directly or indirectly by cancer. In the United States, the 
highest cancer incidence rates per 100,000 population exist in the Northeast. 
Age-adjusted death rates across all cancer types is highest in states along the 
Ohio and Mississippi river valleys. (NCI  http://statecancerprofiles.cancer.gov) 
The only state that ranks in the highest category in both of these statistics is 
Kentucky making it a prime area for the research presented in this dissertation. 
Kentucky ranks first in the U.S. in overall cancer mortality and second in overall 
cancer incidence. With regard to specific cancer types, Kentucky ranks first in the 
nation in incidence of lung, colorectal, and mouth and throat cancers, second in 
renal cancer, and third in brain cancer. Rates in the Appalachian region of 
Kentucky are even higher, especially for lung and cervical cancers. (ACS Cancer 
Facts & Figures 2012, SEER registries, and Kentucky Cancer Registry). 
Common anti-cancer treatments include surgery, radiation, and chemotherapy. 
The work presented here focus on the latter, more specifically on those 
chemotherapeutic agents that induce production of reactive oxygen species as a 
consequence of their use. The US FDA has approved over 130 anticancer drugs. 
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(http://www.fda.gov/cder/cancer/approved.htm). Approximately half of these have 
been reported to induce oxidative stress (Chen et al. 2007).  
 
2.2 Chemotherapy-induced cognitive impairment (CICI, “Chemobrain”) 
 
2.2.1 CICI, definition and prevalence 
 
A large percentage of cancer patients report memory and cognitive impairment 
following chemotherapy, called “chemobrain” by patients, adversely affecting 
quality of life (Ahles et al. 2005). Chemotherapy-induced cognitive impairment 
(CICI) is now widely recognized as a complication of chemotherapy (Tannock et 
al. 2004; Ahles et al. 2007; Foley et al. 2008; Aluise et al. 2010; Cheng et al. 
2013; Seigers et al. 2013). The complexity of cancer, lack of a scientific 
explanation, and lack of definitive diagnostic criteria, coupled to the fact that 
many anti-cancer drugs do not cross the BBB, likely contribute to the delay in 
dealing with CICI. Cognitive symptoms following cancer chemotherapy vary 
greatly, but memory and executive functions appear to be preferentially affected 
(Saykin et al. 2003).  
 
2.2.2 Gray and white matter changes in CICI 
 
Direct neurotoxic effects may include cerebral gray matter atrophy and white 
matter demyelination (Saykin et al. 2003). Several studies have reported white 
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matter changes in human breast cancer patients following adjuvant 
chemotherapy (Inagaki et al. 2007; Deprez et al. 2011; de Ruiter et al. 2012; 
Deprez et al. 2012). Indeed, the integrity of lipid-rich myelin covered white matter 
have been shown to be altered as well as damage to gray matter with associated 
functional deficits  following systemic cancer chemotherapy, in some cases years 
after chemotherapy (de Ruiter et al. 2012; Briones et al. 2013; McDonald et al. 
2013; Simo et al. 2013). Studies have shown that chemotherapy-induced 
neuroinflammation are correlated with changes in myelination and cognitive 
impairment (Briones et al. 2013). Neuroimaging techniques are already being 
used to detect axonal and white matter changes in subjects at risk of Mild 
Cognitive Impairment (MCI) and Alzheimer’s Disease (AD) (Gold et al. 2010; 
Gold et al. 2012) and following traumatic brain injury (Kinnunen et al. 2011). 
Similar techniques may provide useful insights into diagnosis and progression of 
CICI. 
 
2.2.3 Potential reasons for varied patient outcomes 
 
Saykin and Ahles (2007) suggest that cancer and cognitive problems share 
genetic risk factors providing a possible explanation for why only some patients 
experience cognitive deficits following chemotherapy. Immune response 
dysregulation, DNA-repair deficits, inefficient efflux pumps, reduced antioxidant 
capacity, decreased neurotransmitter activity, and impaired capacity for neuronal 
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repair may all contribute to the neurotoxic consequences of chemotherapy (Ahles 
et al. 2007). 
 
2.2.4 Clinical presentation of and current treatments for CICI 
 
Clinically, consequences of chemotherapy can include both peripheral 
neuropathy and CNS neurotoxicity including cognitive deficits, encephalopathy, 
dementia, and beyond (Verstappen et al. 2003). Currently, management of these 
detrimental consequences is limited to dose reduction, though some ability to 
compensate for memory deficits has been reported using cognitive-behavioral 
treatment (Ferguson et al. 2007).  The work presented in this manuscript outlines 
the central role played by TNF-α in CICI and the protective effects of MESNA 
versus the toxic consequences of the acti-cancer drug, doxorubicin.  
 
2.2.5 Our model of CICI 
 
Based on our previous studies, we proposed the following model. Plasma protein 
oxidation, including apolipoprotein A-I (ApoA-I), induced by the redox cycling of 
Dox leads to elevation of tumor necrosis factor-alpha (TNF-α) in the periphery. 
TNF-α crosses the BBB by receptor-mediated endocytosis to induce microglial 
activation, further TNF-α release, increased production of NO, mitochondrial 
dysfunction, neuronal death, and consequent cognitive impairment (Tangpong et 
al. 2006; Tangpong et al. 2007; Tangpong et al. 2008; Aluise et al. 2009; Aluise 
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et al. 2010; Joshi et al. 2010; Aluise et al. 2011). Studies presented in this 
dissertation led us to propose an expanded model of CICI presented in later 
chapters.  
 
2.3 Doxorubicin (Dox) 
 
Doxorubicin (Dox) is a prototypical chemotherapeutic agent known to produce 
reactive species (Handa et al. 1975; Gutteridge 1984; Cummings et al. 1991). 
Dox is an anthracycline antineoplastic agent commonly used in multidrug 
chemotherapy regimens primarily to treat solid tumors and leukemias. The 
cancer killing effects of Dox have been shown to involve three proposed 
mechanisms: DNA intercalation, inhibition of topoisomerase II, and production of 
ROS (Bachur et al. 1977; Chuang et al. 1979; Reich et al. 1979; Tanaka et al. 
1980; Cummings et al. 1991; Fornari et al. 1994; Deres et al. 2005). The quinone 
moiety present in the Dox structure is capable of undergoing a one-electron 
reduction to the semi-quinone (Chen et al. 2007; Aluise et al. 2011). Through the 
redox cycling of this structure back to the quinone, in vivo, the reactive O2-• is 
produced from molecular oxygen (Figure 2.2).  
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Figure 2.1. Our early model of the stages following Dox administration that 
lead to chemotherapy-induced cognitive impairment (CICI). In this proposed 
model, peripheral doxorubicin redox cycling between the quinone and 
semiquinone states within the circulatory system produces the reactive oxygen 
species superoxide (O2.−) in abundance (Box 1) that oxidatively modifies ApoA-I 
on HDL particles (Box 2). This modified ApoA-I is no longer able to inhibit the 
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monocyte/macrophage interaction (Box 3) and because of this, TNF-α is 
produced. TNF-α is subsequently able to cross the BBB (Box 4) and activate 
microglia initiating the production of a host of pro-inflammatory mediators 
ultimately leading to central TNF-α production as well as increased ROS/RNS 
(Box 5), which damage neurons and ultimately lead to neuronal death (Box 6). 
 
 
 
 
 
Figure 2.2. Redox cycling of doxorubicin. Redox cycling of doxorubicin back 
and forth between the semi-quinone and  quinone  produces superoxide from 
molecular oxygen. 
Previous studies by our laboratory demonstrated that though neither Dox nor its 
primary metabolite crosses the blood-brain barrier (BBB), peripheral Dox 
treatment does cause brain injury as evidenced by increased oxidative stress, 
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the inflammatory cytokine, tumor necrosis factor-alpha (TNF-α), and 
mitochondrial dysfunction (Tangpong et al. 2006; Joshi et al. 2007; Tangpong et 
al. 2007; Tangpong et al. 2008).  
 
Our laboratory and others previously demonstrated Dox-induced oxidative stress 
in blood and damage to plasma proteins leading to detrimental central nervous 
system consequences (Thayer 1988; Fadillioglu et al. 2003; Tangpong et al. 
2006; Othman et al. 2008; Aluise et al. 2009; Aluise et al. 2011). Central to this 
paradigm is apolipoprotein A-I (ApoA-I) (Aluise et al. 2010; Aluise et al. 2011; 
Perluigi et al. 2011; Keeney et al. 2013). ApoA-I promotes cholesterol efflux as 
part of the high density lipoprotein (HDL) complex. Additionally, ApoA-I has been 
shown to suppress TNF-α in plasma (Hyka et al. 2001; Perry et al. 2002; Weber 
et al. 2011). Previous studies in our laboratory have shown that, when oxidized, 
ApoA-I loses this ability to suppress TNF-α release and may exacerbate the 
problem (Aluise et al. 2011). 
 
2.4 Apolipoprotein A-I (ApoA-I) 
 
ApoA-I is a multifunctional apolipoprotein that plays a variety of roles in human 
physiology among which are cholesterol transport and regulation of inflammation. 
Through the ATP-binding cassette protein (ABCA1), ApoA-I serves as the 
primary lipid acceptor protein for lipids such as cholesterol and 
phosphatidylcholine as they are effluxed from the lipid bilayer (Quazi et al. 2011) 
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as part of the high-density lipoprotein (HDL) complex taking excess cholesterol 
from tissues (Hyka et al. 2001). HDL is associated with a reduced risk of 
atherosclerosis through intervening in either lipoprotein and cholesterol 
metabolism or modulation of inflammatory processes (Rader et al. 2008).  
 
In addition to its role in reverse cholesterol transport ApoA-I has been reported to 
have antioxidant and anti-inflammatory properties and other studies have 
reported decreased serum ApoA-I with inflammation (Tape et al. 1990) and 
increased ApoA-I levels in CSF after brain injury (Saito et al. 1997). As described 
further below, redox proteomics has identified ApoA-I as oxidatively modified in 
plasma of persons subjected to ROS/RNS as a result of chemotherapy. 
 
2.4.1 Cholesterol and Its Transport 
 
Cholesterol is predominantly an amphipathic molecule which is dominated by its 
hydrophobic sterol ring that allows for the insertion of cholesterol into the bilayer, 
yet is able to maintain its proper orientation due to the hydrophilic 3β-hydroxyl 
group present in the molecule. Cholesterol has been found to play a major 
stabilizing role, reducing membrane lipid bilayer fluidity and increasing turgidity. 
Cholesterol is also well known to play a role in bile acid production and steroid 
hormone synthesis while much more recently cholesterol has been implicated in 
the formation of micro-signaling domains called lipid- or membrane-rafts (Liscum 
et al. 1995; Dominiczak 2001; Waarts et al. 2002; Shadan et al. 2004; Oh et al. 
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2007; Chaudhuri et al. 2011). Because cholesterol is centrally stored in the liver, 
there must be a mechanism in place for the transport of cholesterol to and from 
the cells that require it. Due to the fact that the majority of the surface area of 
cholesterol is hydrophobic in nature, transport of cholesterol through the aqueous 
blood supply is facilitated by a group of proteins called lipoproteins. 
 
Lipoprotein sub-classes are classified based on their hydrated density into five 
main groups (chylomicrons, very-low density lipoproteins (VLDL), intermediate 
density lipoproteins, low-density lipoproteins (LDL) and high-density lipoproteins 
(HDL)) that may also differ in the relative size as well as the overall lipid and 
apolipoprotein content (Dominiczak et al. 2011). Predominantly important to this 
discussion is the ability of apolipoproteins to direct the action of lipoproteins 
through direct interaction with other cell types by way of membrane lipoprotein 
receptors. 
 
There are three main ways in which cholesterol and triglycerides are mobilized 
throughout the body: the fuel transport pathway (FTP), the over-flow pathway 
(OFP), and reverse cholesterol transport (RCT). In order to move triglycerides 
from the liver for use in peripheral tissues, the FTP employs both chylomicrons 
as well as VLDL using an array of apolipoproteins such as ApoA-I, A-II, A-IV and 
A-V, apoB48 and B100, apoC-I, C-II, and C-III, and apoE (Hill et al. 1997; 
Dominiczak 2001; Dominiczak et al. 2011). Once in the periphery, lipoprotein 
lipase acts on chylomicrons to release fatty acids to cells while returning 
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apolipoproteins to nearby HDL particles. VLDL particles remain partially intact 
after interaction with lipoprotein lipase, and the resulting VLDL remnants are 
returned by LDL receptors that bind apolipoprotein E (apoE). As a result of 
excessive remnant generation by the FTP, an increase in LDL, which has been 
referred to as an extracellular cholesterol depot, can accumulate in the blood 
supply, a process that has been linked to atherosclerosis. To combat this 
increase in LDL, the OFP is in place to metabolize LDL using apoB100, the 
predominant apolipoprotein in LDL, that interacts with the apoB/E LDL receptor 
and causes the internalization of the LDL particles (Dominiczak et al. 2011). 
 
The RCT system comprises the metabolism of HDL and the subsequent 
transport of cholesterol from the periphery back to the liver, and because of this 
role, HDL levels have been found to have an inverse relationship with 
cardiovascular disease (Cucuianu et al. 2007; Yang et al. 2010; Zhao et al. 
2012). The primary apolipoprotein component of HDL is ApoA-I, responsible for 
the free cholesterol loading of HDL from cells by binding to ABCA1 as well as the 
secretion of apoE, which stimulates Lecithin-cholesterol acyltransferase (LCAT) 
activity(Dominiczak 2001; Bencharif et al. 2010) (Figure 2.3). Once loaded, the 
cholesterol is esterified by LCAT, producing cholesteryl esters and transforming 
HDL to HDL3. HDL3 can then function to interchange the cholesteryl esters and 
apolipoproteins A, C and E for triglycerides from lipoproteins, in which 
triglycerides are abundant, forming HDL2 which can subsequently deposit the 
cholesteryl esters into the scavenger receptor BI (SRB-1) at the liver (Hill et al. 
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1997; Dominiczak et al. 2011). Interestingly, in bovine aortic endothelial cells 
oxidative modification of HDL, likely on ApoA-I, by myeloperoxidase was 
sufficient to decrease HDL interaction with SR-B1 as well as induce a pro-
inflammatory state via tumor necrosis factor-α (TNF-α)-induced expression of the 
vascular cell adhesion molecule 1protein as well as nuclear factor kappa-B 
(NFκB) activation (Undurti et al. 2009). 
 
2.4.2 HNE modification of ApoA-I 
 
ApoA-I is particularly susceptible to modification by lipid peroxidation products 
such as the reactive aldehydes, 4-hydroxy-2-trans-nonenal (HNE) and acrolein. 
Electrophilic sites on these reactive aldehydes may be attacked by nucleophilic 
centers like those in the amino acid side chains of histidine (H), lysine (K), or 
cysteine (C) to form covalent adducts that has been shown to alter both the 
structure and function of proteins (Subramaniam et al. 1997; Liebler 2008; Kim et 
al. 2009; Butterfield et al. 2010). Liebler and colleagues (Szapacs et al. 2008) 
found ApoA-I to be highly modified by free radical oxidation using a novel biotin-
modified linoleoylglycerylphosphatidylcholine probe (PLPBSO). Free radical 
oxidation of human plasma containing the probe produced covalent Michael-
adducts to plasma proteins. These proteins were identified and phospholipid 
binding sites mapped using liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) on streptavidin-purified proteins (Szapacs et al. 2008; Kim et al. 
2009). 
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To determine potential binding sites, human plasma was oxidized using 2, 2-
azobis(2-(2-imidazolin-2-yl)propane)-dihydrochloride (AIPH), a compound known 
to produce reactive aldehydes upon oxidation of the PLPBSO probe. In 
independent experiments, HNE was added in varying concentrations directly to 
isolated HDL. The formation of HNE adducts on ApoA-I was found at an 
increasing number of sites and with increasing frequency as concentrations of 
either AIPH in plasma or HNE in isolated HDL were increased (Szapacs et al. 
2008). These sites include H162, H193 at HNE concentrations of 1uM; H155 at 
10uM; H135, H199, K208, K94, K96; and K107, K238, K12, K23 at 1000uM. At 
low concentrations of AIPH or HNE respectively, HNE modifications on ApoA-I 
were found that included H162, located in a key functional region of ApoA-
I(Szapacs et al. 2008). Oxidative modification of H162 on ApoA-I may disrupt the 
maturation of the HDL complex by structural changes in the ApoA-I domain 
responsible for activation of LCAT which, as discussed, converts free cholesterol 
to the more hydrophobic cholesteryl esters for packaging in the formation of HDL 
particles (Figure 2.3). 
 
2.4.3 ApoA-I and ABCA1 interaction and subsequent signaling 
 
The binding of ApoA-I to ABCA1 has been shown to have a major role in RCT 
and the exporting of free cholesterol from cells for return to the liver, a process 
believed to be of crucial importance for anti-atherosclerosis (Vergeer et al. 2010; 
Zhao et al. 2012). More recently this interaction has been found to affect many 
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areas of cellular processes, including not only direct cellular cholesterol and 
phospholipid efflux, but also various cell signaling pathways that may turn out to 
have more far reaching effects than were first thought. 
 
Aside from the activation of Rho GTPases such as Cdc42, Rho, and Rac, small 
G-proteins that are responsible for the reorganization of cytoskeletal architecture, 
as well as the direct binding of calmodulin, the binding of ApoA-I and ABCA1 has 
been shown to cause the activation of Janus kinase 2 (JAK2).This activation has 
been implicated in the majority of the lipid transport conducted by ABCA1, a 
process that is significantly impaired when in the presence of JAK2-specific 
inhibitors (Matsunaga et al. 1991; Tsukamoto et al. 2001; Tang et al. 2004; Tang 
et al. 2006; Vaughan et al. 2009; Iwamoto et al. 2010). Interestingly, STAT3 also 
has been shown to be active post ApoA-I/ABCA1 interaction to decrease the 
secretion of inflammatory cytokines in macrophages, a process linked to anti-
inflammation (Murray 2006; Tang et al. 2009; Yin et al. 2011). 
 
In addition to JAK2/STAT3 activation, the ApoA-I/ABCA1 interaction has been 
shown to activate both protein kinase A (PKA) and protein kinase C (PKC). PKA 
is activated by increased cyclic-adenosine monophosphate by the activation of 
adenylyl cyclase through Gαs coupling with ABCA1. The result of PKA activation 
is the phosphorylation of ABCA1 and a subsequent increase in ApoA-I lipidation, 
a process blocked by specific PKA inhibition (Yang et al. 2007; Hu et al. 2009; 
Jeon et al. 2010; Zhao et al. 2012). PKC on the other hand is activated as a 
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result of an initial depletion of free cholesterol, phostphatidylcholine and 
sphingomyelin from the cell membrane by ApoA-I/ABCA1 interaction. This later 
interaction stimulates phosphatidylcholine-specific phospholipase C activity 
resulting in an increase of both phosphatidylcholine as well as diacylglycerol, a 
major activator of PKC. The activation of PKC not only leads to the 
phosphorylation of ABCA1, a process believed to increase the lifetime of ABCA1 
via protection from degradation, but also increases cholesterol. The interaction of 
PKC-ζ with specificity protein-1 controls the expression level of ABCA1 
(Yamauchi et al. 2003; Yamauchi et al. 2004; Chen et al. 2011; Zhao et al. 2012). 
 
From the above, it is apparent that ApoA-I/ABCA1 interaction is a critical event 
that, if impaired through damage such as oxidative stress, could have much 
larger ramifications than simply cholesterol and fatty acid efflux impairment, i.e., 
may affect a large array of cellular processes directly or tangentially related to the 
activation or inactivation of this important intracellular signaling process. 
 
In the context of atherosclerosis, increased oxidative modification of ApoA-I 
mediated by myeloperoxidase led to decreased ABCA1-dependent cholesterol 
efflux from macrophages (Zheng et al. 2004) as well as impaired activation of 
LCAT (Wu et al. 2007). A possible, albeit weak, link has been established 
between a polymorphism of the ApoA-I gene negatively affecting HDL function 
and cognitive decline (Helbecque et al. 2008).Overall, current evidence suggests 
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ApoA-I to be a promising diagnostic marker as well as a potential target for 
therapeutic strategies. 
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Figure 2.3. Unmodified vs. oxidatively modified ApoA-I. The left-hand side of 
the figure depicts an HDL particle with bound ApoA-I that has not undergone 
oxidative damage, and as shown, is able to function normally interacting with 
LCAT, peripheral ABCA1 and scavenger receptor BI (SRB-1). The right-hand 
side of the figure displays an HDL particle that has undergone extensive 
oxidative modification on ApoA-I, a process that has been shown to negatively 
affect the ability of the HDL particle to interact peripherally with ABCA-1, LCAT, 
and SRB-1. This loss of function of ApoA-I has many consequences such as 
impaired ABCA1 signaling and cholesterol deposition to HDL, impaired 
cholesterol to cholesteryl conversion by LCAT, and the inability to dock with 
SRB-1. See text. Used by permission of John Wiley and Sons. 
 
2.4.4 ApoA-I and chemotherapy-induced cognitive impairment 
 
Redox proteomics  provided new insights into mechanisms involved in 
chemotherapy induced cognitive dysfunction (Aluise et al. 2011), found in up to 
75% of breast cancer survivors (Raffa et al. 2006). Given that nearly 50 percent 
of FDA-approved chemotherapeutic agents are associated with ROS, a 
significant proportion of the millions of cancer survivors in the United States likely 
show symptoms of cognitive dysfunction. 
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Oxidative modification of ApoA-I has been implicated in a cascade of events 
involving elevation of inflammatory species leading to chemotherapy-induced 
cognitive dysfunction (Aluise et al. 2011). Chemotherapy patients often complain 
of noticeable memory impairment as well as cognitive decline following 
chemotherapy, an ailment described by the patients with the term “Chemobrain”, 
with symptoms that persist sometimes for years post-treatment. The 
anthracycline, doxorubicin (Dox), used to treat a variety of solid tumors and 
leukemias often as part of multidrug chemotherapy regimens, leads to the 
production of ROS and RNS(Bachur et al. 1977; Deres et al. 2005; Aluise et al. 
2011) that can damage biomolecules including proteins, lipids, and DNA (Fornari 
et al. 1994; Jungsuwadee et al. 2006; Chen et al. 2007). A quinone in the Dox 
structure undergoes redox cycling to the semiquinone, accepting a single 
electron from an oxidant potentially involving NADPH oxidases, Fe2+, Cu+, or 
cytochrome P450. In the presence of molecular oxygen, the quinone is reformed 
by transferring the extra electron to oxygen producing the superoxide radical 
anion. Superoxide can damage biomolecules directly or indirectly through 
formation of other ROS/RNS (Aluise et al. 2010).  
 
Oxidative stress analysis of plasma samples from human patients treated with 
Dox showed global elevation of plasma protein carbonylation compared to 
plasma samples from the same persons prior to Dox administration. A subset of 
these patients also showed elevated plasma protein-bound HNE, a lipid 
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peroxidation byproduct of arachidonic acid (Jungsuwadee et al. 2006; Aluise et 
al. 2010; Aluise et al. 2011).  
 
Our group hypothesized that the oxidative damage to plasma resident ApoA-I, as 
a result of ROS/RNS induced by Dox and other chemotherapeutic agents, leads 
to peripheral elevation of the inflammatory cytokine, TNF-α, which, as mentioned 
above, crosses the BBB (Gutierrez et al. 1993; Osburg et al. 2002) via TNFR1 
and TNFR2 endocytosis and activates distant receptors located in the CNS. In 
brain, TNF-α was shown to lead to biomolecule and mitochondrial damage, and 
neuronal death, and cognitive decline in these cancer patients is proposed to 
result from such changes (Tangpong et al. 2006; Tangpong et al. 2007; Aluise et 
al. 2011).  An activated T-cell-monocyte contact interaction results in monocyte 
production of TNF-α.  ApoA-I inhibits TNF-α release either by inhibition of the 
monocyte-macrophage contact interaction or by interaction with ABCA1 (Hyka et 
al. 2001; Tang et al. 2009). Our group showed, based on redox proteomic 
evidence, elevated oxidative alterations of ApoA-I induced by protein 
carbonylation and protein-bound HNE in the plasma of chemotherapy patients, 
results that were confirmed in Dox treated mouse models compared to saline 
treated controls (Aluise et al. 2011). Once oxidized, ApoA-I loses the ability to 
inhibit the monocyte-macrophage interaction thereby allowing increased TNF-α 
release (Aluise et al. 2011).  Despite the inability of Dox or its metabolites to 
cross the BBB, through ApoA-I oxidation, Dox increases levels of TNF-α in the 
periphery which can migrate in the bloodstream to the brain and other tissues 
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and stimulate local inflammation and oxidative stress leading to apoptosis and, 
potentially, the deleterious cognitive effects experienced by chemotherapy 
patients (Tangpong et al. 2006; Aluise et al. 2011). Once in the CNS, TNF-α 
activates astrocytes, specifically microglia, elevation of iNOS is induced causing 
damage to mitochondrial MnSOD, leading to a cascade involving cytochrome C, 
caspase 3, and cell execution (Tangpong et al. 2007). Anti-TNF-α antibody 
prevents these effects (Tangpong et al. 2006). Sustained activation of microglia 
can lead to long-term elevation of TNF-α in the CNS (Dammann et al. 2001; 
Wang et al. 2012). 
 
2.5 Tumor necrosis factor-alpha (TNF-α) 
 
2.5.1 Overview of TNF-α and CICI 
 
The inflammatory cytokine, tumor necrosis factor-alpha (TNF-α), plays a variety 
of roles including inflammatory responses and innate immunity (Dinarello 2007). 
The inflammatory and immune responses of TNF-α can be beneficial when 
acute, controlled, and localized, but quite detrimental if elevated or sustained 
demonstrating the pleiotropic nature of this and other cytokines. Macrophages 
are a principle cell source of TNF-α. Interaction of ApoA-I with the ATP-binding 
membrane cassette transporter A1 (ABCA1) involved in cholesterol transport 
(Quazi et al. 2011; Weber et al. 2011) results in inhibition of TNF-α release 
through production of a tristetraprolin (TTP) (Yin et al. 2011). TTP degrades the 
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mRNA message for TNF-α (Yin et al. 2011). Once oxidized, ApoA-I loses the 
ability to inhibit TNF-α release (Aluise et al. 2011). TNF-α, produced in the 
periphery, traverses the BBB via receptor-mediated endocytosis. Resulting 
microglial activation in the CNS results in further release of TNF-α, oxidative 
stress, and CNS toxicity (Tangpong et al. 2006; Tangpong et al. 2007; Tangpong 
et al. 2008; Joshi et al. 2010; Aluise et al. 2011). 
 
2.5.2 TNF-α signaling, inflammation, and apoptosis 
 
TNF-α is a multifunctional cytokine with involvement in pathways including pro-
apoptotic, anti-apoptotic, inflammatory response, and immune function regulation 
and has been implicated in a large variety of diseases such as rheumatoid 
arthritis, Crohn’s disease, and Alzheimer disease. Within the CNS, TNF-α has 
both neuroprotective and neurotoxic roles facilitating both necrosis and caspase-
mediated apoptosis (Selmaj et al. 1990; Schneider-Brachert et al. 2004; Badiola 
et al. 2009). TNF-α is normally found in low levels in healthy brain, but can be 
found at high levels in cerebral and transient ischemic attacks, and in aged 
human brains (Gupta et al. 2005; Rubio-Perez et al. 2012). 
 
Extracellular TNF-α binds and activates two main receptors, TNFR1 (p55) and 
TNFR2 (p75) that are responsible for mediating the intracellular cytokine activity. 
Because the two receptors lack metabolic activity, they must recruit and bind 
intracellular proteins in order to transduce the signal initiated by TNF-α. TNFR1 
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and TNFR2 are single transmembrane glycoproteins with similar extracellular 
structures, yet differ in their intracellular domains (MacEwan 2002). 
  
TNFR1, also known as the death-receptor, has an intracellular death domain 
(DD) consisting of 80 amino acids and is located near the carboxy-terminus 
(MacEwan 2002). Silencer of death domain (SODD) is responsible for binding 
and silencing the DD of inactive TNFR1 and dissociates upon receptor activation 
facilitated by TNF binding to its extracellular domain. Dissociation of SODD from 
the DD of TNFR1 allows the binding of the adaptor protein, TNF-receptor-
associated death-domain (TRADD), and its subsequent recruitment of additional 
proteins to the receptor, as demonstrated by the interaction between TNF 
receptor-associated factor (TRAF2) and receptor-interacting kinase (RIP). 
TRADD-dependent recruitment of proteins to TNFR1 allows the initiation of the 
following three main pathways: NFκB activation, mitogen-activated protein kinase 
(MAPK) pathway activation, and caspase-mediated apoptosis.  
 
NFκB is a heterodimeric transcription factor responsible for a large variety of 
cellular responses under stress and anti-apoptotic actions. Inactive NFκB is 
sequestered in the cytoplasm by inhibitor of κB (IκB), which dissociates upon its 
phosphorylation at two serine residues by inhibitor of κB kinase β (IKKβ).  
Recruitment and activation of IKKβ to TNFR1 is dependent on the presence of 
TRAF2 and RIP, respectively (Song et al. 1997; Wajant et al. 2003). Once NFκB 
is released from the inhibitory subunit, IκB, it may then translocate to the nucleus 
26 
 
and induce the gene expression of its downstream anti-apoptotic proteins. Within 
the CNS this anti-apoptotic NFκB pathway, activated through TNF-α, generally 
has neuroprotective roles (Liu et al. 1996). 
 
Of the three main MAPK pathways, the stress related and pro-apoptotic c-jun 
NH2-terminal kinase (JNK) cascade is most strongly stimulated by the 
TNFR1/TRADD/TRAF2 complex (Chen et al. 2002). The recruited TRAF2 protein 
is believed to be responsible for activation of a mitogen-activated protein kinase 
kinase kinase (MAPKKK), for example, apoptosis-stimulated kinase 1 (ASK1) 
(Nishitoh et al. 1998). Stimulation of a variety of MAPKKKs can lead to the 
activation of a cascade of kinases that ultimately result in JNK activation. Once 
activated, JNK translocates to the nucleus where it then may phosphorylate and 
subsequently activate the pro-apoptotic transcription factor c-Jun.  
 
Stimulation of caspase-mediated apoptosis by the TNF-α-activated TNFR1 
receptor involves the recruitment and binding of fas-associated death domain 
(FADD) to TRADD. The TNFR1/TRADD/FADD complex then recruits and 
activates the cysteine protease caspase-8, which leads to the activation of 
caspase-3, the executioner of apoptosis. The mentioned pro-apoptotic caspase 
cascade and anti-apoptotic NFκB pathway both play negative regulatory roles of 
one another; caspase-8 and caspase-3 inhibits RIP and IKKβ respectively, and 
the NFκB-transcribed cellular inhibitor of apoptosis protein 1 and 2 inhibits both 
caspase-8 as well as caspase-3.  
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TNFR2, the less understood of the two TNF-α receptors, lacks a death domain 
and currently appears to have a stronger anti-apoptotic role than TNFR1. TRAF2 
was initially recognized as a signal transduction protein of TNFR2, in which it 
may bind directly to the receptors intracellular domain of this receptor. In contrast 
to TNFR1 where TRAF2 indirectly interacts with the TNFR2 receptor by binding 
to the adaptor protein TRADD. Through direct interaction with TRAF2, TNFR1 is 
able to stimulate the anti-apoptotic transcriptional factor, NFκB. 
 
An excitotoxic effect of excessive synaptic glutamate is promoted by the 
collaboration of TNF-α receptors located on the surfaces of microglia and 
astrocytes. Activation of microglial TNF-α receptors lead to the up regulation of 
the glutamate generating enzyme glutaminase and subsequent extracellular 
release of excess glutamate through hemichannels (Takeuchi et al. 2006). 
Extracellular TNF-α also has been found to stimulate the generation of microglial 
TNF-α (Tangpong et al. 2008), increasing its extracellular levels. In astrocytes 
TNFR1-associated caspase 3 and NFkB pathways work to decrease the 
reuptake of synaptic glutamate by respectively inactivating and reducing the 
expression of the influx transporter, excitatory amino acid transporter 2 (EAAT2), 
from the membrane of astrocytes (Sitcheran et al. 2005; Zou et al. 2005; Boston-
Howes et al. 2006). EAAT2 is an important part of the glutamine shuttle, 
responsible for the reuptake of glutamate from the synaptic cleft and into 
astrocytes, where it can be converted to its inactive form of glutamine. With the 
TNF-α-associated down regulation of EAAT2 activity, and increased generation 
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and release of glutamate from microglia, this puts neurons in danger of 
excitotoxicity caused by high extracellular levels of glutamate.  
 
Within neurons, TNF-α-mediated activation of TNFR1 contributes more directly to 
neuronal cell death through activation of the caspase-mediated apoptosis 
cascade described earlier (Kogo et al. 2006). Neuronal TNFR1 also has 
influence over Ca2+ -mediated cell death by increasing the membranous 
expression of iontropic glutamate receptor AMPA, through the activation of IP3 
(Stellwagen et al. 2005). The increased expression of ligand gated ion channel 
AMPA is yet another factor into the excitotoxic effect of high synaptic glutamate 
levels. Further jeopardizing neuronal survival is the TNF-α-mediated decrease of 
surface receptor GABAA, responsible for inhibitory effects that work to counteract 
the excitatory effect of glutamate (Stellwagen et al. 2005).  
 
Through activated TNF-α receptors on microglial, astrocyte, and neuronal cell 
surfaces, TNF-α is able to directly and indirectly contribute to neuronal cell death. 
These neurotoxic effects of TNF-α help highlight the cytokine’s role in a variety of 
neurodegenerative diseases. Such processes are likely involved in 
chemotherapy-induced cognitive decline (Aluise et al. 2011). 
 
2.6 MESNA 
2-mercaptoethane sulfonate sodium (MESNA) is a drug developed for use to 
protect the urinary bladder from hemorrhagic cystitis caused by chemotherapy. 
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MESNA is FDA-approved for use with Dox as part of multidrug chemotherapy 
regimens that include ifosfamide or cyclophosphamide. MESNA does not enter 
cells, does not interfere with cancer chemotherapy (Bernacki et al. 1987). A 
biproduct of ifosfamide metabolism is acrolein [2-propen-1-al], an alpha, beta 
unsaturated aldehyde that can build up in the bladder leading to the 
complications. The structure of MESNA contains a free sulfhydryl group 
imparting much of its antioxidant properties by affording it the ability to scavenge 
free radicals and reactive aldehydes such as HNE and acrolein. Our laboratory 
has demonstrated that ApoA-I oxidation in plasma and subsequent increased 
TNF-α release is suppressed with co-administration of MESNA (Aluise et al. 
2011).  
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Figure 2.4. MESNA scavenges free radicals and reactive aldehydes such as 
HNE and acrolein and is excreted in urine. 
 
 
2.7 Oxidative Stress 
 
Oxidative stress refers a condition where an imbalance exists between those 
species that cause oxidative damage to biomolecules, reactive oxygen and 
reactive nitrogen species (ROS, RNS), and the antioxidant defenses intended to 
MESNA 
Acrolein 
 
EXCRETED IN URINE 
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protect against them (Sies 1997; Dasuri et al. 2012; Schulz et al. 2012). The 
brain is particularly vulnerable to oxidative damage due to relatively low 
antioxidant defenses, high oxygen consumption, areas rich in iron, and high 
concentrations of polyunsaturated fatty acids containing labile allylic hydrogens 
that are prime targets of free radical attack. 
 
2.7.1 Reactive oxygen and reactive nitrogen species 
 
ROS and RNS include, among many others, superoxide radical anion (O2-.), 
hydrogen peroxide (H2O2), hydroxyl radical (.OH), nitric oxide (NO.), and 
peroxynitrite (ONOO-), many of which are free radicals. ROS/RNS play 
necessary and beneficial roles in many biological processes (Dasuri et al. 2012). 
In addition to free radicals produced from environmental exposure, excess 
production of free radicals or other reactive species and a failure of antioxidant 
defense systems to adequately handle the ROS/RNS load results in damage to 
biomolecules including proteins, lipids, and genetic material (Valko et al. 2007; 
Uttara et al. 2009; Butterfield et al. 2012; Halliwell 2012). 
 
2.7.2 Mitochondria as a source of ROS 
 
Human mitochondria process oxygen at great potential self-risk due to production 
and leakage of the damaging O2-. (Figure 2.5) from age-related decreases in the 
efficiency of electron transport chain reactions, primarily from Complex I (Adam-
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Vizi 2005; Calabrese et al. 2005; Dasuri et al. 2012; Scialo et al. 2012; De Giusti 
et al. 2013). The reactive O2-. has been shown to oxidize biomolecules directly 
through lipid peroxidation and protein oxidation (Halliwell et al. 1984; Fridovich 
1986; Deby et al. 1990) and indirectly inducing oxidative/nitrosative stress in the 
brain through production of other reactive species and by mechanisms including 
the inflammatory cytokine tumor necrosis factor alpha (TNF-α) (Halliwell et al. 
1984; Dean et al. 1997; Klamt et al. 2002; Tangpong et al. 2008; Aluise et al. 
2011).  
 
The mitochondrial resident superoxide scavenger, manganese superoxide 
dismutase (MnSOD) in the mitochondria react with O2-. producing H2O2 . H2O2 is 
only a weak oxidant otherwise but becomes much more damaging in the 
presence of free copper or iron ions through Fenton Chemistry as H2O2 is 
converted to the extremely reactive .OH radical and OH- (Halliwell et al. 1984; 
Halliwell 2012). The .OH radical is responsible for much of the downstream 
indirect damage from superoxide. Hard nucleophiles such as the hydroxyl radical 
attack biomolecules at carbonyls resulting in structural and functional changes. 
 
2.7.3 Free radicals and lipid peroxidation 
 
Free radicals in close proximity to allylic hydrogens on biomolecules abstract 
such hydrogens leaving a carbon-centered radical. When this occurs to PUFA in 
the lipid bilayer, reaction of this radical with molecular oxygen forms a peroxyl 
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radical leading to a chain reaction involving further abstraction of other allylic 
hydrogens from nearby biomolecules, again forming a C-centered radical. Once 
initiated, lipid peroxidation can lead to increased production of reactive alkenals 
in the bilayer, loss of lipid asymmetry, and apoptosis (Castegna et al. 2004; 
Bader Lange et al. 2010; Butterfield et al. 2010; Perluigi et al. 2012; Sultana et al. 
2013).  
 
1. LH + X•  L• + XH 
2. L• + O2  LOO•  
3. LOO• + LH  LOOH + L•  
4. LOO• + LOO•  nonradical + O2 
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Figure 2.5. ROS formation involving mitochondria-derived superoxide. ROS 
formation involving mitochondria-derived superoxide free radicals and 
subsequent processing by MnSOD and Fenton chemistry and RNS formation 
following NO production via i-NOS and reaction of NO with superoxide free 
radicals. Used by permission from Elsevier Scientific Publishers, Inc. 
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A major reactive alkenal produced is 4-hydroxy-2-trans-nonenal (HNE). HNE is 
primarily produced in the brain via lipid peroxidation of arachidonic acid (Figure 
2.6), an abundant omega-6 PUFA found in the lipid bilayer in brain (Butterfield et 
al. 2010). Arachidonic acid is released through cleavage of a phospholipid by 
phospholipase A2 (PLA2)  and serves as a second messenger involved in 
cellular signaling and the regulation of signaling enzymes (Prentki et al. 1987; 
Jones et al. 1993; Frisardi et al. 2011). HNE binds proteins by Michael Addition 
to certain amino acids resulting in protein dysfunction (Figure 2.7) (Butterfield et 
al. 2002). Amyloid beta (Aβ)-peptide itself has been shown to be a source of 
ROS and an initiator of free radical damage to biomolecules in brain including 
lipid peroxidation (Harris et al. 1995; Hensley et al. 1995; Butterfield 1997; 
Butterfield et al. 1997; Varadarajan et al. 2000; Yatin et al. 2000; Lauderback et 
al. 2001; Butterfield et al. 2002; Boyd-Kimball et al. 2005). 
 
2.7.4 NO and tyrosine nitration 
 
A free radical in its natural form, NO. is synthesized from L-arginine by 
endothelial, neuronal, or inducible nitric oxide synthases (NOS). NO. has 
beneficial effects such as a biological mediator in several processes including 
neurotransmission, vascular smooth muscle contraction as well as having 
antitumor, and antimicrobial activities (Xu et al. 1994; Shinde et al. 2000; Cole et 
al. 2006) but becomes toxic at high concentrations (McCarty 2006).  
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Figure 2.6. HNE formation from arachidonic acid. 
 
Figure 2.7. A linear depiction of HNE adducts with amino acids, histidine 
(His), lysine (Lys), and cysteine (Cys). Cyclization does occur in some of these 
products. 
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Figure 2.8. Mechanism of tyrosine nitration.  
 
NO. and O2-. exert more damaging effects together. Nitration of tyrosine occurs 
from the reaction NO. with O2-. by radical-radical recombination producing the 
reactive intermediate peroxynitrite (ONOO-)  leading to tyrosine nitration by .NO2 
radical at the 3-position sterically blocking tyrosine kinase-mediated 
phosphorylation site at the 4-position (Figure 2.8). This effect would alter 
regulation of protein activity leading to changes in protein function (MacMillan-
Crow et al. 1998; Amirmansour et al. 1999; Tangpong et al. 2007; Ischiropoulos 
2009; Surmeli et al. 2010; Feeney et al. 2012). In addition to .NO2, .OH is another 
potential breakdown product of ONOO- (Amirmansour et al. 1999). 
 
MnSOD itself has been shown to be susceptible to tyrosine nitration in the active 
site of the enzyme (MacMillan-Crow et al. 1998; Tangpong et al. 2007; Tangpong 
et al. 2008; Surmeli et al. 2010), potentially altering the affinity of MnSOD for the 
O2-. substrate by changing the redox potential of the active site (Feeney et al. 
2012). Tyrosine nitration leads to damaged MnSOD and subsequent 
mitochondrial dysfunction (Tangpong et al. 2008; Surmeli et al. 2010). 
Increases in 3-nitrotyrosine (3NT) and protein-bound HNE have been found even 
in brain of subjects with early neurodegenerative disorders such as AD (Reed et 
al. 2009).  
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2.7.5 Protein carbonyl formation 
 
Protein modification can occur through the formation of protein carbonyl groups, 
which can be introduced into proteins by direct oxidation of certain amino acid 
side chains, peptide backbone scission, by Michael addition reactions with 
alkenal products of lipid peroxidation, or glycooxidation (Berlett et al. 1997; 
Butterfield et al. 1997; Butterfield et al. 2002). The brain is rich in polyunsaturated 
fatty acids (PUFA) and has areas rich in iron coupled with high oxygen usage 
and a relatively low antioxidant capacity, which make the brain particularly 
susceptible to oxidative damage. 
 
2.7.6 Oxidation of DNA and RNA 
 
Similar to proteins and lipids, nucleic acids are also susceptible to oxidative 
modification by ROS, RNS (Cooke et al. 2003; Moreira et al. 2008), and by 
products of lipid peroxidation (Moreira et al. 2008) leading to alterations in 
replication or translation that lead to mutations or decreased protein synthesis. 
RNA may be more susceptible to ROS attack due to its closer proximity to 
mitochondria, RNA are single stranded entities not protected from ROS by 
hydrogen bonding, (Nunomura et al. 2009) and RNA are not protected by 
histones like DNA are. RNA oxidation has been detected in neurodegenerative 
diseases (Lovell et al. 2008).  
Copyright © Jeriel T. R. Keeney 2013 
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Plasma Isolation and tissue collection 
 
Plasma is the liquid portion of blood that suspends cells such as red blood cells, 
white blood cells, and platelets. Plasma is pale-yellow in color and rather viscous. 
Plasma can be isolated from whole blood by centrifugation at low speeds in the 
presence of an anticoagulant such as ethylenediaminetetraacetic acid (EDTA).  
For this research, mouse plasma was obtained by cardiac puncture and blood 
transferred into tubes containing EDTA. Tubes were inverted ten times to ensure 
proper mixing with anticoagulant. Blood was centrifuged at 3000 rpm at 4oC for 
10 minutes to separate blood components. 60 uL plasma was aliquots were 
placed into pre-labeled microfuge tubes, and immediately frozen in liquid nitrogen 
until analysis.  
 
Following blood collection, brain from sacrificed animals were extracted, placed 
in pre-labeled microfuge tubes, and immediately frozen in liquid nitrogen until 
analysis. 
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3.2 Bicinchoninic Acid Assay (BCA) 
 
Estimation of protein concentrations used for this dissertation were determined 
using the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA).  
This assay uses the Biuret reaction, protein-mediated reduction of Cu2+ to Cu+ by 
the peptide bond between amino acids.  When reduced, Cu+ forms a complex 
with BCA that absorbs at 562 nm.   Bovine serum albumin (BSA) was used a 
protein standard, and a Beer’s law standard plot was used to calculate the 
protein concentration of plasma and brain samples. 
 
3.3 Biological sample preparation 
 
Protein estimation was performed using the bicinchoninic acid (BCA, Pierce) 
assay. Homogenized brain and plasma samples were diluted according to initial 
protein estimation results using 20 ug sample in isolation buffer [0.32 M sucrose, 
2 mM EDTA, 2mM EGTA, and 20mM HEPES pH 7.4 with protease inhibitors, 0.2 
mM PMSF, 20ug/mL trypsin inhibitor, 4 μg/ml leupeptin, 4 μg/ml pepstatin A, and 
5 μg/ml aprotinin]. 
 
3.4 Slot blot assay 
 
The slot-blot method is used to determine levels of protein carbonyl (PC), 3-
nitrotyrosine (3NT) and protein-bound 4-hydroxy-2-transnonenal (HNE) in brain 
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as previously described [37, 38]. For protein carbonyl determination, samples 
were derivatized with 2,4-dinitrophenylhydrazine (DNPH) prior to analysis. For 
HNE and 3NT, samples were solubilized in Laemmli buffer. To standardize the 
protocol, a consistent amount of protein (250 ng) from each sample is loaded 
onto a nitrocellulose membrane in respective wells in a slot-blot apparatus (Bio-
Rad) under vacuum. Development results in a colored product. Colorimetric 
intensity reflects of the levels of a specific modification in the sample. This 
technique requires only a small amount of sample (approximately 1 µg of 
protein), and a large number of samples can be run simultaneously.   
 
3.5 Detection of oxidatively modified proteins 
 
3.5.1 Protein carbonyl determination 
 
For protein carbonyl determination, samples were derivatized with 2,4-
dinitrophenylhydrazine (DNPH) prior to analysis. DNPH reacts with ketones and 
aldehydes with high specificity to form a Schiff base. Protein bound 2,4-
dinitrophenylhydrazones can be detected using an antibody directed at the 
hydrazone adduct, which can be detected immunochemically or fluorescently. 
Membranes from slot blot or western blot are blocked in 3% bovine serum 
albumin (BSA) in PBS with 0.2% (v/v) Tween-20 for 1.5 h and then incubated in 
primary antibody (anti-dinitrophenylhydrazone primary produced in rabbit, Sigma-
Aldrich) for 2 h, washed three times in PBS with 0.2% (v/v) Tween-20 and then 
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incubated for 1 h with secondary antibody (goat anti-rabbit secondary linked to 
alkaline phosphatase). Membranes were developed with 5-bromo-4-chloro-3-
indolyl-phosphate (BCIP) dipotassium and nitro blue tetrazolium (NBT) chloride 
in alkaline phosphatase activity (ALP) buffer, dried, and scanned for analysis. 
Image analysis was performed using Scion Image (Scion Corporation, Frederick, 
MD).  
 
3.5.2 Protein-bound HNE and 3-nitrotyrosine determination  
 
Membranes from slot blot or western blot are blocked in 3% bovine serum 
albumin (BSA) in PBS with 0.2% (v/v) Tween-20 for 1.5 h and then incubated in 
primary antibody (anti-nitrotyrosine  or anti-protein-bound HNE produced in 
rabbit, Sigma-Aldrich) for 2 h, washed three times in PBS with 0.2% (v/v) Tween-
20 and then incubated for 1 h with secondary antibody (goat anti-rabbit 
secondary linked to alkaline phosphatase). Membranes were developed with 5-
bromo-4-chloro-3-indolyl-phosphate (BCIP) dipotassium and nitro blue 
tetrazolium (NBT) chloride in alkaline phosphatase activity (ALP) buffer, dried, 
and scanned for analysis. Image analysis was performed using Scion Image 
(Scion Corporation, Frederick, MD). When measuring tyrosine nitration, a 
negative control for nitration should be performed by reducing nitrotyrosine to 
aminotyrosine according to the method of Miyagi and Crabbet al. (Miyagi et al. 
2002) as follows. One replicate membrane is treated with 10 mM sodium 
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dithionite in 50 mM pyridine-acetate buffer (pH=5.0) for 1h at room temperature, 
rinsed thoroughly with nanopure water, and developed as above. 
 
3.6 Behavioral testing: Novel object recognition and open field testing 
 
3.6.1 Novel object recognition 
 
Cognitive performance was evaluated using a NOR paradigm (Ennaceur et al. 
1988; Schoch et al. 2012).  One day prior to treatment, each mouse was 
acclimated for 1 h to an empty, Plexiglas cage which was dedicated to this 
mouse for all trials.  Immediately thereafter, the mouse was introduced to two 
identical objects (object A) placed at opposite corners of the cage, and the time 
spent exploring each object was recorded. Several hours after the initial object 
exposure, mice were returned to the cage containing the two “familiar” objects 
(object A) to reinforce object recognition.  Throughout the protocol, trial duration 
was 5 min unless total exploration time was less than 10 s.  In this case, the trial 
was extended to ensure a minimum of 10 s of exploration. A mouse was 
considered to be exploring when it pointed its nose toward the object at a 
distance of 2 cm or less.  The following morning, baseline memory function was 
evaluated by replacing one of the familiar objects with a novel object (object B). 
In the afternoon, mice received injections of MESNA or vehicle and then Dox or 
vehicle.  The morning after injections, the mice were exposed to the original two 
(familiar) objects (object A) and, after a 4 h interval, one of the familiar objects 
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was replaced with a novel object (object C).  At 3 days after treatment, memory 
was tested again (novel object D paired with familiar object A).  Data are reported 
as a recognition index (RI), which represents the time spent exploring the novel 
object as a percentage of total exploration time.  All trials were performed by an 
investigator blinded to treatment conditions. 
 
3.6.2 Motor activity in an open field 
 
Motor activity was tested using an Open Field test (Leibrock et al. 2013).  Mice 
were placed in a 48 x 33cm empty Plexiglas box and videotaped from above for 
a 5 minute trial (EZVideoDV version 5.51).  Trials were performed by an 
investigator blinded to treatment conditions. Behavioral testing was performed by 
the K. E. Saatman laboratory, Spinal Cord and Brain Injury Research Center, 
University of Kentucky. 
 
3.7 Hydrogen magnetic resonance imaging spectroscopy 
 
H1-MRS (hydrogen magnetic resonance imaging spectroscopy) was used to 
quantify neurochemical changes in the mouse hippocampus. MRS data was 
acquired on a 7T BrukerClinscan horizontal bore system (7.0T, 30cm, 300Hz) 
equipped with a triple-axis gradient system (630 mT/m and 6300 T/m/s). A closed 
cycle, 14K quadrature cryocoil allowed for a 2.8 signal to noise increase relative 
to standard coils. The mice were anesthetized with 1.3 % percent isoflurane 
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using MRI compatible CWE Inc. equipment. Mice were held in place on a Bruker 
scanning bed with a tooth bar, ear bars and tape. Body temperature and 
respiration rate were monitored using equipment from SA Instruments Inc. The 
animals were maintained at 37°C with a water heating system built into the 
scanning bed. T2 weighted turbo spin echo sequences (TE 40ms, TR 2890ms, 
Turbo 7, FOV 20mm, 0.156 x 0.156 x 5.0 mm3) were acquired and used for the 
placement of the spectroscopy voxel. The scanning procedure took 40 min. A 
2x5.5x3mm3 PRESS spectroscopic voxels (TE 135ms, TR 1500ms, 400avg, 
CHESS water suppression) was placed to cover both hippocampi. Spectrum 
analysis was performed using jMRUI (Naressi et al. 2001) to quantify the area 
under 10 peaks in the spectrum. The creatine peak was used to normalize the 
choline peak. H1-MRS scans were performed by Dr. David Powell, Magnetic 
Resonance Imaging and Spectroscopy Center, University of Kentucky Medical 
Center. 
 
3.8 Phospholipase C and Phospholipase D Activity Assays 
 
Phosphatidylcholine-specific phospholipase C (PC-PLC) and phospholipase D 
(PLD) activity assays were performed using manufacturers’ instructions provided 
with the EnzChek® Direct Phospolipase C Assay Kit and Amplex® Red 
Phospholipase D Assay Kit by Invitrogen/Life Technologies (Carlsbad, CA ).  
Fluorescence intensity for each assay was measured using a SPECTRAFluor 
Plus instrument and quantified using associated MagellanTM software by TECAN 
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over a period of 24 h with the kinetic peaks of the positive controls used for 
comparison. 
 
3.9 Assessment of mitochondrial function 
3.9.1 Isolation of Brain Mitochondria 
 
Mice were perfused via cardiac puncture with cold mitochondrial isolation buffer, 
the brain promptly removed, the cerebellum dissected away, and the 
mitochondria immediately isolated from the brain by a modification of the method 
described by Mattiazzi et al. (Mattiazzi et al. 2002). Brain mitochondria were 
isolated in cold mitochondrial isolation buffer, containing 0.07 M sucrose, 0.22 M 
mannitol, 20 mM HEPES, 1 mM EGTA, and 1% bovine serum albumin, pH 7.2. 
Tissues were homogenized with a Dounce homogenizer and centrifuged at 1500 
× g at 4°C for 5 min before transferring the supernatants. The pellets were 
resuspended and centrifuged at 1500 × g at 4°C for 5 min. The supernatants 
were combined and recentrifuged at 1500 × g at 4°C for 5 min. The supernatants 
were separated and centrifuged at 13,500 × g at 4°C for 10 min. Non-
synaptosomal mitochondrial fraction separation was performed using a 3%/6% 
(w/v) Ficoll gradient at 4oC prepared before use in 100 mL mitochondrial isolation 
buffer. Mitochondrial pellets were purified with a 4% Ficoll solution and the 
mitochondrial pellet was resuspended in 50 μL cold mitochondrial isolation buffer. 
This method allows rapid isolation of viable mitochondria from brain. Purity 
testing of resulting mitochondria samples was not performed due to time and 
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sample volume constraints to ensure mitochondrial viability. There is a tension 
between time of processing and purity of sample obtained. Thus, the results 
obtained required a short time to obtain viable mitochondria, but in so doing, the 
results may be affected by potential interfering contaminants.  Protein 
concentration of isolated mitochondria was determined by the Bradford assay 
(Bradford 1976).  
 
3.9.2 Bioenergetic analysis in mitochondria  
 
The XF96 Analyzer, Seahorse Bioscience (North Billerica, MA, USA) was used to 
measure bioenergetic function in mitochondria freshly isolated by differential 
centrifugation from brain of adult male C57BL6 mice. The XF96 creates a 
transient 3µl chamber in specialized microplates that allows for the measurement 
of oxygen consumption rate (OCR) in real time.  Respiration by the mitochondria 
(5 µg/well) was sequentially measured with substrate present (basal respiration) 
following conversion of ADP to ATP, induced with the addition of oligomycin. 
Next, maximal uncoupler-stimulated respiration was detected by the 
administration of the uncoupling agent FCCP. At the end of the experiment, the 
complex III inhibitor, antimycin A, was applied to completely inhibit mitochondrial 
respiration. Oxygen Consumption rate were measured four times and plotted as 
a function of cells, showing the relative contribution of oxygen consumption, ATP-
linked oxygen consumption, the maximal OCR after the addition of FCCP, and 
the reserve capacity of the cells. Seahorse assays were performed by the D.K. 
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St. Clair laboratory, Graduate Center for Toxicology, Department of Radiation 
Medicine, Markey Cancer Center, University of Kentucky. 
 
3.10 Superoxide experiments  
3.10.1 Solvent selection and potassium superoxide solution preparation 
 
KO2 is a yellow solid that reacts readily with water and would decompose if 
exposed to water vapor or carbon dioxide in air. To avoid this situation, a 
saturated solution of KO2 was prepared fresh, according to the method 
previously described (Valentine et al. 1975; McPherson et al. 2002; Miller 2003), 
in a solvent of anhydrous dimethyl sulfoxide (DMSO) containing 200mM crown 
ether (18crown6) to aid in solubility. To the prepared solvent, excess KO2 was 
added and the KO2 concentration estimated by UV-vis absorbance and using 
molecular absorptivity of   (Kim et al. 1979; Miller 2003). A saturated solution of 
KO2 was approximately 250 µM under the stated conditions. Serial dilutions of 
this saturated solution were performed using the DMSO+18crown6 solvent to 
obtain the desired O2-• concentrations. 
 
3.10.2 Plasma oxidation with potassium superoxide 
 
KO2 was added to plasma from WT mice and incubated at 37oC for 0, 15, 30, 
and 90 min according to Table 3.1. Concentrations of 0, 0.1, 1.0, or 10 µM KO2 
were added to plasma to broadly encompass Dox concentrations used in 
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previous studies. The solvent, DMSO and 18crown6, was added to all control 
incubations.  
 
Table 3.1. Superoxide protocol volumes. Plasma samples from 2-3 months old 
WT, male, SKH1 hairless, albino mice (purchased from the Jackson Laboratory) 
were treated with 0, 0.1, 1.0, or 10 µM KO2 and incubated for 0, 15, 30, and 90 
min. 
Tube 
# 
Incubation 
Time (min) 
KO2 conc  
to add (uM) 
Plasma 
Volume (uL) 
Solvent Vol (uL) 
(used for KO2) 
1 90 10 48 2 
2 90 1.0 48 2 
3 90 0.1 48 2 
4 30 10 48 2 
5 30 1.0 48 2 
6 30 0.1 48 2 
7 15 10 48 2 
8 15 1.0 48 2 
9 15 0.1 48 2 
10 0 0 (control) 48 2 
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3.10.3 Macrophage stimulation with potassium superoxide 
 
Cell culture experiments were carried out using mouse BALB/c monocyte 
macrophage cell line (J774A.1) collected form blood. The mouse macrophage 
cell line J774A.1 (American Type Culture Collection) was cultured in Dulbecco's 
modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum, 
streptomycin (100μg/ml), and penicillin (100U/ml). All cultures were incubated at 
37 °C in a humidified atmosphere with 5% CO2. J774A.1 macrophage cells were 
plated at a density of 5 × 105 cells/well in 48-well plates. Potassium superoxide 
(KO2) was prepared as previously described. Lipopolysaccharide (LPS; 1 μg/ml), 
KO2 (0.1µM; 1µM; 10µM) was added and the cells were incubated for 24 h. The 
supernatant was collected and levels of TNF-α (pg/ml) were determined with a 
specific ELISA kit for mouse TNF-α (R&D Systems). Macrophage culture 
experiments were performed by the D.K. St. Clair laboratory, Graduate Center for 
Toxicology, Department of Radiation Medicine, Markey Cancer Center, 
University of Kentucky. 
 
 
Figure 3.1. Experimental design: macrophage simulation with potassium 
superoxide. J774.A1 macrophages were seeded onto a 48-well plate at 5×105 
Experimental design 
 J774A.1 
J774A.1+ Lipopolysaccharide (LPS) (1 μg/ml) – 24hours incubation 
J774A.1+ DMSO+ Crown ether 
J774A.1+KO2 (0 μM) – 24hours incubation 
J774A.1+KO2 (0.1 μM)  – 24hours incubation 
J774A.1+KO2 (10 μM) – 24hours incubation 
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cells/well and allowed to grow overnight under standard culture conditions. 
Preincubation of solvent, lipopolysaccharide (LPS; 1 μg/ml), KO2 (0.1µM; 1µM; 
10µM) for 1 h was performed prior to addition to J774.A1 macrophages. 
Supernatants were collected and analyzed for TNF-α concentration. 
 
3.11 Proteomics (Butterfield et al. 2012)  
3.11.1 Isoelectric focusing (IEF) 
 
Aliquots (containing 150ug of protein) of the homogenized cortical samples 
prepared above were precipitated using cold 100% trichloroacetic acid (TCA) to 
obtain a concentration of 15% (v/v) TCA in solution and incubated on ice for 15 
minutes. Samples were centrifuged at 14,000 rpm for 10 min at 4 °C. The 
resulting pellets were resuspended and rinsed four times in a cold ethanol: ethyl 
acetate (1:1 v/v) mixture. After allowing the final pellets to dry completely at room 
temperature, the pellets were rehydrated for 2 h in rehydration buffer [8 M urea, 2 
M thiourea, 50 mM DTT, 2.0% (w/v) CHAPS, 0.2% Biolytes, Bromophenol Blue] 
then sonicated for 10 s at 20% power. Each entire sample was added to an 11 
cm pH 3-10 ReadyStrip™ IPG strip in a lane of the IEF tray. After 45 min of run 
time, 2 mL of mineral oil were added to each lane to prevent evaporation. Strips 
were actively rehydrated at 20 °C for 18 h at 50 V, focused at a constant 
temperature of 20 °C beginning at 300 V for 2 h, 500 V for 2 h, 1000 V for 2 h, 
8000 V for 8 h, and finishing at 8000 V for 10 h rapidly. IPG strips were stored at 
−80 °C until needed for the second dimension of analysis.  
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3.11.2 Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) 
 
IEF strips were allowed to come to room temperature (~30 min) and equilibrated 
for 10 min in the dark in 4 mL equilibration buffer A [50 mMTris–HCl, pH 6.8, 6 M 
urea, 1% (w/v) SDS, 30% v/v glycerol, 0.5% DTT] and then re-equilibrated for 10 
min in the dark in equilibration buffer B [50 mMTris–HCl, pH 6.8, 6 M urea, 1% 
(w/v) SDS, 30% v/v glycerol, 4.5% IA]. All strips were rinsed in TGS running 
buffer to remove residual equilibration buffers before being placed onto Criterion 
precast linear gradient (8–16%) Tris–HCl polyacrylamide gels. Precision Plus 
Protein™ All Blue Standards and samples were run at a constant voltage of 200 
V for 65 min. 
 
3.11.3 SYPRO Ruby® staining 
 
Following 2D-PAGE, gels were incubated in 50 mL fixing solution [7% (v/v) acetic 
acid, 10% (v/v) methanol] for 20 min at room temperature. SYPRO Ruby® Protein 
Gel Stain (50-55 mL) was added to gels and allowed to stain overnight at room 
temperature on a gently rocking platform. The stain was then removed and gels 
were rinsed with deionized (DI) water and stored in 50 mL DI water in the 
refrigerator until scanning. Gels were scanned into Adobe Photoshop 6.0 with a 
Molecular Dynamics STORM phosphoimager (λex/λem: 470/618 nm) and stored in 
DI water at 4 °C. 
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3.11.4 Image analysis: differential expression 
 
Spot intensities from SYPRO Ruby®-stained 2D-gel images of cortex samples 
were quantified according to total spot density using PDQuest software (Bio-
RAD, Hercules, CA, USA). Intensities were normalized to total gel densities. Only 
low or high VitD samples with normalized spot densities that were significantly 
increased or decreased by at least 1.25 fold from control were considered for 
mass spectrometry (MS) analysis. 
 
3.11.5 In-gel trypsin digestion 
 
Protein spots identified as significantly altered in VitD deficient rat brain relative 
to normal VitD controls were excised from 2D-gels with new, sterilized 
micropipette tips and transferred to Eppendorfmicrocentrifuge tubes. Gel plugs 
were then washed with 0.1 M ammonium bicarbonate (NH4HCO3) at room 
temperature for 15 min, followed by incubation with 100% acetonitrile at room 
temperature for 15 min. Solvent was removed, and gel plugs were dried in their 
respective tubes in a biosafety cabinet at room temperature. Gel plugs were 
incubated for 45 min in 20 μl of 20 mM DTT in 0.1 M NH4HCO3 at 56 °C. The 
DTT solution was then removed and replaced with 20 μl of 55 mM IA in 0.1 M 
NH4HCO3 and incubated with gentle agitation at room temperature in the dark for 
30 min. Excess IA solution was removed, and the gel plugs were incubated for 
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15 min with 200 μl of 50 mM NH4HCO3 at room temperature. 200 μL of 100% 
acetonitrile was added to this solution in each tube and incubated for 15 min at 
room temperature. All solvent was removed, and gel plugs were allowed to dry 
for 30 min at room temperature in a biosafety cabinet. Gel plugs were rehydrated 
with 20 ng/μL of modified trypsin (Promega, Madison, WI, USA) in 50 mM 
NH4HCO3 in a shaking incubator overnight at 37 °C. Enough trypsin solution was 
added in order to completely submerge the gel plugs (approximately 10uL). 
 
3.11.6 Mass spectrometry 
 
Salts and other contaminants were removed from tryptic digest solutions using 
C18 ZipTips (Sigma-Aldrich, St. Louis, MO, USA), reconstituted to a volume of 
approximately15 μl in a 50:50 DIwater:acetonitrile solution containing 0.1% 
formic acid. Tryptic peptides were analyzed with an automated Nanomate 
electrospray ionization (ESI) [Advion Biosciences, Ithaca, NY, USA] Orbitrap XL 
MS (ThermoScientific, Waltham, MA, USA) platform. The Orbitrap MS was 
operated in a data-dependent mode whereby the eight most intense parent ions 
measured in the Fourier Transform (FT) at 60,000 resolution were selected for 
ion trap fragmentation with the following conditions: injection time 50 ms, 35% 
collision energy, MS/MS spectra were measured in the FT at 7500 resolution, 
and dynamic exclusion was set for 120 s. Each sample was acquired for a total 
of approximately 2.5 min. MS/MS spectra were searched against the 
International Protein Index (IPI) database using SEQUEST and the following 
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parameters: two trypsin miscleavages, fixed carbamidomethyl modification, 
variable Methionine oxidation, parent tolerance 10 ppm, and fragment tolerance 
of 25 mmu or 0.01 Da. Results were filtered with the following criteria: Xcorr>1.5, 
2.0, 2.5, 3.0 for +1, +2, +3, and +4 charge states, respectively, Delta CN>0.1, 
and P-value (protein and peptide) <0.01. IPI accession numbers were cross-
correlated with SwissProt accession numbers for final protein identification 
(Robinson et al. 2011).  
 
3.11.7 Database search and peptide identification 
 
Results from the mass spectrum are compared to theoretical protein spectra in a 
database. The research in this dissertation was performed using the SEQUEST 
database. From the mass spectrum, exact peptide masses of the digested 
protein are compared with theoretical peptide masses in the database, producing 
a list of potential peptide matches. The database contains theoretical MS/MS 
spectra of the peptides with masses similar to the unidentified peptide. By 
subjecting the unidentified peptide to MS/MS, a fragmentation spectrum is 
generated. Using cross correlation analysis,  the overlap in fragmentation 
patterns between the unidentified peptide and the database spectra of possible 
matches is compared. Proteins receive scores based on the quality of overlap. 
From these data, protein identification is made based on uniqueness of identity 
and probability of match with theoretical spectra. 
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3.11.8 One-dimensional polyacrylamide gel electrophoresis 
 
Sample homogenates were incubated in sample buffer (0.5 M Tris (pH 6.8), 40% 
glycerol, 8% sodium dodecyl sulfate (SDS), 20% β-mercaptoethanol, and 0.01% 
bromophenol) for 5 min in a water bath at 95°C and loaded onto precast Criterion 
TGX (4-15%) or Criterion XT (12% Bis-Tris) Precast Gels as appropriate for the 
molecular weight of the protein of interest. Precision Plus Protein™ All Blue 
Standards and samples were run at 80 V for 15 min, increasing the voltage to 
120 V and run for 90 min in TGS or MES running buffer as appropriate for the 
gel. 
 
3.11.9 Western Blotting 
 
In-gel proteins were transferred to a nitrocellulose membrane (0.45 μm) using a 
Trans-Blot® TurboTM Blotting system at 25 V for 30 min (BioRAD, Hercules, CA, 
USA). After transfer, membranes were incubated in blocking solution [3% BSA in 
phosphate buffer (PBS) solution with 0.2% (v/v) Tween 20] at room temperature 
for 1.5 h.Membranes were then incubated with rabbit anti-inducible nitric oxide 
synthase (iNOS) antibody (Calbiochem/Millipore, Billerica, MA) or rabbit anti-NF-
κB (p65) antibody (Enzo, Farmingdale, NY) for 2 h on a gentle rocking platform, 
followed by three rinses for 5 min each with PBS solution with 0.2% (v/v) Tween 
20. Blots were then incubated for 1 h with ECL anti-rabbit IgG, horseradish 
peroxidase-linked whole antibody. The resulting blots were rinsed three times for 
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5, 10, and 10 min each in PBS solution with 0.2% (v/v) Tween 20 and signals 
were detected using ClarityTM Western ECL Substrate (BioRAD) and the 
ChemiDocTMMP Imaging System (BioRAD).Blots were stripped using Re-blot 
Plus Strong Solution (Millipore, Billerica, MA, USA) according to package 
instructions and re-probed with mouse anti-actin antibody (Sigma-Aldrich, St. 
Louis, MO) or mouse anti-histone H2B antibody (Chemicon, Temecula, CA) for 
normalization. Analysis was performed using the ImageLab software (BioRAD). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Jeriel T. R. Keeney 2013 
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Chapter 4 
Doxorubicin-induced elevated oxidative stress in brain and 
cognitive decline: protection by MESNA and insights into 
mechanisms of chemotherapy-induced cognitive impairment 
(“chemobrain”). 
 
4.1 Overview of Study 
 
Chemotherapy-induced cognitive impairment (CICI) is now widely recognized as 
a real and too common complication of cancer chemotherapy experienced by an 
ever growing number of cancer survivors. Previously, we reported that 
Doxorubicin (Dox), a prototypical reactive oxygen species (ROS)-producing anti-
cancer drug, results in oxidation of plasma proteins, including apolipoprotein A-I 
(ApoA-I) leading to tumor necrosis factor-alpha (TNF-α)-mediated oxidative 
stress in plasma and brain. We also reported that co-administration of the 
antioxidant drug, 2-mercaptoethane sulfonate sodium (MESNA), prevents Dox-
induced protein oxidation and subsequent TNF-α elevation in plasma. In this 
study, we measured oxidative stress in both brain and plasma of Dox-treated 
mice both with and without MESNA. MESNA ameliorated Dox-induced oxidative 
protein damage in plasma, confirming our prior studies, and in a new finding led 
to decreased oxidative stress in brain. This study also provides further functional 
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and biochemical evidence of the mechanisms of CICI. Using novel object 
recognition (NOR), we demonstrated the Dox administration resulted in memory 
deficits, effects that were rescued by MESNA. Using hydrogen magnetic 
resonance imaging spectroscopy (H1-MRS) techniques, we demonstrated that 
Dox administration led to a dramatic decrease in 
choline(phosphocholine)/creatine ratios in the hippocampus in mice. To better 
elucidate a potential mechanism for this MRS observation, we tested the 
activities of the phospholipase enzymes known to act on phosphatidylcholine 
(PtdCho), a key component of phospholipid membranes and a source of choline 
for the neurotransmitter, acetylcholine (ACh). The activities of both 
phosphatidylcholine-specific phospholipase C (PC-PLC) and phospholipase D 
were severely diminished following Dox administration. The activity of PC-PLC 
was preserved when MESNA was co-administered with Dox; however, PLD 
activity was not protected. This study is the first to demonstrate the protective 
effects of MESNA on Dox-related protein oxidation, cognitive decline, 
phosphocholine levels, and PC-PLC activity in the brain. 
 
4.2 Introduction 
 
Chemotherapy-induced cognitive impairment (CICI), termed “chemobrain” by 
patients, is increasingly recognized as a real complication of cancer 
chemotherapy (Tannock et al. 2004; Ahles et al. 2007; Foley et al. 2008; Konat et 
al. 2008; Aluise et al. 2010; Cheng et al. 2013; Seigers et al. 2013). CICI consists 
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of impairments in various aspects of memory and executive function (McDonald 
et al. 2013; Simo et al. 2013). Despite the increased attention this issue has 
garnered from the clinical and research communities, the mechanisms of the 
resulting cognitive impairment are still poorly understood but is thought to include 
peripheral toxic effects caused by the chemotherapy drugs leading to 
downstream structural and functional changes in the brain including 
neuroinflammatory consequences and even changes in neurotransmitter levels 
and function (Saykin et al. 2003; Joshi et al. 2010; Aluise et al. 2011; Raffa 
2011). Reasons for the failure to address the problem may include the complexity 
of cancer and its treatments, especially by agents that do not cross the blood-
brain barrier (BBB). Moreover, a hitherto lack of a scientific explanation for 
cognitive consequences of chemotherapy has hampered progress. A better 
understanding of the underlying mechanisms by which CICI occurs is necessary 
to allow cancer survivors to have a better quality of life by protecting non-targeted 
tissues against undesired toxicities of the anticancer drugs.  
 
In the present studies, we used doxorubicin (Dox) as a representative 
chemotherapeutic agent known to produce reactive species (Handa et al. 1975; 
Gutteridge 1984; Cummings et al. 1991). Dox is an anthracycline antineoplastic 
agent commonly used in multidrug chemotherapy regimens primarily to treat 
solid tumors and leukemias. The cancer killing effects of Dox have been shown 
to involve three proposed mechanisms: DNA intercalation, inhibition of 
topoisomerase II, and production of ROS (Bachur et al. 1977; Chuang et al. 
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1979; Reich et al. 1979; Tanaka et al. 1980; Cummings et al. 1991; Fornari et al. 
1994; Deres et al. 2005). The quinone moiety present in the Dox structure is 
capable of undergoing a one-electron reduction to the semi-quinone (Chen et al. 
2007; Aluise et al. 2011). Through the redox cycling of this structure back to the 
quinone, in vivo, the reactive O2-• is produced from molecular oxygen. In addition, 
previous studies by our laboratories demonstrated that even though neither Dox 
nor its primary metabolite crosses the blood-brain barrier (BBB), peripheral Dox 
treatment does cause brain injury as evidenced by increased oxidative stress, 
the inflammatory cytokine, tumor necrosis factor-alpha (TNF-α), and 
mitochondrial dysfunction (Tangpong et al. 2006; Joshi et al. 2007; Tangpong et 
al. 2007; Tangpong et al. 2008).  
 
Our laboratory and others previously demonstrated Dox-induced oxidative stress 
in blood and damage to plasma proteins leading to detrimental central nervous 
system consequences (Thayer 1988; Fadillioglu et al. 2003; Tangpong et al. 
2006; Othman et al. 2008; Aluise et al. 2009; Aluise et al. 2011). Central to this 
paradigm is apolipoprotein A-I (ApoA-I) (Aluise et al. 2010; Aluise et al. 2011; 
Perluigi et al. 2011; Keeney et al. 2013). ApoA-I promotes cholesterol efflux as 
part of the high density lipoprotein (HDL) complex. Additionally, ApoA-I has been 
shown to suppress TNF-α in plasma (Hyka et al. 2001; Perry et al. 2002; Weber 
et al. 2011). Previous studies in our laboratory have shown that, when oxidized, 
ApoA-1 loses this ability to suppress TNF-α release and may exacerbate the 
problem (Aluise et al. 2011). 
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However, our group has also demonstrated that ApoA-I oxidation and 
subsequent increased TNF-α release is suppressed with co-administration of the 
drug MESNA (2-mercaptoethane sulfonate sodium) (Aluise et al. 2011). The 
structure of MESNA contains a free sulfhydryl group imparting much of its 
antioxidant properties by affording it the ability to scavenge free radicals and 
reactive aldehydes such as HNE and acrolein. MESNA is FDA approved for 
prevention of hemorrhagic cystitis and routinely used with Dox as part of 
multidrug chemotherapy regimens that include ifosfamide or cyclophosphamide. 
MESNA does not enter cells, does not interfere with cancer chemotherapy 
(Bernacki et al. 1987), and blocks protein oxidation, including ApoA-I, in the 
plasma (Aluise et al. 2011). Modulating the location and production of 
chemotherapy-induced production of ROS may be paramount in decreasing the 
unwanted toxicities associated with chemotherapy while enhancing the cancer-
killing effects (Fang et al. 2009). 
 
The current study was undertaken to test the hypothesis that MESNA would 
block Dox-induced, TNF-α-mediated markers of brain damage, indexed by 
changes in oxidative stress and magnetic resonance spectroscopy (MRS) 
spectra in brain, with consequent improved cognition. 
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4.3 Materials and methods 
 
4.3.1 Chemicals 
 
Precision Plus Protein™ All Blue Standards, BCA reagents, and nitrocellulose 
membranes were purchased from Bio-RAD (Hercules, CA, USA). EnzChek® 
Direct Phospolipase C Assay Kit and Amplex® Red Phospholipase D Assay Kit 
were purchased from Invitrogen/Life Technologies (Carlsbad, CA ). Chemicals, 
proteases, protease inhibitors, and antibodies used in this study were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise noted. 
 
4.3.2 Statistical analysis 
 
All data are presented as mean±SEM, and statistical analyses were performed 
using ANOVA with Bonferroni's Multiple Comparison Test followed by a two-
tailed Student's t-test to make individual comparisons where relevant, with 
p<0.05 considered significant. The D'Agostino & Pearson omnibus normality test 
was used where appropriate.  
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4.3.3 Animals 
 
Mice used in this study were the F1 progeny of C57BL/6 x C3H hybrids (B6C3) 
purchased from the Jackson Laboratory. B6C3 hybrids are more robust and 
tolerated the Dox dose better than inbred C57BL/6. Male B6C3 mice (2-3 months 
old), each weighing approximately 30 grams were kept under standard conditions 
housed in the University of Kentucky Animal Facility, and all experimental 
procedures were approved by the Institutional Animal Care and Use Committee 
of the University of Kentucky. Doxorubicin HCl was purchased from Bedford 
Laboratories™, and MESNA was purchased from Baxter Healthcare Corporation. 
Mice were injected using a single intraperitoneal (i.p.) dose of 25 mg/kg Dox or 
the same volume of saline as a control (Yen et al. 1996; Desai et al. 2013).  
MESNA was administered at 160 mg/kg i.p. 15 min before Dox as well as 3 h 
and 6 h after Dox.  Animals tested using MRS were scanned 72 h post-treatment. 
Following MRS or novel object recognition (NOR) studies, these animals were 
euthanized and blood and tissues collected for molecular or biochemical 
analysis.  
 
4.3.4 Behavioral testing: Novel object recognition and open field testing 
 
4.3.4.1 Novel object recognition 
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Cognitive performance was evaluated using a NOR paradigm (Ennaceur et al. 
1988; Schoch et al. 2012).  One day prior to treatment, each mouse was 
acclimated for 1 h to an empty, Plexiglas cage which was dedicated to this 
mouse for all trials.  Immediately thereafter, the mouse was introduced to two 
identical objects (object A) placed at opposite corners of the cage, and the time 
spent exploring each object was recorded. Several hours after the initial object 
exposure, mice were returned to the cage containing the two “familiar” objects 
(object A) to reinforce object recognition.  Throughout the protocol, trial duration 
was 5 min unless total exploration time was less than 10 s.  In this case, the trial 
was extended to ensure a minimum of 10 s of exploration. A mouse was 
considered to be exploring when it pointed its nose toward the object at a 
distance of 2 cm or less.  The following morning, baseline memory function was 
evaluated by replacing one of the familiar objects with a novel object (object B). 
In the afternoon, mice received injections of MESNA or vehicle and then Dox or 
vehicle.  The morning after injections, the mice were exposed to the original two 
(familiar) objects (object A) and, after a 4 h interval, one of the familiar objects 
was replaced with a novel object (object C).  At 3 days after treatment, memory 
was tested again (novel object D paired with familiar object A).  Data are reported 
as a recognition index (RI), which represents the time spent exploring the novel 
object as a percentage of total exploration time.  All trials were performed by an 
investigator blinded to treatment conditions. 
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4.3.4.2 Motor activity in an open field 
 
At 1 and 3 days after treatment, motor activity was tested using an Open Field 
test (Leibrock et al. 2013).  Mice were placed in a 48 x 33cm empty Plexiglas box 
and videotaped from above for a 5 minute trial (EZVideoDV version 5.51).  Trials 
were performed by an investigator blinded to treatment conditions. Behavioral 
testing was performed by the K. E. Saatman laboratory, Spinal Cord and Brain 
Injury Research Center, University of Kentucky. 
 
4.3.5 Hydrogen magnetic resonance imaging spectroscopy 
 
H1-MRS (hydrogen magnetic resonance imaging spectroscopy) was used to 
quantify neurochemical changes in the mouse hippocampus. MRS data was 
acquired on a 7T BrukerClinscan horizontal bore system (7.0T, 30cm, 300Hz) 
equipped with a triple-axis gradient system (630 mT/m and 6300 T/m/s). A closed 
cycle, 14K quadrature cryocoil allowed for a 2.8 signal to noise increase relative 
to standard coils. 
 
The mice were anesthetized with 1.3 % percent isoflurane using MRI compatible 
CWE Inc. equipment. Mice were held in place on a Bruker scanning bed with a 
tooth bar, ear bars and tape. Body temperature and respiration rate were 
monitored using equipment from SA Instruments Inc. The animals were 
maintained at 37°C with a water heating system built into the scanning bed. T2 
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weighted turbo spin echo sequences (TE 40ms, TR 2890ms, Turbo 7, FOV 
20mm, 0.156 x 0.156 x 5.0 mm3) were acquired and used for the placement of 
the spectroscopy voxel. The scanning procedure took 40 min. A 2x5.5x3mm3 
PRESS spectroscopic voxels (TE 135ms, TR 1500ms, 400avg, CHESS water 
suppression) was placed to cover both hippocampi. Spectrum analysis was 
performed using jMRUI (Naressi et al. 2001) to quantify the area under 10 peaks 
in the spectrum. The creatine peak was used to normalize the choline peak. H1-
MRS scans were performed by Dr. David Powell, Magnetic Resonance Imaging 
and Spectroscopy Center, University of Kentucky Medical Center. 
 
4.3.6 Sample preparation 
 
Protein estimation was performed using the bicinchoninic acid (BCA, Pierce) 
assay. Homogenized brain and plasma samples were diluted according to initial 
protein estimation results using 20 ug sample in isolation buffer [0.32 M sucrose, 
2 mM EDTA, 2mM EGTA, and 20mM HEPES pH 7.4 with protease inhibitors, 0.2 
mM PMSF, 20ug/mL trypsin inhibitor, 4 μg/ml leupeptin, 4 μg/ml pepstatin A, and 
5 μg/ml aprotinin]. 
 
4.3.7 Slot blot assay 
 
The slot-blot method was used to determine levels of protein carbonyl and HNE 
in brain as previously described [37, 38]. For protein carbonyl determination, 
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samples were derivatized with 2,4-dinitrophenylhydrazine (DNPH). For HNE, 
samples were solubilized in Laemmli buffer. Protein (250 ng) from each sample 
was loaded onto a nitrocellulose membrane in respective wells in a slot-blot 
apparatus (Bio-Rad) under vacuum. Membranes were blocked in 3% bovine 
serum albumin (BSA) in PBS with 0.2% (v/v) Tween-20 for 1.5 h and then 
incubated in primary antibody (anti-dinitrophenylhydrazone primary or anti-
protein-bound HNE, respectively, each produced in rabbit, Sigma-Aldrich) for 2 h, 
washed three times in PBS with 0.2% (v/v) Tween-20 and then incubated for 1 h 
with secondary antibody (goat anti-rabbit secondary linked to alkaline 
phosphatase). Membranes were developed with 5-bromo-4-chloro-3-indolyl-
phosphate (BCIP) dipotassium and nitro blue tetrazolium (NBT) chloride in 
alkaline phosphatase activity (ALP) buffer, dried, and scanned for analysis. 
Image analysis was performed using Scion Image (Scion Corporation, Frederick, 
MD).  
 
4.3.9 Phospholipase C and Phospholipase D Activity Assays 
 
Phosphatidylcholine-specific phospholipase C (PC-PLC) and phospholipase D 
(PLD) activity assays were performed using manufacturers’ instructions provided 
with the EnzChek® Direct Phospolipase C Assay Kit and Amplex® Red 
Phospholipase D Assay Kit by Invitrogen/Life Technologies (Carlsbad, CA ).  
Fluorescence intensity for each assay was measured using a SPECTRAFluor 
Plus instrument and quantified using associated MagellanTM software by TECAN 
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over a period of 24 h with the kinetic peaks of the positive controls used for 
comparison. 
 
4.4 Results 
 
4.4.1 Dox administration results in increases in oxidative stress markers in 
brain and plasma 
 
We previously showed that, despite its inability to cross the BBB, peripheral Dox 
administration leads to increased levels of TNF-α and oxidative stress in brain 
(Joshi et al. 2005; Tangpong et al. 2006; Joshi et al. 2007; Joshi et al. 2010; 
Aluise et al. 2011). Here, we tested for indicators of oxidative stress in brain and 
plasma of animals used in this study. Test subjects were administered either 
saline, MESNA, Dox, or Dox plus MESNA. Brain and blood samples were 
collected at approximately 72 h post-Dox treatment, immediately following 
cognitive or MRS studies.   
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Figure 4.1. PC and protein-bound HNE levels in brain and plasma following 
Dox and MESNA treatments. Levels of protein carbonyl (PC) and protein-bound 
HNE are indicators of protein oxidation and lipid peroxidation respectively. 
Graphs a-d depict protein carbonyl and protein-bound HNE in brain and plasma 
of 2-3 month old, male B6C3 mice treated with saline, MESNA, Dox, or Dox with 
MESNA. Protein carbonyl levels were significantly increased in brain (a) and 
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plasma (b) of mice treated with Dox relative to saline. (In brain, the MESNA alone 
group did show slight but significant elevation in PC compared to saline.) 
MESNA, co-administered with Dox, ameliorated Dox-induced increases in PC in 
both brain and plasma.  Protein-bound HNE levels were significantly elevated in 
brain and plasma of mice treated with Dox relative to saline.  MESNA, co-
administered with Dox, significantly suppressed Dox-induced elevation in protein-
bound HNE in both brain and plasma.  (n = 10 - 13 per treatment group; *p<0.05, 
**p<0.005, ***p<0.001, ****p<0.001). 
 
Protein carbonyl levels and protein-bound HNE were used as a gauge of damage 
to proteins and lipids, respectively. Significantly higher levels of protein carbonyls 
and protein-bound HNE in brain of Dox-treated animals compared to saline-
treated controls were observed (p<0.005, Figure 4.1a and p<0.005, Figure 4.1c, 
respectively). MESNA protected the brain from these oxidative damages 
(p<0.005, p<0.005). Plasma results revealed similarly increased protein carbonyl 
and protein-bound HNE levels in Dox vs. saline treated animals (p<0.0001, 
Figure 4.1b and p<0.001, Figure 4.1d, respectively). Both effects were 
ameliorated when MESNA was administered with Dox (p<0.005, p<0.05).  These 
results are consistent with our previous findings in plasma (Aluise et al. 2011) 
and brain (Joshi et al. 2007; Joshi et al. 2010). These findings also provide 
further support that Dox induces oxidative stress in the plasma and brain, 
consistent with subsequent cognitive deficits and the notion that concomitant 
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MESNA administration may be able to reduce or prevent these consequences in 
brain.  
 
4.4.2 Dox administration results in cognitive impairment 
 
Behavior studies were performed by the K.E. Saatman laboratory. In order to 
determine the cognitive consequences of Dox-induced oxidative stress in brain 
and the potential for MESNA to protect brain function, NOR was performed on 
animals in each of the previously mentioned treatment groups (Figure 4.2a). 
NOR provides a measure of cognitive function in rodent models by assessing the 
preference for investigating a novel object in a familiar environment. Preference 
for the novel object indicates memory of a familiar object through the animal’s 
natural propensity to explore an unfamiliar object.  
 
Novelty recognition is thought to require complex cognitive function (Bevins et al. 
2006; Antunes et al. 2012). NOR employs the executive function of the frontal 
cortex, which is thought to be a key brain region affected in CICI (“chemobrain”). 
Open field testing was employed as a measure of locomotor activity (Figure 
4.2b). 
 
Prior to treatment, animals spent an average of approximately 70% of total 
exploration time investigating a novel object with no difference among the 
treatment groups. The day after treatment, each subject was re-acclimated to the 
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environment containing the two original familiar objects followed by exposure to 
one familiar and one novel object. The RI used in these studies is a ratio of time 
spent exploring the novel object to total time spent exploring either object. (i.e., a 
RI of 70 means that 70% of the total object exploration time was spent exploring 
the novel object, while a RI of 50 means there was no preference of the novel 
object over the familiar one.) One day after treatment, there was no statistically 
significant difference among groups.  However, Dox treated groups appeared to 
have slightly lower RI at 24 h. 
 
At 72 h post-treatment, the saline and MESNA treatment groups maintained an 
average RI of approximately 70, similar to previous performance. Meanwhile, RI 
was significantly decreased in the Dox treatment group, which exhibited a mean 
RI of below 50 (approximately 40) suggesting a preference for the familiar over 
the novel object. This loss of the natural preference for novelty supplanted by a 
preference for the familiar has been seen in rodent models with perirhinal cortex 
lesions (Mumby et al. 2002). Processes involved in recognition memory may be 
deleteriously affected. A preference for the familiar may be due to incomplete 
encoding of the familiar stimulus or a discrepancy between the memory of the 
familiar object and the actual perception of the same object (Ennaceur 2010). 
Another plausible explanation is that the natural bias for novelty may have been 
eliminated or at least altered (Mumby 2001; Ennaceur 2010). Additionally, 
anxiety resulting from Dox treatment could be a possible reason for the RI being 
lower than 50 in these animals. The RI of Dox treated group at 72 h post-Dox 
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was significantly lower than the 72 h saline treated group (p<0.001) and 
significantly lower than the same group’s performance at the 24 h post-Dox mark 
(p<0.05). At 72 h post-treatment, the group that received MESNA with Dox had a 
mean RI of approximately 60, significantly higher than the Dox-treated group 
(p<0.01), indicating a protection of memory function though not a full return to the 
RI of the 72 h saline-treated group. 
 
Dox treatment was associated with a delayed decline in locomotor activity 
(Figure 4.2b). Both the Dox and Dox with MESNA groups exhibited a small, but 
non-significant, decrease in movement time at 24 h after treatment.  However, at 
72 h, Dox-induced decline in motor activity was clearly evident in both groups 
receiving Dox (Figure 4.2b; Dox p<0.05 and Dox+MESNA p<0.005 compared to 
their respective controls at 72 h; 72 h Dox p<0.0001 and 72 h Dox+MESNA 
p<0.0001 compared to 24 h).  MESNA treatment did not alleviate this decrease in 
spontaneous locomotion.  The similar decrease in total locomotor activity of the 
Dox and Dox with MESNA groups (Figure 4.2b) removes a potential cofounding 
variable when comparing cognitive function results between these two groups. 
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Figure 4.2. Behavior testing following Dox and MESNA administration. 
Behavior testing for male B6C3 mice treated with saline, MESNA, Dox, or 
Dox+MESNA. (n = 7 – 8 per group; Data is presented as mean±SEM.) (a) Novel 
Object Recognition (NOR) testing provides a measure of cognitive function 
through recognition memory. At 72 h post-treatment, the Dox group performed at 
a significantly lower RI (p<0.001, Dox vs. saline, and p<0.05, Dox-24 h vs. Dox-
72 h). MESNA given with Dox rescued this measure of cognitive function 
(p<0.01, Dox+MESNA vs. Dox) though not fully to the level of the saline-treated 
group. (b) Open Field Testing was used to provide a comparison of average total 
locomotor activity among groups. Both the Dox and Dox+MESNA groups showed 
decreased average total movement 72 h post-treatment compared to their 
corresponding 24 h post-Dox levels and to the 72 h saline and MESNA groups. 
(*p<0.05, **p<0.01, ***p<0.001, ****p<0.001). Behavior studies were performed 
by the K.E. Saatman laboratory. 
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4.4.3 Dox administration results in changes to the neurochemical profile in 
the hippocampus determined by MRS 
 
The involvement of the hippocampus in learning and memory (Sarkisyan et al. 
2009; Clarke et al. 2010; Goulart et al. 2010; Antunes et al. 2012; Meck et al. 
2013) led us to pursue MRS scans of the hippocampus in our murine 
chemotherapy treatment groups. H1-MRS non-invasively measures 
neurochemical aspects of the living brain. The peaks observed in this spectrum 
(Figure 4.3a) include N-acetylaspartate (NAA), Choline (Cho)-containing 
compounds, creatine (Cr), myo-inositol, glutamate and glutamine, lipids, and 
lactate allowing quantification of these and other metabolites in the living brain 
(Jansen et al. 2006). Quantification is generally achieved using ratios to other 
species, commonly to Cr.  
 
Unilateral and bilateral hippocampal H1-MRS showed a slight, but significant, 
decrease in the NAA/Cr ratio in the Dox treated group compared to saline 
controls (*p<0.05, Figure 4.3b). A decrease in NAA/Cr is indicative of decreased 
neuronal integrity. Strikingly, MRS scans revealed, on average, a much larger six 
standard-deviation decrease in the choline/creatine (Cho/Cre) ratio in Dox-
treated mice compared to saline-treated mice (***p<0.0001, Figure 4.3c). Though 
not significant, a slight increase in the Cho/Cr to peak was seen in the 
Dox+MESNA group compared to Dox alone (Figure 4.3d). This result suggests 
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that MESNA may be protecting cognition by a different mechanism other than 
restoration of the Cho/Cr ratio. Phosphocholine and glycerophosphorylcholine 
are the major contributors to the choline peak, while Cho itself is a smaller 
contributor.  
 
 
 
 
Figure 4.3. H1-MRS of mouse hippocampus after Dox and MESNA 
treatment. (a) H1-MRS uses proton signatures from hydrogen in much the same 
way as NMR to create two-dimensional images of the tissue (right) and a 
spectrum of peaks reflecting a neurochemical profile that includes NAA, Cho, Cr, 
and others (left).  (b) Bilateral H1-MRS scans of mouse hippocampus revealed a 
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slight but statistically significant decrease in the NAA/Cr ratio (*p<0.05) and (c) a 
six standard deviation decrease in the Cho/Cr ratio in the Dox-treated group 
compared to saline control (***p<0.0001). (d) Co-administration of MESNA with 
Dox resulted in a trend toward rebound in Cho/Cr compared to Dox alone. 
Greater variability was seen in Cho/Cr in the Dox+MESNA group. H1-MRS scans 
were performed by Dr. David Powell, Magnetic Resonance Imaging and 
Spectroscopy Center, University of Kentucky Medical Center. 
 
4.4.4 Dox administration results in decreased PC-PLC and PLD activity 
 
To gain insight into a possible mechanism for the MRS-indexed changes in the 
choline-containing compounds, the activities of phospholipase enzymes known to 
act on phosphatidylcholine (PtdCho), a major source of Cho and phosphocholine 
(PCho) in the brain were tested. Phosphatidylcholine-specific phospholipase C 
(PC-PLC) cleaves PtdCho at the glycerol-phosphate bond producing the second 
messenger, diacylglycerol (DAG), and phosphocholine. Phospholipase D (PLD), 
located in the plasma membrane, cleaves the headgroup from phospholipids 
thereby releasing soluble choline from PtdCho into the cytosol leaving 
phosphatidic acid. Activity of both PC-PLC and PLD in brain were severely 
impaired at 72 h following Dox administration (p<0.01 and p<0.01, respectively; 
Figure 4.4) providing a possible explanation for the dramatic decrease seen in 
the choline-containing peaks (as measured by MRS Cho/Cr ratio). MESNA, co-
administered with Dox, completely rescued PC-PLC activity back to the activity 
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observed in the saline-treated group. However, adding MESNA to the treatment 
regimen with Dox did not prevent the Dox-related decrease in PLD activity.  
 
 
Figure 4.4. PC-PLC and PLD activity in brain following Dox and MESNA 
treatment, presented as percent saline control. (a) PC-PLC activity at 22.5h of 
incubation, the peak fluorescence of the corresponding positive control in these 
trials, at room temperature in the dark. Cleavage of the assay substrate by PC-
PLC yields a dye-labeled DAG which fluoresces using an excitation and emission 
maxima of 509 and 516nm, respectively. Dox administration caused a significant 
decrease in PC-PLC activity compared to saline treated mice (**p<0.01). Co-
administration of MESNA rescued PC-PLC activity (**p<0.01, Dox vs. 
Dox+MESNA). (b) PLD activity at 1h of incubation, the peak fluorescence of the 
corresponding positive control in these trials, at 37oC protected from light. PLD 
cleaves the headgroup from phospholipids thereby releasing the choline from 
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PtdCho. Assay reactions involving the choline produce a product that fluoresces 
using an excitation and emission maxima of 571 and 585nm, respectively. Dox 
treatment resulted in significantly decreased PLD activity compared to saline 
treated controls (**p<0.01). PLD activity in the Dox+MESNA group was not 
significantly different from the group receiving Dox alone.  
 
4.5 Discussion 
 
Based on our previous studies, we proposed this model. Plasma protein 
oxidation, including ApoA-I, induced by the redox cycling of Dox leads to 
elevation of TNF-α in the periphery. TNF-α crosses the BBB by receptor-
mediated endocytosis to induce microglial activation, further TNF-α release, 
increased production of NO, mitochondrial dysfunction, neuronal death, and 
consequent cognitive impairment (Tangpong et al. 2006; Tangpong et al. 2007; 
Tangpong et al. 2008; Aluise et al. 2009; Aluise et al. 2010; Joshi et al. 2010; 
Aluise et al. 2011). Our laboratory has previously shown that oxidative damage 
occurs early in neurodegenerative processes (Reed et al. 2008; Owen et al. 
2009; Sultana et al. 2009; Sultana et al. 2010; Aluise et al. 2011). Nearly  half of 
the FDA-approved anti-cancer drugs have been shown to result in elevation of 
ROS and induce oxidative stress (Chen et al. 2007). A large percentage of 
cancer survivors suffer from CICI, now widely recognized as a chemotherapy 
complication (Tannock et al. 2004; Foley et al. 2008; Aluise et al. 2010; Cheng et 
al. 2013; Seigers et al. 2013). The goals of this study were to gain insight into 
82 
 
mechanisms of CICI and its potential prevention, with the long-term goal to 
progress toward prevention or at least successful management of CICI and an 
improved quality of life for an ever growing number of cancer survivors.  
 
Direct toxic effects caused by the chemotherapy drugs leads to damage to 
biomolecules including lipids, proteins, lipoproteins, and genetic material 
(Sterrenberg et al. 1984; Bagchi et al. 1995; Chen et al. 2007; Nithipongvanitch 
et al. 2007; Joshi et al. 2010; Aluise et al. 2011). Oxidative stress caused by 
anticancer drugs leads to damage to biomolecules in non-targeted, non-
cancerous tissues including the blood, heart, and brain (Chen et al. 2007).  
 
Reactive oxygen and reactive nitrogen species (ROS, RNS) include such species 
as superoxide radical anion (O2-•), nitric oxide (NO), peroxynitrite (ONOO-), and 
hydroxyl radical (HO•). Some of these have both functions essential to life and 
effects damaging to biomolecules necessary for life. O2-• is produced by 
inefficient reduction of molecular oxygen in the mitochondria (Raha et al. 2000; 
Chen et al. 2007; Barja 2013; Figueira et al. 2013). NO, a free radical, is 
produced from L-arginine by catalysis of various forms of the enzyme, nitric oxide 
synthase. Together, O2-• and NO combine to form another reactive species, 
ONOO- (Squadrito et al. 1998; Szabo et al. 2007).  Hydrogen peroxide (H2O2), 
produced through the actions of superoxide dismutases (SOD) (Fridovich 1995; 
Liochev et al. 2007), is converted to water and molecular oxygen by peroxidases 
but can result in production of HO• in the presence of iron(II) or copper(I) ions via 
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Fenton Chemistry (Fenton 1894; Haber 1932; Stadtman et al. 1991; Wardman et 
al. 1996). These radical species can cause the formation carbon centered 
radicals, alkoxyl radicals, and peroxyl radicals further damaging biomolecules 
through a free radical chain reaction (Porter et al. 1995; Pratt et al. 2011). In 
particular, this type of oxidative stress can lead to lipid peroxidation in the lipid 
bilayer and the formation of reactive alkenals such as 4-hydroxy-2-transnonenal 
(HNE), a lipid peroxidation product of the brain abundant arachidonic acid, which 
can covalently bind proteins by Michael addition to alter protein structure and 
function (Halliwell et al. 1984; Butterfield et al. 1997; Butterfield et al. 2002; 
Sultana et al. 2013). The brain is particularly vulnerable to oxidative damage due 
to relatively low antioxidant defenses, high oxygen consumption, and high 
concentrations of polyunsaturated fatty acids. 
 
Administration of the prototypical ROS generating anti-cancer drug, Dox, leads to 
oxidative damage to plasma proteins through both direct and indirect toxicity 
independent of its cancer killing ability. Dox directly continually causes oxidative 
stress in peripheral tissues by redox cycling of the quinone moiety in its structure. 
Dox-induced cardiac dysfunction in part is due to mitochondrial damage is well 
established and is used as a dose limiting criteria in treatment protocols (DeAtley 
et al. 1999; Chen et al. 2006; Jungsuwadee et al. 2006; Jungsuwadee et al. 
2012). Indirectly, Dox elevates levels of TNF-α in the blood and, subsequently, 
the brain leading to neuronal death (Tangpong et al. 2006; Aluise et al. 2011). 
Macrophages are the principal cell source of TNF-α; however, cellular targets 
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and biological effects are varied including inflammation, neutrophil activation, 
catabolism in fat and muscle, triggering the synthesis of acute-phase proteins, 
and apoptosis in many cell types. Such responses can be beneficial if acute but 
quite harmful if chronic or sustained.  
 
Under normal conditions, ApoA-I suppresses TNF-α release in plasma (Hyka et 
al. 2001; Yin et al. 2011). Once oxidized, ApoA-I loses this ability and may 
actually exacerbate TNF-α release (Aluise et al. 2011). The oxidative status of 
ApoA-I is crutial to its role in TNF-α suppression. Dox-induced ApoA-I oxidation 
and TNF-α increase is suppressed by co-administration of MESNA (Aluise et al. 
2011). MESNA is rapidly oxidized, scavenging reactive species in circulation. 
MESNA’s time in circulation is short-lived as it is rapidly renally eliminated, 
thereby, reducing the chance for potential unwanted side effects (Mashiach et al. 
2001).  
 
Oxidative stress data presented here supports the results of our previous studies. 
Dox administration leads to oxidative stress in both plasma and brain as 
evidenced by increases in both PC and protein-bound HNE. Both of these 
damages are prevented when MESNA is administered just prior to Dox. These 
results, shown for the first time in brain, confirm our prior results in plasma. 
 
Cognitive testing of saline, Dox, MESNA, and Dox+MESNA treatment groups 
revealed learning and memory impairment in animals receiving Dox alone. 
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Cognitive performance, as measured by NOR, was largely rescued in the group 
that received MESNA with Dox. Open field testing was employed as a gauge of 
locomotor activity and ability. The treatment groups receiving Dox, both with and 
without MESNA displayed less total movement than those in the saline or 
MESNA treated groups. The Dox and Dox+MESNA treatment groups displayed 
similar total movement in the test environment decreasing potential confounds 
when comparing NOR performance between these two groups. Total object 
exploration time was similar among all treatment groups and decreased with 
repeated exposure to the environment. After only 24 h post-injection, animals in 
the Dox-treated group were already showing a trend of decreased preference for 
the novel object compared to the other treatment groups. By day three, the Dox-
treated animals on average displayed a preference for the familiar object over the 
novel one. Incomplete encoding of the familiar stimulus or a discrepancy 
between the memory of the familiar object and the actual perception of the same 
object may be responsible for the apparent preference for the familiar object. 
This is compelling evidence for Dox-induced cognitive impairment. MESNA 
rescued much of this Dox-induced cognitive deficit (Figure 4.2a).  
 
H1-MRS of hippocampus of similarly treated animals revealed changes in the 
neurochemical profile in Dox-treated group versus saline control. A slight but 
significant decline in the NAA/Cr ratio was observed in the Dox group suggesting 
neuronal damage. More profoundly, MRS revealed, on average, a dramatic six 
standard deviation decline in the Cho/Cr ratio in the hippocampus of the Dox-
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treated group compared to the saline-treated group. These results are consistent 
with results from another study in which Ciszkowska-Łysoń et al. observed a 
time-related decrease in the Cho/Cr ratio following chemotherapy which they 
attributed to potential myelin damage (Ciszkowska-Lyson et al. 2003). Three 
days after Dox treatment may be too soon to see measurable myelin damage in 
brain detectable on MRS.  
 
Changes in choline-containing compounds on MRS are thought to be associated 
with membrane turnover (phospholipid synthesis and degradation) (Soares et al. 
2009; Bertholdo et al. 2013). Cho levels have been shown to be proportional to 
cell density (Gupta et al. 2000) and to correlate with degree of malignancy in 
cancers (Soares et al. 2009; Bertholdo et al. 2013). A decrease in the Cho peaks 
in brain has also been seen in brain aging as well as a decrease in choline 
uptake in older adults (Cohen et al. 1995; Dezortova et al. 2008; Soares et al. 
2009). A decrease in Cho/Cre ratio is seen as indicative of decreased cell density 
and necrosis (Gupta et al. 2000; Soares et al. 2009). Upon Dox administration, 
the decreased PCho and/or Cho is consistent with changes in the production or 
metabolism of PtdCho or the neurotransmitter, acetylcholine (ACh) (Mallampalli 
et al. 2000; Zhao et al. 2001). Due to the widespread functions of ACh in both the 
motor and somatic divisions of the autonomic nervous system, the effects of 
chemotherapy-induced changes to this neurotransmitter may be varied and 
dramatic and need to be further explored. Evidence exists that ACh-associated 
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memory, intelligence, and mood may, in part, be mediated by Cho levels and 
ACh metabolism in the brain (Poly et al. 2011).  
 
The decrease in the Cho peak in brain revealed by MRS spectra of Dox-treated 
mice may be due to decreased membrane synthesis, decreased myelination, and 
potentially cell loss. Such changes in the MRS observed, conceivably, may be 
consistent with the white matter changes seen in human breast cancer patients 
(Inagaki et al. 2007; Deprez et al. 2011; de Ruiter et al. 2012; Deprez et al. 
2012). Magnetic resonance imaging (MRI) and magnetic resonance 
spectroscopy (MRS) are proving to be useful tools both for visualization of white 
matter changes and changes in the neurochemical profile indicative of axonal 
degeneration and demyelination in the brains of living subjects following 
chemotherapy (de Ruiter et al. 2012). Indeed, the integrity of lipid-rich myelin 
covered white matter have been shown to be altered as well as damage to gray 
matter with associated functional deficits  following systemic cancer 
chemotherapy, in some cases years after chemotherapy (de Ruiter et al. 2012; 
Briones et al. 2013; Simo et al. 2013). Studies have shown that chemotherapy-
induced neuroinflammation, including increases in TNF-α, are correlated with 
changes in myelination and cognitive impairment (Briones et al. 2013). Coupled 
with neuropsychological tests, neuroimaging techniques can provide important 
information to help outline a mechanism for clinical and biochemical changes in 
the brain that results from chemotherapy and help researchers and clinicians 
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work together to decrease or prevent unnecessary cognitive decline in cancer 
patients (Correa et al. 2008; Raffa 2010; Raffa 2010). 
 
Elevated TNF-α is reported to decrease synthesis of PtdCho (Mallampalli et al. 
2000; Church et al. 2005). Our group previously hypothesized that TNF-α 
elevated in the periphery and in brain following cancer chemotherapy plays a 
central role in CICI (Joshi et al. 2005; Tangpong et al. 2006; Tangpong et al. 
2008; Aluise et al. 2010; Aluise et al. 2011). PtdCho is also the principal 
phospholipid found in high-density lipoprotein (HDL), teaming with ApoA-I in 
cholesterol transport, one of the most common constituents found in biological 
membranes. PtdCho is usually located in the outer leaflet with the choline 
headgroup exposed to the aqueous cytosolic environment playing vital roles in 
membrane-mediated cell signaling. The turnover of PtdCho has been shown to 
be accelerated in models of mitochondrial dysfunction mimicking Alzheimer’s 
Disease (AD) patterns of metabolic changes in the brain (Farber et al. 2000).  
Cleavage of PtdCho by PC-PLC yields PCho and the second messenger DAG 
whereas cleavage of PLD releases choline used in the synthesis of the 
neurotransmitter, ACh. PC-PLC plays vital roles in several cell signaling 
pathways involved in both apoptosis and cell survival and in a variety of disease 
processes. Hence, decreased DAG could severely impair normal cell signaling 
and be important for CICI. Dox-treatment severely impaired the activity of both 
PC-PLD and PLD in brain of the mouse model of chemotherapy used in this 
study. The decrease in activity of these two enzymes may, in part, explain the 
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changes in the Cho signal seen on hippocampal H1-MRS. The slight though not 
statistically significant recovery of the Cho peaks when MESNA was co-
administered with Dox may be due to protection of PC-PLC function by MESNA 
but no protection of PLD. Therefore, more studies are warranted to further 
elucidate this mechanism. 
 
Based on previous work by our group and the results of the current study, we 
propose the following expanded model for CICI over that published by our group 
previously (Aluise et al. 2011). ROS-associated chemotherapeutic agents cause 
oxidative damage to plasma proteins, including ApoA-I, and lead to peripheral 
elevation of the inflammatory cytokine, TNF-α (Tangpong et al. 2006; Aluise et al. 
2011). Unaltered ApoA-I interacts with the ATP-binding membrane cassette 
transporter A1 (ABCA1) involved in cholesterol transport (Weber et al. 2011; Yin 
et al. 2011). Given that protein structure changes when oxidized (Subramaniam 
et al. 1997), the initial interaction of ApoA-I with ABCA1 is altered when ApoA-I is 
oxidized. Hence, TNF-α would be elevated in plasma. Elevated TNF-α crosses 
the BBB leading to microglial activation, increased ROS and further TNF-α 
release in the brain, leading to mitochondrial dysfunction and subsequent 
cognitive decline (Aluise et al. 2010; Joshi et al. 2010). TNF-α inhibition of 
PtdCho synthesis may result in decreased PCho availability. Since ceramide 
couples with PCho to produce sphingomyelin (Siegel 2006), decreased PCho 
would lead to elevated ceramide. The latter is a known inducer of apoptosis 
(Geilen et al. 1997; Qin et al. 1998; De Nadai et al. 2000; Car et al. 2012; Wang 
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et al. 2012), and we previously showed elevated apoptosis in brain of Dox-
treated mice (Tangpong et al. 2007) (Figure 4.5). Dox-induced decreased PC-
PLC and PLD activities may result in dysregulation of cell survival and apoptosis 
pathways that involve PC-PLC and decreases in choline available for ACh 
synthesis via PLD. 
 
CICI severely impacts the quality of life of cancer survivors. This paper shows for 
the first time strong evidence that brain oxidative stress following Dox 
administration leads to cognitive decline, and both are rescued by MESNA. 
These studies form the basis of additional investigations to gain insights into 
CICI.  
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Figure 4.5. A pathway to apoptosis. Elevated TNF-α inhibits biosynthesis of 
PtdCho leading to decreased PC-PLC-mediated cleavage of PCho from PtdCho. 
Decreased PCho results in increased ceramide due to decreased conversion to 
sphingomyelin. Increased ceramide leads to apoptosis. (Figure designed by A. 
M. Swomley, Butterfield Laboratory, University of Kentucky). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Jeriel T. R. Keeney 2013  
92 
 
CHAPTER 5 
Prevention of mitochondrial damage in brain and oxidative 
stress in plasma of TNF-α knockout mice treated with the anti-
cancer drug doxorubicin: Implications for chemotherapy-
induced cognitive impairment (“Chemobrain”) 
 
5.1 Overview of Study 
 
Approximately fifty percent of FDA-approved anti-cancer drugs generate reactive 
oxygen species (ROS). Doxorubicin (Dox) is a prototypical ROS generating 
chemotherapeutic agent used to treat solid tumors often as part of multi-drug 
chemotherapeutic regimens. Dox produces the reactive superoxide radical anion 
(O2-•) in vivo through redox cycling between the quinone and semi-quinone 
forms. We previously reported that peripheral Dox-administration leads to plasma 
protein damage and elevation of tumor necrosis factor-alpha (TNF-α) in plasma 
and brain of mice. TNF-α elevation in brain led to further central nervous system 
toxicity including mitochondrial dysfunction, neuronal death, and cognitive 
impairment. In the present study, we demonstrate that Dox-induced oxidative 
stress is ameliorated and mitochondrial oxygen consumption rate (OCR) is 
preserved in brain of TNF-α null (TNFKO) mice. Further, we show protection 
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against Dox-related decreases in the Cho/Cr ratio determined by magnetic 
resonance spectroscopy (MRS) and phospholipase D (PLD) activity of TNFKO 
mouse brain. This study demonstrates that, in the absence of TNF-α, MRS-
indexed Cho/Cr ratio, PLD activity, and mitochondrial oxygen consumption are 
preserved in brain, and markers of oxidative stress are reduced. Together with 
results from our previous studies, these results provide strong evidence that 
TNF-α is responsible for chemotherapy-induced cognitive impairment (CICI), 
particularly by anti-cancer drugs like Dox that do not cross the BBB. These 
results have important implications for potential interventions to modulate the 
cognitive consequences of chemotherapy experienced by a large percentage of 
cancer survivors. 
 
5.2 Introduction 
 
Approximately half of FDA approved anti-cancer drugs are known to generate 
reactive oxygen species (ROS) resulting in oxidative stress (Chen et al. 2007). 
Doxorubicin (Dox), an antineoplastic anthracycline used primarily to treat solid 
tumors as part of multi-drug chemotherapy regimens, is one such ROS inducing 
chemotherapeutic agent (Handa et al. 1975; Bachur et al. 1977; Gutteridge 1984; 
Cummings et al. 1991; Deres et al. 2005; Aluise et al. 2011). The redox cycling of 
Dox between the quinone and semi-quinone forms results in production of 
superoxide radical anion (O2-•) (Handa et al. 1975; Bachur et al. 1977; 
Cummings et al. 1991). Dox-induced extracellular protein oxidation and resulting 
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toxicities are thought to be independent of the anti-tumor ability of Dox (Bernacki 
et al. 1987; Aluise et al. 2011). Oxidation of plasma proteins following Dox 
administration results in elevation of tumor necrosis factor-alpha (TNF-α) and 
oxidative and nitrosative stress in the brain, despite the inability of Dox to cross 
the blood-brain barrier (BBB) (Tangpong et al. 2006; Joshi et al. 2007; Tangpong 
et al. 2007; Tangpong et al. 2008; Aluise et al. 2010; Joshi et al. 2010).  
 
Apolipoprotein A-I (ApoA-I) plays a variety of roles including cholesterol transport 
and regulation of inflammation (Rader et al. 2008; Keeney et al. 2013). ApoA-I 
acts as the primary lipid acceptor protein in the high-density lipoprotein (HDL) 
complex for lipids such as cholesterol and phosphatidylcholine (PtdCho) (Quazi 
et al. 2011). Interaction of ApoA-I with the ATP-binding membrane cassette 
transporter A1 (ABCA1) involved in cholesterol transport (Quazi et al. 2011; 
Weber et al. 2011) results in inhibition of TNF-α release through production of a 
tristetraprolin (TTP) (Yin et al. 2011). TTP degrades the mRNA message for 
TNF-α (Yin et al. 2011). Once oxidized, ApoA-I loses the ability to inhibit TNF-α 
release (Aluise et al. 2011). Subsequently, TNF-α crosses the BBB via receptor-
mediated endocytosis to elicit microglial activation resulting in further TNF-α 
release, oxidative and nitrosative stress, mitochondrial dysfunction, and neuronal 
death (Tangpong et al. 2006; Tangpong et al. 2007; Tangpong et al. 2008; Joshi 
et al. 2010; Aluise et al. 2011). Our group has demonstrated these to be key 
events leading to chemotherapy-induced cognitive dysfunction (CICI) (Joshi et al. 
2005; Joshi et al. 2010; Aluise et al. 2011; Keeney et al. 2014). 
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Mitochondrial dysfunction induced by Dox is well established, especially in the 
heart (DeAtley et al. 1999; Chen et al. 2006; Jungsuwadee et al. 2006). Cardiac 
toxicity is used as the dose-limiting factor in Dox treatment (Tangpong et al. 
2007). Prior studies by our group demonstrated that Dox-induced mitochondrial 
dysfunction also occurs in brain via a mechanism involving nitration of the 
mitochondrial O2-• scavenger, manganese superoxide dismutase (MnSOD) 
(Tangpong et al. 2007). TNF-α and inducible nitric oxide synthase (iNOS) are 
both downstream products of the nuclear factor κ-light-chain enhancer of 
activated B-cells (NF-κB) pathway (Griscavage et al. 1996; Keeney et al. 2013). 
Mitochondrial ROS are thought to be involved in the activation of this pathway 
(Chandel et al. 2000). 
 
Brain function is energetically expensive. The brain accounts for approximately 
2% of body weight but accounts for about 20% of the body’s total energy usage, 
most of this for signaling and maintaining membrane potentials. Due to low 
stores of energy and energy substrates, the brain relies primarily on continuous 
energy production via mitochondrial respiration for normal function (Siegel 2006). 
Therefore, Dox-induced mitochondrial dysfunction would lead to cognitive 
decline. Previously, we reported that Dox administration led to cognitive 
dysfunction in mice within a few days following treatment (Keeney et al. 2014).  
In the current study, given the centrality of TNF-α in our model for CICI, we 
tested the hypothesis that in TNFKO mice, brain oxidative stress, the magnetic 
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resonance spectroscopy (MRS)-indexed neurochemical profile, and 
mitochondrial function following Dox administration would be compromised in 
contrast to that of WT mice.  
 
5.3 Methods and Materials 
 
5.3.1 Chemicals 
 
Precision Plus Protein™ All Blue Standards, BCA reagents, and nitrocellulose 
membranes were purchased from Bio-RAD (Hercules, CA, USA). Chemicals, 
proteases, protease inhibitors, and antibodies used in this study were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise noted. EnzChek® 
Direct Phospolipase C Assay Kit and Amplex® Red Phospholipase D Assay Kit 
were purchased from Invitrogen/Life Technologies (Carlsbad, CA ).  
 
5.3.2 Statistical analysis 
 
All data are presented as mean±SEM unless otherwise noted. Statistical 
analyses using GraphPad Prism 5 software were performed using ANOVA 
followed by a two-tailed Student's t-test to make individual comparisons between 
groups where relevant, with p<0.05 considered significant. The D'Agostino & 
Pearson omnibus normality test were used where appropriate.  
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5.3.3 Animals 
 
All procedures were approved by the Institutional Animal Care and Use 
Committee of the University of Kentucky in accordance with the U.S. National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. The 
animals were housed in an air-conditioned environment (22.1°C, 50.5% relative 
humidity, 12 h light-dark cycle), with free access to food and water.  
 
Male, wild-type (WT) B6C3F1/J (B6C3) mice and B6.129S6-Tnftm1Gkl/J (TNF-α 
knockout, TNFKO) purchased from the Jackson Laboratory, 2-3 months old and 
each weighing approximately 30 grams, were kept under standard conditions 
housed in the University of Kentucky Animal Facility. Doxorubicin HCl was 
purchased from Bedford Laboratories™. Mice were injected using a single 
intraperitoneal (i.p.) dose of 25mg/kg Dox or the same volume of saline as a 
control.  MRS was performed 72 h post treatment. Following MRS studies, 
animals were euthanized and blood and tissues collected for molecular or 
biochemical analysis.  
 
5.3.4 Sample preparation 
 
Protein estimation was performed using the bicinchoninic acid (BCA, Pierce) 
assay (Bradford 1976). Homogenized brain and plasma samples were diluted 
according to initial protein estimation results using 20 ug sample in isolation 
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buffer [0.32 M sucrose, 2 mM EDTA, 2mM EGTA, and 20mM HEPES pH 7.4 with 
protease inhibitors, 0.2 mM PMSF, 20ug/mL trypsin inhibitor, 4 μg/ml leupeptin, 4 
μg/ml pepstatin A, and 5 μg/ml aprotinin]. 
 
5.3.5 Slot blot assay 
 
The slot blot method was used to determine levels of protein carbonyl (PC) and 
protein-bound 4-hydroxy-2-transnonenal (HNE) in brain as previously described 
(Bernacki et al. 1987; Fang et al. 2009). For PC determination, samples were 
derivatized with 2,4-dinitrophenylhydrazine (DNPH). For HNE, samples were 
solubilized in Laemmli buffer. Protein (250 ng) from each sample was loaded 
onto a nitrocellulose membrane in respective wells in a slot-blot apparatus (Bio-
Rad) under vacuum. Membranes were blocked in 3% bovine serum albumin 
(BSA) in PBS with 0.2% (v/v) Tween-20 for 1.5 h and then incubated in primary 
antibody (anti-dinitrophenylhydrazone primary or anti-protein-bound HNE, 
respectively, each produced in rabbit, Sigma-Aldrich) for 2 h, washed three times 
in PBS with 0.2% (v/v) Tween-20 and then incubated for 1 h with secondary 
antibody (goat anti-rabbit secondary linked to alkaline phosphatase). Membranes 
were developed with 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) dipotassium 
and nitro blue tetrazolium (NBT) chloride in alkaline phosphatase activity (ALP) 
buffer, dried, and scanned for analysis. Image analysis was performed using 
Scion Image (Scion Corporation, Frederick, MD).  
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5.3.6 Isolation of brain mitochondria 
 
Mice were perfused via cardiac puncture with cold mitochondrial isolation buffer, 
the brain promptly removed, the cerebellum dissected away, and the 
mitochondria immediately isolated from the brain by a modification of the method 
described by Mattiazzi et al. (Mattiazzi et al. 2002). Brain mitochondria were 
isolated in cold mitochondrial isolation buffer, containing 0.07 M sucrose, 0.22 M 
mannitol, 20 mM HEPES, 1 mM EGTA, and 1% bovine serum albumin, pH 7.2. 
Tissues were homogenized with a Dounce homogenizer and centrifuged at 1500 
× g at 4°C for 5 min before transferring the supernatants. The pellets were 
resuspended and centrifuged at 1500 × g at 4°C for 5 min. The supernatants 
were combined and recentrifuged at 1500 × g at 4°C for 5 min. The supernatants 
were separated and centrifuged at 13,500 × g at 4°C for 10 min. Non-
synaptosomal mitochondrial fraction separation was performed using a 3%/6% 
(w/v) Ficoll gradient at 4oC prepared before use in 100 mL mitochondrial isolation 
buffer. Mitochondrial pellets were purified with a 4% Ficoll solution and the 
mitochondrial pellet was resuspended in 50 μL cold mitochondrial isolation buffer. 
This method allows rapid isolation of viable mitochondria from brain. Purity 
testing of resulting mitochondria samples was not performed due to time and 
sample volume constraints to ensure mitochondrial viability. There is a tension 
between time of processing and purity of sample obtained. Thus, the results 
obtained required a short time to obtain viable mitochondria, but in so doing, the 
results may be affected by potential interfering contaminants.  Protein 
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concentration of isolated mitochondria was determined by the Bradford assay 
(Bradford 1976).  
 
5.3.7 Bioenergetic analysis in mitochondria 
 
The XF96 Analyzer, Seahorse Bioscience (North Billerica, MA, USA) was used to 
measure bioenergetic function in mitochondria freshly isolated by differential 
centrifugation from brain of adult male C57BL6 mice. The XF96 creates a 
transient 3µl chamber in specialized microplates that allows for the measurement 
of oxygen consumption rate (OCR) in real time.  Respiration by the mitochondria 
(5 µg/well) was sequentially measured with substrate present (basal respiration) 
following conversion of ADP to ATP, induced with the addition of oligomycin. 
Next, maximal uncoupler-stimulated respiration was detected by the 
administration of the uncoupling agent FCCP. At the end of the experiment, the 
complex III inhibitor, antimycin A, was applied to completely inhibit mitochondrial 
respiration. Oxygen Consumption rate were measured four times and plotted as 
a function of cells, showing the relative contribution of oxygen consumption, ATP-
linked oxygen consumption, the maximal OCR after the addition of FCCP, and 
the reserve capacity of the cells. Seahorse assays were performed by the D.K. 
St. Clair laboratory, Graduate Center for Toxicology, Department of Radiation 
Medicine, Markey Cancer Center, University of Kentucky. 
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5.3.8 Hydrogen magnetic resonance imaging spectroscopy 
 
H1-MRS (hydrogen magnetic resonance imaging spectroscopy) was used to 
quantify neurochemical changes in the mouse hippocampus. MRI data was 
acquired on a 7T BrukerClinscan horizontal bore system (7.0T, 30cm, 300Hz) 
equipped with a triple-axis gradient system (630 mT/m and 6300 T/m/s). A closed 
cycle, 14K quadrature cryocoil allowed for a 2.8 signal to noise increase relative 
to standard coils. 
 
The mice were anesthetized with 1.3 % percent isoflorane using MRI compatible 
CWE Inc. equipment. Mice were held in place on a Bruker scanning bed with a 
tooth bar, ear bars and tape. Body temperature and respiration rate were 
monitored using equipment from SA Instruments Inc. The animals were 
maintained at 37°C with a water heating system built into the scanning bed. T2 
weighted turbo spin echo sequences (TE 40ms, TR 2890ms, Turbo 7, FOV 
20mm, 0.156 x 0.156 x 5.0 mm3) were acquired and used for the placement of 
the spectroscopy voxel. The scanning procedure took 40 min. A 2x5.5x3mm3 
PRESS spectroscopic voxels (TE 135ms, TR 1500ms, 400avg, CHESS water 
suppression) was placed to cover both hippocampi. Spectrum analysis was 
performed using jMRUI (naressi, et al. 2001) to quantify the area under 10 peaks 
in the spectrum. The creatine peak was used to normalize the choline peak. H1-
MRS scans were performed by Dr. David Powell, Magnetic Resonance Imaging 
and Spectroscopy Center, University of Kentucky Medical Center. 
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5.3.9 Phospholipase C and phospholipase D activity assays 
 
Phosphatidylcholine-specific phospholipase C (PC-PLC) and phospholipase D 
(PLD) activity assays were performed using manufacturers’ instructions provided 
with the EnzChek® Direct Phospolipase C Assay Kit and Amplex® Red 
Phospholipase D Assay Kit by Invitrogen/Life Technologies (Carlsbad, CA ).  
Fluorescence intensity for each assay was measured using a SPECTRAFluor 
Plus instrument and quantified using associated MagellanTM software by TECAN 
over a period of 24h with the kinetic peaks of the positive controls used for 
comparison. 
 
5.4 Results 
 
5.4.1 Dox administration results in increases in oxidative stress markers in 
brain and plasma of wild-type mice and plasma but not brain of TNFKO 
mice 
 
Our laboratory previously demonstrated that peripheral administration of Dox to 
WT mice caused increased global oxidative stress in plasma and brain (Joshi et 
al. 2007; Aluise et al. 2011; Keeney et al. 2014) as well as oxidative damage to 
key plasma and brain proteins (Joshi et al. 2010). The consequent Dox-induced 
elevation of plasma TNF-α resulted in elevation of TNF-α and oxidative stress in 
brain (Joshi et al. 2005; Tangpong et al. 2006; Joshi et al. 2007; Joshi et al. 
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2010; Aluise et al. 2011), which led us to examine the effects of Dox 
administration on oxidative stress in plasma and brain in a TNFKO mouse model. 
Test subjects were administered either saline or Dox. Samples were collected at 
approximately 72 h post-Dox treatment, immediately following MRS studies. PC 
levels were used as a gauge of protein oxidation (Butterfield et al. 1997), while 
lipid peroxidation product, protein-bound HNE, was used as a measure of lipid 
damage (Subramaniam et al. 1997). Confirming our prior studies, Dox 
administration resulted in elevation of oxidative stress markers, PC and protein-
bound HNE, in both plasma and brain of WT mice (Figure 5.1a-d). Dox-treated 
TNFKO mice still exhibited elevated PC levels (p<0.005, Figure 5.1a) and 
protein-bound HNE (p<0.05, Figure 5.1b) in plasma, likely due to Dox redox 
cycling. However, in brain of TNFKO mice, PC and protein-bound HNE levels 
were not found to be significantly different from levels observed in saline-treated 
mice. This result is strong evidence to support our hypothesis that TNF-α plays a 
central role in Dox-induced oxidative stress in brain. Additionally, 3-NT was found 
to be significantly elevated in both plasma and brain of Dox-treated WT mice. In 
Dox-treated TNFKO mice, 3-NT was significantly elevated in plasma but not in 
brain compared to relevant control. Baseline 3-NT was significantly higher than 
the baseline observed in WT counterparts perhaps due to activation of the NF-κB 
pathway (Schreck et al. 1992; Griscavage et al. 1996; Chandel et al. 2000; Baker 
et al. 2011; Keeney et al. 2013). In the mouse’s attempt to produce more TNF-α, 
a product of the NF-κB pathway, no TNF-α will be produced as it was genetically 
ablated. As this attempt to produce TNF-α continues, iNOS, another product of 
104 
 
NF-κB activation will consequently be produced resulting in increased production 
of NO and resulting protein nitration.  
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Figure 5.1. PC and protein-bound HNE levels in brain and plasma following 
Dox treatment in wild-type and TNFKO mice. Protein carbonyl (PC) and 
protein-bound HNE (HNE) are measures of protein oxidation and lipid 
peroxidation. Samples were collected approximately 72 h following treatment. (a) 
PC levels in plasma were significantly elevated following Dox administration in 
brain of both wild-type (WT) and tumor necrosis factor-alpha knockout (TNFKO) 
mice compared to saline-treated mice. (b) In brain, PC levels were significantly 
elevated following Dox treatment; however, PC levels in brain of TNFKO mice 
was similar to that observed in saline-treated control mice. (c, d) Dox 
administration resulted in significant elevation of protein-bound HNE in both 
plasma and brain of WT mice. In TNFKO mice, protein-bound HNE levels were 
significantly elevated in plasma; however, protein-bound HNE levels in brain 
were not significantly different than levels observed in saline-treated mice. (e) 
Dox administration resulted in significant elevation of 3-NT in plasma of both WT 
and TNFKO mice. (f) In brain, 3-NT was significantly elevated in WT but not 
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TNFKO mice compared to its relevant control. TNFKO baseline 3-NT was higher 
than WT in both brain and plasma. (n=6 per treatment group; *p<0.05, **p<0.01, 
***p<0.005, ##p<0.0001, NS=not significant). 
 
5.4.2 Dox administration results in altered oxygen consumption rate in 
brain mitochondria that is absent in TNF-α null mice 
 
Our prior studies demonstrated TNF-α-mediated mitochondrial dysfunction in 
brain as a consequence of peripheral Dox administration (Tangpong et al. 2006; 
Tangpong et al. 2007; Tangpong et al. 2008). Previously, we observed a decline 
in brain mitochondrial respiration via complex I and increases in TNF-α following 
peripheral Dox administration (Tangpong et al. 2006). In the present study, we 
used Seahorse technology to measure mitochondrial oxygen consumption rate 
(OCR) in mitochondria isolated from brain of saline-treated WT (blue circles), 
Dox-treated WT (red squares), saline-treated TNFKO (purple x’s), and Dox-
treated TNFKO (green triangles) mice (Figure 5.2a) . Basal, ATP-linked, maximal 
capacity, and reserve capacity OCR were ascertained in fresh brain mitochondria 
of each treatment group (Figure 5.2b). 
 
Consistent with our earlier study, here we observed a significant decline in 
mitochondrial respiration in brain of Dox-treated mice as indexed by OCR. 
Compared to saline-treated WT mice, Dox-treated WT mice exhibited decreased 
mitochondrial OCR at every phase measured (Figure 5.2b; basal, p<0.01; ATP-
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linked, p<0.01; maximal capacity, p<0.0001; reserve capacity, p<0.005). 
Compellingly, mitochondrial OCR observed in brain of Dox-treated TNFKO mice 
was similar to that observed in brain of saline-treated WT and saline-treated 
TNFKO mice at every phase of mitochondrial OCR measured (Figure 5.2b). This 
result supports the notion that TNF-α is a key player in mitochondrial dysfunction 
in brain following chemotherapy involving ROS generating chemotherapeutic 
agents like Dox, which cannot cross the BBB. 
 
5.4.3 Changes to the neurochemical profile following Dox administration 
the hippocampus determined by MRS  
Bilateral H1-MRS scans of hippocampus revealed a dramatic decrease in the 
Cho/Cr ratio in Dox-treated wild-type mice compared to saline-treated control 
mice (##p<0.0001, Figure 5.3) confirming our earlier studies (Keeney et al. 
2014). Similar MRS analysis of hippocampus of Dox-treated TNFKO mice 
showed significant protection in the Cho/Cr ratio over that observed in Dox-
treated wild-type mice (#p<0.0005, Figure 5.3). The Cho/Cr ratio in Dox-treated 
TNFKO mouse brain was still lower than that observed in saline-treated mice, but 
profoundly higher than that (the Cho/Cr in brain) of Dox-treated wild-type mice. 
This result also provides compelling evidence of TNF-α involvement in the Dox-
induced decrease in the Cho/Cr ratio in brain.  
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Figure 5.2. Mitochondrial function in brain following Dox treatment in wild-
type and TNFKO mice. Measurement of mitochondrial function in brain 
mitochondria using the Seahorse XF96 analyzer. 5µg of mitochondrial protein 
were plated into Seahorse Bioscience tissue culture plates and centrifuged 
before the measurement of total oxygen consumption rate (OCR). (a) OCR were 
measured four times and plotted as a function of cells under the basal condition 
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followed by the sequential addition of Oligomycin (1μg/ml), FCCP (3μM) and 
Antimycin (2µM). (b) Quantification showing the relative contribution of oxygen 
consumption, ATP-linked oxygen consumption, the maximal OCR after the 
addition of FCCP, and the reserve capacity of the mitochondria. All data are the 
Mean±SEM, of triplicate samples and are representative of 3 independent 
experiments. Seahorse assays were performed by the D.K. St. Clair laboratory, 
Graduate Center for Toxicology, Department of Radiation Medicine, Markey 
Cancer Center, University of Kentucky. 
 
 
 
Figure 5.3. H1-MRS of mouse hippocampus following Dox treatment in 
wild-type and TNFKO mice. Bilateral H1-MRS scans of hippocampus revealed a 
large decrease in the Cho/Cr ratio in the Dox-treated group compared to saline 
control mice (##p<0.0001). Dox treatment of TNFKO mice resulted in rebound of 
the Cho/Cr ratio over Dox-treated wild-type mice (#p<0.0005). H1-MRS scans 
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were performed by Dr. David Powell, Magnetic Resonance Imaging and 
Spectroscopy Center, University of Kentucky Medical Center. 
5.4.4 Dox administration to TNFKO mice results in preservation of PLD 
activity 
 
Our laboratory reported previously that Dox administration resulted in significant 
decreases in the activities of both PC-PLC and PLD in mouse hippocampus as 
determined by MRS (Keeney et al. 2014). The protection of the Cho/Cr ratio 
observed by MRS in the hippocampus of TNFKO mice (Figure 5.3) led to 
examination of the effect of TNF-α on activities on phospholipases responsible 
for the cleavage of choline and phosphocholine from PtdCho. Confirming our 
prior studies, Dox administration to wild-type mice resulted in significant decline 
in PC-PLC (Figure 5.4a) and PLD (Figure 5.4b) activity compared to saline-
treated mice (***p<0.005 and **p<0.01, respectively). 
 
The observed Dox-induced decrease in PLD activity was ameliorated when Dox 
was administered to TNF null mice (*p<0.05, Dox-treated TNFKO compared to 
Dox-treated WT) demonstrating involvement of TNF-α in Dox-induced decline of 
PLD activity in brain. PC-PLC activity was not protected in the absence of TNF-α. 
In the face of Dox-adminstration, PLD activity was restored in brain of TNFKO 
mice to a level not significantly different from saline-treated WT mice. This results 
suggests that TNF-α plays a role in Dox-induced inhibition of PLD. 
 
111 
 
 
Figure 5.4. PC-PLC, PLD activity in brain after Dox treatment in wild-type 
and TNFKO mice. Phosphatidylcholine-specific phospholipase C (PC-PLC) and 
Phospholipase D (PLD) activity in brain post-treatment presented as percent 
saline control. (a) PC-PLC activity at 22.5h of incubation, the peak fluorescence 
of the corresponding positive control in these trials, at room temperature in the 
dark. Cleavage of the assay substrate by PC-PLC yields a dye-labeled 
diacylglycerol (DAG) which fluoresces using an excitation and emission maxima 
of 509 and 516nm, respectively. Dox administration caused a significant 
decrease in PC-PLC activity compared to saline treated mice (***p<0.005). Dox 
treatment of TNFKO mice resulted in similar decrease in PC-PLC activity 
compared to saline treated mice (p<0.001). (b) PLD activity at 1h of incubation, 
the peak fluorescence of the corresponding positive control in these trials, at 
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37oC protected from light. PLD cleaves the headgroup from phospholipids 
thereby releasing the choline from PtdCho. Assay reactions involving the choline 
produce a product that fluoresces using an excitation and emission maxima of 
571 and 585nm, respectively. Dox treatment resulted in significantly decreased 
PLD activity compared to saline treated controls (**p<0.01). PLD activity was 
preserved in TNFKO mice, significantly higher than PLD activity in brain of Dox-
treated wild-type mice (*p<0.05), but not significantly different from saline-treated 
controls.  
 
5.5 Discussion 
 
Prior studies by our group have shown that Dox administration leads to 
peripheral elevation of oxidative stress markers and TNF-α followed by elevation 
of TNF-α and oxidative stress in brain despite the inability of Dox or its primary 
metabolite to cross the BBB (Tangpong et al. 2006; Tangpong et al. 2007; 
Tangpong et al. 2008; Aluise et al. 2011). Resultant CNS toxicity included 
damage to key anti-oxidant enzymes, mitochontrial dysfunction, neuronal death, 
and cognitive dysfunction (Tangpong et al. 2006; Joshi et al. 2007; Tangpong et 
al. 2007; Joshi et al. 2010; Keeney et al. 2014). A large percentage of cancer 
survivors who underwent chemotherapy experience cognitive deficits following 
chemotherapy including memory impairment, difficulty reasoning, and problems 
multi-tasking (Raffa et al. 2010). Our laboratory recently demonstrated learning 
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and memory impairment in mice following Dox administration (Keeney et al. 
2014). 
 
In the current study, we investigated the central role played by the inflammatory 
cytokine, TNF-α in a potential mechanism for CICI that occurs following treatment 
with ROS-producing anti-cancer drugs using Dox as a prototype. We observed 
that oxidative stress present in plasma and brain of Dox-treated WT mice was 
also present in plasma of Dox-treated TNFKO mice but likely due to O2-• 
produced by redox cycling of Dox (Figure 5.1c, 5.1d). However, in brain of 
TNFKO mice, oxidative stress was absent. This result demonstrates that TNF-α 
is a key player in oxidative stress in brain following chemotherapy involving ROS-
generating chemotherapy agents, even if they are unable to cross the BBB.  
 
One of the most detrimental consequences in brain of chemotherapy is damage 
to mitochondrial function (Tangpong et al. 2006; Tangpong et al. 2007; Tangpong 
et al. 2008; Joshi et al. 2010). Evidence exists of mitochondrial dysfunction as a 
potential causal factor in a variety of neurodegenerative disorders including 
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and 
Huntington’s disease (Butterfield et al. 2012; Chaturvedi et al. 2013). The brain 
has a high and constant energy requirement coupled with low energy stores. 
Mitochondria are responsible for meeting much of this energy demand (Siegel 
2006). Previously, our laboratory observed impairment of mitochondrial function 
in brain shown by a decrease in Complex I activity of the electron transport chain 
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following systemic Dox administration (Tangpong et al. 2006; Tangpong et al. 
2007). Here, using Seahorse technology, we tested the hypothesis that Dox 
administration would not alter mitochondrial respiration indexed by OCR in 
mitochondria isolated from TNFKO mice brain (Figure 5.2). Peripheral Dox-
treatment resulted in decreased mitochondrial basal and ATP-linked OCR as well 
as reduced OCR maximal and reserve capacities in mitochondria isolated from 
brain of WT mice (red, Figure 5.2b). Strikingly, mitochondrial OCR in brain of 
TNFKO mice was preserved to the level of that observed in saline-treated mice 
(purple, Figure 5.2) indicating a central role of TNF-α in the decreased 
mitochondrial function in brain present following chemotherapy.  
 
H1-MRS allows non-invasive measurement of neurochemical changes in living 
brain (Jansen et al. 2006). Previously, we observed changes in the 
neurochemical profile indexed by MRS in brain following Dox administration 
(Keeney et al. 2014). Dox-treatment resulted in dramaticly decreased Cho/Cr 
ratio in hippocampus. The hippocampus is involved in various aspects of learning 
and memory (Sarkisyan et al. 2009; Clarke et al. 2010; Goulart et al. 2010; Meck 
et al. 2013). In H1-MRS, phosphocholine (PCho) and glycerophosphorylcholine 
(GPC) are major contributors to a cluster of peaks representing choline-
containing compounds. Elevated TNF-α has been shown to inhibit synthesis of 
PtdCho, a major source of PCho and GPC in the brain (Mallampalli et al. 2000; 
Church et al. 2005). In the current study, bilateral hippocampal H1-MRS showed 
profound decreases in the Cho/Cr ratio at 72 h following Dox treatment of WT 
115 
 
mice (Figure 5.3), confirming our earlier study (Keeney et al. 2014). Similar MRS 
measurements in brain of TNFKO mice showed a significant rebound of the 
Cho/Cr ratio from levels observed in Dox-treated WT mice (Figure 5.3). Changes 
in choline-containing compounds on MRS are thought to be associated with 
membrane turnover (phospholipid synthesis and degradation) (Soares et al. 
2009; Bertholdo et al. 2013) and have been attributed to myelin damage 
following chemotherapy (Ciszkowska-Lyson et al. 2003). The absence of TNF-α 
afforded protection of the Cho/Cr ration in brain suggesting involvement of TNF-α 
in neuronal membrane damage and consistent with the oxidative stress indices.  
 
In order to gain further insight into the involvement of TNF-α in the observed 
effect of Dox on the Cho/Cr ratio indexed by MRS in brain and a potential 
mechanism of eventual CICI, our laboratory investigated the activities of 
phospholipases responsible for the cleavage of choline and phosphocholine from 
PtdCho in the brain in our TNFKO model of cancer chemotherapy. Consistent 
with our prior studies (Keeney et al. 2014), activities of both PC-PLC and PLD 
were found to significantly diminished in brain of Dox-treated WT mice at 72 h 
post-treatment (Figure 5.4). PC-PLC activity remained decreased in brain of Dox-
treated TNFKO mice. However, PLD activity was largely preserved in brain of 
TNFKO mice following Dox treatment providing evidence of TNF-α involvement 
in Dox-induced inhibition of PLD activity.  
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In addition to TNF-α-related inhibition of PtdCho biosynthesis (Mallampalli et al. 
2000), TNF-α has been linked to decline in phosphatidic acid levels, an 
intermediate of the PLD pathway (Oprins et al. 2002). PLD activity as well as the 
mRNA message for PLD have been shown to be increased during cellular 
differention and decreased during apoptosis (Nakashima et al. 1999; Jang et al. 
2008). Enzymatic activity of PLD is seen as essential to cell survival, and 
structural damage to PLD and decreased PLD activity are thought to promote 
apoptotic events (Nozawa 2002; Jang et al. 2008).  
 
Taken together, the current study has demonstrated the central role played by 
TNF-α from the plasma in elevated oxidative stress, mitochondrial dysfunction, 
and neurochemical markers of membrane damage in brain. Potential therapeutic 
modulation of elevated TNF-α in plasma conceivably could modulate the 
cognitive consequences of chemotherapy (CICI). Studies to test this notion are 
undergoing in our laboratory. 
 
 
 
 
 
 
 
Copyright © Jeriel T. R. Keeney 2013 
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Chapter 6 
Superoxide induces protein oxidation in plasma and TNF-α 
elevation in macrophage culture: Insights into mechanisms of 
neurotoxicity caused by Doxorubicin 
 
6.1 Overview of study 
Chemotherapy-induced cognitive dysfunction (CICI) is a quality of life-altering 
consequence of chemotherapy experienced by a large percentage of cancer 
survivors. Approximately half of FDA-approved anti-cancer drugs are known to 
produce reactive oxygen species (ROS). Doxorubicin (Dox), primarily used to 
treat solid tumors often as part of multi-drug chemotherapy regimens, is a 
prototypical example of an ROS-generating chemotherapeutic agent. Redox 
cycyling of Dox, in the presence of molecular oxygen, generates the superoxide 
radical anion (O2-•). Our group previously demonstrated that Dox, which does not 
cross the blood brain barrier (BBB), induced oxidative damage to plasma 
proteins leads to TNF-α elevation in the periphery and, subsequently, in brain 
following cancer chemotherapy. We hypothesize that such processes play a 
central role in CICI. The current study tested the notion that O2-• is responsible 
for Dox-induced plasma protein oxidation and TNF-α release. Addition of O2-• as 
the potassium salt (KO2) stabilized by the molecular cage of a crown ether 
(18crown6), to plasma resulted in significantly increased oxidative damage to 
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proteins, indexed by protein carbonyl (PC) and protein-bound HNE levels. We 
then adapted this protocol for use in cell culture. Incubation of J774A.1 
macrophage culture with 1 and 10 µM KO2 resulted in dramatically increased 
levels of TNF-α produced. These results are consistent with our previous results 
demonstrating increased protein oxidation and lipid peroxidation markers in 
plasma and subsequent TNF-α elevation following Dox administration in vivo and 
in macrophage culture. These findings, together with our prior results, provide 
strong evidence that O2-• is responsible for Dox-induced plasma protein oxidation 
and TNF-α release. 
 
6.2 Introduction 
More than half of the FDA approved anti-cancer drugs are known to cause 
reactive oxygen species (ROS) production (Chen et al. 2007). Doxorubicin (Dox), 
a prototypical ROS producing chemotherapeutic agent, generates the reactive 
superoxide radical anion (O2-•) via redox cycling (Handa et al. 1975; Bachur et al. 
1977; Cummings et al. 1991). Dox is a quinone containing antineoplastic 
anthracycline used commonly in multi-drug chemotherapy regimens primarily to 
treat solid tumors (Aluise et al. 2011). Our group has demonstrated that, despite 
the inability of Dox or its major metabolite to cross the blood-brain barrier (BBB), 
Dox-induced oxidative damage to plasma proteins in vivo induces the elevation 
of the inflammatory cytokine, tumor necrosis factor-alpha (TNF-α), in the 
periphery (Joshi et al. 2005; Chen et al. 2007; Aluise et al. 2011).  
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TNF-α crosses the BBB via receptor mediated endocytosis resulting in central 
nervous system toxicities including further TNF-α elevation in brain, oxidative and 
nitrosative damage to key biomolecules, mitochondrial dysfunction, and neuronal 
death (Joshi et al. 2005; Tangpong et al. 2006; Joshi et al. 2007; Tangpong et al. 
2007; Tangpong et al. 2008; Joshi et al. 2010). O2-• is considered a key reactive 
radical generated within the cell leading to protein oxidation, lipid peroxidation, 
and hydrogen peroxide (H2O2) and hydroxyl radical (•OH) production that can 
further damage biomolecules (Gutteridge 1984; McPherson et al. 2002; Halliwell 
et al. 2007). Additional biochemical complications could occur through pH 
elevation from the production of hydroxide anion, the other product of H2O2 
produced via Fenton Chemistry (Fenton 1894; Stadtman et al. 1991). The goal of 
this study was to determine if O2-• produces oxidative protein damages in plasma 
and TNF-α elevation in macrophages similar to that observed following Dox 
administration in order to further elucidate the mechanism by which Dox may 
cause chemotherapy-induced cognitive impairment (CICI). Previously, our 
laboratory demonstrated that Dox-induced oxidation of apolipoprotein A-I (ApoA-
I) in J774.A1 macrophage culture led to increased TNF-α production (Aluise et al. 
2011).  
 
To accomplish this goal, O2-• was added to plasma samples from wild-type (WT) 
mice in the form of potassium superoxide salt (KO2) in an appropriate solvent 
including a stabilizer (Valentine et al. 1975; McPherson et al. 2002; Miller 2003), 
and oxidative stress parameters, protein carbonyl (PC) and protein-bound 4-
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hydroxy-2-trans-nonenal (HNE), were measured. PC levels serve as a measure 
of protein oxidation, while protein-bound HNE, a lipid peroxidation product, 
indexes damage to lipids (Butterfield et al. 1997; Subramaniam et al. 1997). 
 
The O2-• protocol we developed for our plasma experiments was then adapted 
for use in macrophage cell culture to determine if O2-• induces Dox-like TNF-α 
consequences. Macrophages are a principal source of TNF-α production in vivo 
(Old 1976; Aluise et al. 2010), and microglial activation in brain following Dox-
induced TNF-α elevation leads to the previously mentioned central nervous 
system toxicities (Aluise et al. 2010; Raffa 2011).  
 
6.3 Methods and Materials 
6.3.1 Chemicals  
Chemicals, proteases, protease inhibitors, and antibodies used in this study were 
purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise noted. 
Precision Plus Protein™ All Blue Standards, BCA reagents, and nitrocellulose 
membranes were purchased from Bio-RAD (Hercules, CA, USA).  
 
6.3.2 Statistical analysis 
All data are presented as mean±SEM. Statistical analyses were performed using 
ANOVA (and Bonferroni's multiple comparison post-test) followed by a two-tailed 
Student's t-test to make individual comparisons between groups where 
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appropriate, with p<0.05 considered significant. Normality of data sets was tested 
using the D'Agostino & Pearson omnibus normality test where appropriate. 
 
6.3.3 Animals 
Wild-type, male, SKH1 hairless, albino mice (2-3 months old) were purchased 
from the Jackson Laboratory. Mice were kept under standard conditions housed 
in the University of Kentucky Animal Facility, and all experimental procedures 
were approved by the Institutional Animal Care and Use Committee of the 
University of Kentucky. These animals were euthanized and blood and tissues 
collected for molecular or biochemical analysis. Whole blood collected by cardiac 
puncture, was immediately collected in EDTA tubes and plasma immediately 
separated by centrifugation. 
 
6.3.4 Sample preparation 
Protein estimation was performed using the bicinchoninic acid (BCA, Pierce) 
assay. 
Homogenized plasma samples were diluted according to initial protein estimation 
results using 20 ug sample in isolation buffer [0.32 M sucrose, 2 mM EDTA, 2mM 
EGTA, and 20mM HEPES pH 7.4 with protease inhibitors, 0.2 mM PMSF, 
20ug/mL trypsin inhibitor, 4 μg/ml leupeptin, 4 μg/ml pepstatin A, and 5 μg/ml 
aprotinin]. 
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6.3.5 Slot blot assay 
The slot-blot method was used to determine levels of protein carbonyl and 
protein-bound HNE in plasma as previously described [37, 38]. For protein 
carbonyl determination, samples were derivatized with 2,4-
dinitrophenylhydrazine (DNPH). For protein-bound HNE, samples were 
solubilized in Laemmli buffer. Protein (250 ng) from each sample was loaded 
onto a nitrocellulose membrane in respective wells in a slot-blot apparatus (Bio-
Rad) under vacuum. Nitrocellulose membranes were blocked in 3% bovine 
serum albumin (BSA) in PBS with 0.2% (v/v) Tween-20 for 1.5 h and then 
incubated in primary antibody (anti-dinitrophenylhydrazone primary or anti-
protein-bound HNE, respectively, each produced in rabbit, Sigma-Aldrich) for 2 h, 
washed three times in PBS with 0.2% (v/v) Tween-20 and then incubated for 1 h 
with secondary antibody (goat anti-rabbit secondary linked to alkaline 
phosphatase). Nitrocellulose membranes were developed with 5-bromo-4-chloro-
3-indolyl-phosphate (BCIP) dipotassium and nitro blue tetrazolium (NBT) chloride 
in alkaline phosphatase activity (ALP) buffer, dried, and scanned for analysis. 
Image analysis was performed using Scion Image (Scion Corporation, Frederick, 
MD).  
 
6.3.6 Solvent selection and potassium superoxide solution preparation 
KO2 is a yellow solid that reacts readily with water and would decompose if 
exposed to water vapor or carbon dioxide in air. To avoid this, a saturated 
solution of KO2 was prepared fresh, according to the method previously 
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described (Valentine et al. 1975; McPherson et al. 2002; Miller 2003), in a 
solvent of anhydrous dimethyl sulfoxide (DMSO) containing 200mM crown ether 
(18crown6) to aid in solubility. To the prepared solvent, excess KO2 was added 
and the KO2 concentration estimated by UV-vis absorbance and using Beer’s law 
(Kim et al. 1979; Miller 2003). A saturated solution of KO2 was approximately 250 
µM under the stated conditions. Serial dilutions of this saturated solution were 
performed using the DMSO+18crown6 solvent to obtain the desired O2-• 
concentrations. 
 
6.3.7 Plasma oxidation with potassium superoxide 
KO2 was added to plasma from WT mice and incubated at 37oC for 0, 15, 30, 
and 90 min according to Table 6.1. Concentrations of 0, 0.1, 1.0, or 10 µM KO2 
were added to plasma to broadly encompass Dox concentrations used in 
previous studies. The solvent, DMSO and 18crown6, was added to all control 
incubations.  
 
 
Table 6.1. Superoxide sample treatment. Plasma samples from 2-3 months old 
WT, male, SKH1 hairless, albino mice (purchased from the Jackson Laboratory) 
were treated with 0, 0.1, 1.0, or 10 µM KO2 and incubated for 0, 15, 30, and 90 
min. 
 
124 
 
Tube# Incubation 
Time(min) 
KO2 conc  
to add (uM) 
Plasma  
Volume(uL) 
Solvent Vol (uL)  
(used for KO2) 
1 90 10 48 2 
2 90 1.0 48 2 
3 90 0.1 48 2 
4 30 10 48 2 
5 30 1.0 48 2 
6 30 0.1 48 2 
7 15 10 48 2 
8 15 1.0 48 2 
9 15 0.1 48 2 
10 0 0 (control) 48 2 
 
 
6.3.8 Macrophage stimulation with potassium superoxide 
Cell culture experiments were carried out using mouse BALB/c monocyte 
macrophage cell line (J774A.1) collected form blood. The mouse macrophage 
cell line J774A.1 (American Type Culture Collection) was cultured in Dulbecco's 
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modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum, 
streptomycin (100μg/ml), and penicillin (100U/ml). All cultures were incubated at 
37 °C in a humidified atmosphere with 5% CO2. J774A.1 macrophage cells were 
plated at a density of 5 × 105 cells/well in 48-well plates. Potassium superoxide 
(KO2) was prepared as previously described. Lipopolysaccharide (LPS; 1 μg/ml), 
KO2 (0.1µM; 1µM; 10µM) was added and the cells were incubated for 24 h. The 
supernatant was collected and levels of TNF-α (pg/ml) were determined with a 
specific ELISA kit for mouse TNF-α (R&D Systems). Macrophage culture 
experiments were performed by the D.K. St. Clair laboratory, Graduate Center for 
Toxicology, Department of Radiation Medicine, Markey Cancer Center, 
University of Kentucky. 
 
 
Figure 6.1. Experimental design: J774.A1 macrophage culture treatment 
with potassium superoxide. J774.A1 macrophages were seeded onto a 48-well 
plate at 5×105 cells/well and allowed to grow overnight under standard culture 
conditions. Preincubation of solvent, lipopolysaccharide (LPS; 1 μg/ml), KO2 
(0.1µM; 1µM; 10µM) for 1 h was performed before their addition to J774.A1 
macrophages. Supernatants were collected and analyzed for TNF-α 
concentration. 
Experimental design 
 J774A.1 
J774A.1+ Lipopolysaccharide (LPS) (1 μg/ml) – 24hours incubation 
J774A.1+ DMSO+ Crown ether 
J774A.1+KO2 (0 μM) – 24hours incubation 
J774A.1+KO2 (0.1 μM)  – 24hours incubation 
J774A.1+KO2 (10 μM) – 24hours incubation 
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6.4 Results 
6.4.1 Protocol development 
 
A variety of solvents and combinations were explored to make a stable solution 
of KO2. KO2 releases O2-• upon addition to an aqueous environment (McPherson 
et al. 2002). O2-• then reacted rapidly with water present in any solvent 
combination forming H2O2. The reaction of KO2 with water was more rapid and 
vigorous than expected. In fact, KO2 reacted with water vapor in the air during 
any attempt at weighing KO2, contrary to some methods (Olojo et al. 2005). 
Transition metals are known to influence the reactivity of dioxygen radicals 
including those present in O2-• and H2O2 (Aust et al. 1985) . Chelex removal of 
metal ions did not prevent this problem (Halliwell et al. 1986), and prior addition 
of catalase to the solvent only accelerated the reaction of KO2 with water 
presumably by reacting away the formed H2O2 and shifting the reaction 
equilibrium toward product (Stadtman et al. 1991; Lardinois 1995; Aksenov et al. 
1998). This prompted the pursuit of a suitable anhydrous solvent for KO2. KO2 is 
slightly soluble in anhydrous DMSO (Weber et al. 1977). A crown ether, 
18crown6, was used to enhance solubility and stability (Valentine et al. 1975).  
 
6.4.2 Plasma oxidation from potassium superoxide 
 
Plasma samples were treated with 0, 0.1, 1.0, or 10 µM KO2 for 0, 15, 30, and 90 
min and analyzed via slot blot to determine relative levels of PC and protein-
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bound HNE as measures of protein oxidation and lipid peroxidation, respectively 
(Butterfield et al. 1997; Subramaniam et al. 1997). PC damage to protein in 
plasma following incubation with KO2 was rapid. After 15 min incubation at 37oC, 
significant increases in PC were observed at 0.1, 1, and 10 µM KO2 (Figure 6.2a, 
***p<0.005, ***p<0.005, and **p<0.01, respectively). At 10 µM KO2, PC levels for 
each successive time point were significantly elevated over the previous one 
indicated by Bonferroni's Multiple Comparison Test.  Significant increases in PC 
in plasma were also observed at each concentration, 0.1, 1, and 10 µM, of KO2 
measured after 15 min incubation at 37oC (Figure 6.2b, ***p<0.005, ***p<0.005, 
and **p<0.01, respectively). Similar experiments were performed to assess KO2-
induced protein-bound HNE in plasma. The higher concentrations of KO2 and 
longer incubation were required to reach significant increases in protein-bound 
HNE following KO2 addition (Figure 6.2c). Decisions for moving forward were 
based on these preliminary KO2 dose-response results with varied incubation 
times. 
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Figure. 6.2. PC and protein-bound HNE levels in plasma after treatment with 
potassium superoxide. Protein carbonyl (PC) and protein-bound HNE (HNE) 
are measures of protein oxidation and lipid peroxidation. (a) PC levels were 
assessed at 15, 30, and 90 min incubations with 10 µM KO2 at 37oC. All 
incubation times tested at 10 µM KO2 and 37oC , 15, 30, and 90 min,  resulted in 
significantly increased PC compared to solvent alone (**p<0.01, ##p<0.0001, 
##p<0.0001, respectively). PC for each successive time point at 10 µM KO2 was 
significantly elevated over the previous one indicated by Bonferroni's Multiple 
Comparison Test. (b), Significant increases in PC were observed at 0.1, 1, and 
10 µM KO2 After 15 min incubation at 37oC (***p<0.005, ***p<0.005, and 
**p<0.01, respectively). (c) Protein-bound HNE was significantly elevated after 30 
and 90 min incubations with 10 µM KO2 at 37oC (*p<0.05, #p<0.001, 
respectively) but not at 15 min incubation or lower KO2 concentrations. 
 
6.4.3 Superoxide induces TNF-α elevation in macrophage culture similar to 
that seen following doxorubicin administration 
Previously, we have reported TNF-α elevation in plasma following Dox treatment 
with O2-• produced through redox cycling of Dox as the likely cause (Tangpong et 
al. 2006; Aluise et al. 2011). Here, we test our hypothesis that O2-•, administered 
as KO2, will lead to TNF-α elevation in macrophage culture similar to that 
observed following Dox administration (Aluise et al. 2011). Significantly increased 
TNF-α elevation in J774.A1 macrophage culture after incubation with KO2 for 24 
h was observed. TNF-α was increased in these cell lines following incubation 
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with 1 and 10 µM KO2 (Figure 6.3; p<*** 0.0001). Incubation of these 
macrophages with the 10 µM KO2 concentration resulted in TNF-α greater than 
treatment of the cells with lipopolysaccharide (LPS; 1 μg/ml), a known initiator of 
TNF-α transcription via nuclear factor κ-light-chain enhancer of activated B cells 
(NF-κB) (Schreck et al. 1992; Griscavage et al. 1996; Chandel et al. 2000; Baker 
et al. 2011; Keeney et al. 2013). 
 
 
Figure 6.3. TNF-α levels in macrophage culture after treatment with 
potassium superoxide. Superoxide (O2-•) induces TNF-α production in J774.A1 
macrophages. J774.A1 macrophages were seeded onto a 48-well plate at 5×105 
cells/well and allowed to grow overnight. Preincubation of solvent, 
lipopolysaccharide (LPS; 1 μg/ml), KO2 (0.1µM; 1µM; 10µM) for 1 h was 
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performed before their addition to J774.A1 macrophages. Supernatants were 
collected and analyzed for TNF-α concentration. Values are means±SEM (n=3). 
(*p<0.05, **p<0.005, ***p<0.0001 compared to solvent alone). One-way ANOVA 
(p<0.0001) with Bonferroni's Multiple Comparison Test also demonstrated these 
significant differences between groups. Macrophage culture experiments were 
performed by the D.K. St. Clair laboratory, Graduate Center for Toxicology, 
Department of Radiation Medicine, Markey Cancer Center, University of 
Kentucky. 
 
6.5 Discussion 
Prior studies by our laboratory have implicated O2-•, produced in vivo via the 
redox cycling of the chemotherapeutic agent Dox, in increased oxidative damage 
to plasma proteins, elevation of TNF-α in the periphery, followed by transfer of 
TNF-α to brain and further TNF-α elevation in the parenchyma, subsequent CNS 
toxicity including mitochondrial dysfunction, neuronal death, and chemotherapy-
induced cognitive impairment (CICI) (Joshi et al. 2005; Tangpong et al. 2006; 
Chen et al. 2007; Joshi et al. 2007; Tangpong et al. 2007; Tangpong et al. 2008; 
Aluise et al. 2010; Joshi et al. 2010; Aluise et al. 2011; Keeney et al. 2014). The 
quinone moiety within the molecular structure of Dox cycles between the quinone 
and semi-quinone, producing superoxide free radical from molecular oxygen as it 
cycles back to the quinone (Handa et al. 1975; Bachur et al. 1977; Cummings et 
al. 1991; Aluise et al. 2010; Aluise et al. 2011). The current study was 
undertaken to test the plausibility of our hypothesis that O2-• from Dox is, in fact, 
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responsible for oxidative protein damage, TNF-α elevation, and cognitive 
consequences observed following chemotherapy with ROS-producing anti-
cancer drugs, like Dox, that do not cross the BBB but result in these unwanted 
clinical signs and symptoms. 
 
In the current study, superoxide caused oxidative damage to plasma proteins in 
vitro rapidly and at small concentrations of KO2, similar to damage caused by 
doxorubicin. All incubation times tested, 15, 30, and 90 min, resulted in 
significantly increased plasma protein oxidative damage as indicated by PC 
elevation with PC at each successive time point significantly increased over the 
previous one (Figure 6.2a) (Butterfield et al. 1997). Significant PC elevation was 
observed in plasma even at the lowest concentrations of KO2 tested (p<0.005, 
Figure 6.2b). Evidence of lipid damage was also found to be elevated in KO2-
treated plasma in the form of protein-bound HNE, a product of lipid peroxidation 
(Subramaniam et al. 1997). Higher concentrations of KO2 and longer incubation 
times tested were required to reach significant increases in protein-bound HNE 
following KO2 addition (Figure 6.2c) which might reflect the negative charge of 
O2-• being slow to enter a hydrophobic environment. 
 
These results demonstrate that O2-•, when added to plasma in the form of KO2 
salt and incubated at physiologic 37oC, results protein oxidation in plasma and 
TNF-α elevation in macrophage culture similar to that observed following Dox 
administration in vivo. Together, these results are compelling evidence for O2-• 
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production as a result of Dox administration as the causative agent in the 
neurotoxicity associated with Dox  and provides useful insights into the 
mechanism of CICI caused by cancer chemotherapy with ROS-producing 
chemotherapeutic agents like Dox. 
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CHAPTER 7 
CONCLUSIONS AND FUTURE STUDIES 
 
7.1 Conclusions 
 
The works presented in this dissertation provide insights into the mechanisms of 
chemotherapy-induced cognitive impairment (CICI or “Chemobrain”) and take 
steps toward outlining a preventive strategy. These studies demonstrate the roles 
that oxidation of plasma proteins, like apolipoprotein A-I (ApoA-I), and elevation 
of the inflammatory cytokine, tumor necrosis factor-alpha (TNF-α), play in the 
neurotoxicity and cognitive impairment that occurs as a consequence of 
chemotherapy.  
 
Chemotherapy-induced cognitive impairment (CICI) is now widely recognized as 
a real and too common complication of cancer chemotherapy experienced by an 
ever growing number of cancer survivors. Approximately fifty percent of existing 
FDA-approved anti-cancer drugs generate reactive oxygen species (ROS). 
Doxorubicin (Dox) is a prototypical ROS-generating chemotherapeutic agent 
used to treat solid tumors often as part of multi-drug chemotherapeutic regimens. 
Dox produces the reactive superoxide radical anion (O2-•) in vivo through redox 
cycling between the quinone and semi-quinone forms within the Dox molecular 
structure. Dox treatment results in oxidation of plasma proteins, including ApoA-I, 
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leading to TNF-α-mediated oxidative stress in plasma and brain. TNF-α elevation 
in brain leads to further central nervous system toxicity including mitochondrial 
dysfunction, neuronal death, and cognitive impairment. Co-administration of the 
antioxidant drug, 2-mercaptoethane sulfonate sodium (MESNA), prevents Dox-
induced protein oxidation and subsequent TNF-α elevation in plasma without 
interfering with the cancer-killing ability of Dox.  
 
In studies presented in this dissertation, we measured oxidative stress in both 
brain and plasma of Dox-treated mice both with and without MESNA. MESNA 
ameliorated Dox-induced oxidative protein damage in plasma, confirming our 
prior studies, and in a new finding led to decreased oxidative stress in brain. This 
study also provides further functional and biochemical evidence of the 
mechanisms of CICI. Using novel object recognition (NOR), we demonstrated the 
Dox administration resulted in memory deficits, effects that were rescued by 
MESNA. Using hydrogen magnetic resonance imaging spectroscopy (H1-MRS) 
techniques, we demonstrated that Dox administration led to a dramatic decrease 
in choline (phosphocholine)/creatine (Cho/Cr) ratios in the hippocampus in mice. 
To better elucidate a potential mechanism for this MRS observation, we tested 
the activities of the phospholipase enzymes known to act on phosphatidylcholine 
(PtdCho), a key component of phospholipid membranes and a source of choline 
for the neurotransmitter, acetylcholine (ACh). The activities of both 
phosphatidylcholine-specific phospholipase C (PC-PLC) and phospholipase D 
were severely diminished following Dox administration. The activity of PC-PLC 
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was preserved when MESNA was co-administered with Dox; however, PLD 
activity was not protected. This study is the first to demonstrate the protective 
effects of MESNA on Dox-related protein oxidation, cognitive decline, 
phosphocholine levels, and PC-PLC activity in the brain. 
 
Further, we demonstrate that Dox-induced oxidative stress is ameliorated and 
mitochondrial oxygen consumption rate (OCR) is preserved in brain of TNF-α null 
(TNFKO) mice. Further, we show protection against Dox-related decreases in the 
Cho/Cr ratio determined by magnetic resonance spectroscopy (MRS) and 
phospholipase D (PLD) activity of TNFKO mouse brain. This study demonstrates 
that, in the absence of TNF-α, MRS-indexed Cho/Cr ratio, PLD activity, and 
mitochondrial oxygen consumption are preserved in brain, and markers of 
oxidative stress are reduced. Together with results from our previous studies, 
these results provide strong evidence that TNF-α is responsible for 
chemotherapy-induced cognitive impairment (CICI), particularly by anti-cancer 
drugs like Dox that do not cross the BBB.  
 
Additional studies presented here tested the notion that O2-• is responsible for 
Dox-induced plasma protein oxidation and TNF-α release. Addition of O2-• as the 
potassium salt (KO2) to plasma resulted in significantly increased oxidative 
damage to proteins, indexed by protein carbonyl (PC) and protein-bound HNE 
levels. We then adapted this protocol for use in cell culture. 24 h incubation of 
J774A.1 macrophage culture with 1 and 10 µM KO2 resulted in dramatically 
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increased levels of TNF-α produced. These results are consistent with our 
previous results demonstrating increased protein oxidation and lipid peroxidation 
markers in plasma and subsequent TNF-α elevation following Dox administration 
in vivo and in macrophage culture. These findings, together with our prior results, 
provide strong evidence that O2-• is responsible for Dox-induced plasma protein 
oxidation and TNF-α release. These results have important implications for 
potential interventions to modulate the cognitive consequences of chemotherapy 
experienced by a large percentage of cancer survivors. 
 
The work presented in this dissertation examined the mechanisms of cognitive 
impairment that occur following chemotherapy in a mouse model of CICI and 
probed some potential points of intervention. More specifically, this work 
elucidated further the functional and biochemical mechanisms by which 
chemotherapy-induced cognitive impairment occurs as a result of doxorubicin 
(Dox) administration, the central role of tumor necrosis factor-alpha (TNF-α) in 
these mechanisms, and the protective effects of the antioxidant drug, MESNA, 
against Dox-induced neurotoxic effects. A large percentage of current anti-cancer 
drugs, including Dox, result in increased levels of reactive oxygen species 
(ROS). Despite the inability of Dox to cross the blood-brain barrier, mounting 
evidence demonstrates CNS toxicity as a result of Dox treatment. 
 
Results of oxidative stress analyses confirmed the presence of increased 
oxidative damage to proteins in both plasma and brain following Dox treatment. 
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These data show that co-administration of MESNA not only ameliorated Dox-
induced oxidative protein damage in plasma but also led to decreased oxidative 
stress in brain. Using novel object recognition (NOR), we demonstrated the Dox 
administration resulted in memory deficits, effects that were fully rescued by 
MESNA. Further explorations of the mechanisms of cognitive deficit led us to 
measure Dox-related changes in the neurochemical profile using hydrogen 
magnetic resonance imaging spectroscopy (H1-MRS) techniques. Unilateral and 
bilateral hippocampal MRS scans in mice revealed a dramatic decrease in the 
choline(phosphocholine)/creatine ratios (Cho/Cr) following Dox treatment. 
MESNA only provided a slight, but not significant, return in these values.  So, 
why do we see a decrease in choline-containing compounds in the brain of 
subjects with CICI? The answer may lie in the choline metabolic pathways being 
altered subsequent to chemotherapy. To better elucidate a potential mechanism 
for this MRS observation, we tested the activities of the phospholipase enzymes 
known to act on phosphatidylcholine (PtdCho), a key component of phospholipid 
membranes and a source of choline for the neurotransmitter, acetylcholine 
(ACh). The activities of both phosphatidylcholine-specific phospholipase C (PC-
PLC) and phospholipase D were severely diminished following Dox 
administration. MESNA fully protected PC-PLC activity against Dox-related 
decrease, but PLD activity was not protected. These studies are the first to 
demonstrate the protective effects of MESNA on Dox-related protein oxidation, 
cognitive decline, phosphocholine levels, and PC-PLC activity in the brain.  
 
138 
 
Elevation of TNF-α occurs both in the periphery and in the brain following 
peripheral Dox administration (Tangpong et al. 2006). In this dissertation 
research, oxidative stress measures revealed, in TNF-α knockout (TNFKO) mice, 
Dox-related oxidative stress still exists in plasma as a direct consequence of 
redox cycling but is absent in brain. This is strong evidence that TNF-α is a major 
moderator of oxidative damage in brain following treatment with brain 
impenetrable-Dox. Using Seahorse technology, we demonstrated that 
mitochondrial oxygen consumption rate (OCR) in brain is severely diminished as 
a result of Dox administration. Strikingly, OCR patterns in mitochondria from 
brain of Dox-treated TNFKO mice is preserved to the level of that observed in 
saline treated mice. H1-MRS results show a partial but significant protection the 
Cho/Cr ratio in living brain of Dox-treated TNFKO mice compared to saline-
treated mice. Additionally, TNF-α is known to inhibit phosphatidylcholine 
(PtdCho) biosynthesis (Mallampalli et al. 2000). TNF-α inhibition of PtdCho 
synthesis may result in decreased PCho availability. Since ceramide couples with 
PCho to produce sphingomyelin (Siegel 2006), decreased PCho would lead to 
elevated ceramide. The latter is a known inducer of apoptosis (Geilen et al. 1997; 
Qin et al. 1998; Car et al. 2012; Wang et al. 2012), and we previously showed 
elevated apoptosis in brain of Dox-treated mice (Tangpong et al. 2007). 
Extracellular TNF-α binds and activates two main receptors, TNFR1 and TNFR2, 
that are responsible for mediating the intracellular cytokine activity. TNFR1, also 
known as the death-receptor, has an intracellular death domain (DD) known as 
TRADD (Hsu et al. 1995). Ceramide potentiates rapidly TNF-α-induced TRADD 
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recruitment and initiator caspase, caspase 8, activity. TNFR1 activation 
stimulates ceramide production and its pro-apoptotic pathways (Rath et al. 1999; 
De Nadai et al. 2000). Dox-induced decreased PC-PLC and PLD activities may 
result in dysregulation of cell survival and apoptosis pathways that involve PC-
PLC and decreases in choline available for ACh synthesis via PLD. 
 
PLD activity was fully preserved in the face of Dox treatment in brain of TNFKO 
mice. Conceivably, preservation of PtdCho production and PLD activity in the 
absence of TNF-α would maintain the Cho levels available for synthesis of ACh. 
The loss of function of ACh as an inhibitory neurotransmitter that lowers heart 
rate may, in part, explain some of the cardiac effects of Dox. These studies 
demonstrate that, in the absence of TNF-α, MRS-indexed Cho/Cr ratio, PLD 
activity, and mitochondrial oxygen consumption are preserved in brain, and 
markers of oxidative stress are reduced. Together, these results provide 
compelling evidence for the central role TNF-α in chemotherapy-induced 
mitochondrial and neuronal damage and the mechanisms of CICI. 
 
There are currently millions of cancer survivors. Thankfully, that number 
continues to grow. A large percentage of them experience cognitive symptoms 
following chemotherapy. Approximately half of the FDA-approved anti-cancer 
drugs are known to generate ROS. As with Dox, the extracellular ROS 
production appears to be independent of the cancer-killing ability of the drug. 
Preventing plasma protein oxidation and resultant TNF-α-related cardiac and 
140 
 
neurotoxic consequences may allow cancer patients to become cancer free 
without compromising quality of life. 
 
7.2 Future studies 
Based on the results in this dissertation, the following experiments may warrant 
future investigation: 
1. Due to the central involvement of ApoA-I and TNF-α in the mechanism of 
CICI, further examination of the mechanisms of their involvement are 
warranted. Unaltered ApoA-I interacts with the ATP-binding membrane 
cassette transporter A1 (ABCA1) involved in cholesterol transport, through 
the JAK2/STAT3 pathways, leads to production of tristetraprolin (TTP). 
TTP destabilizes the mRNA message for TNF-α. Examination of the 
impact of co-administration of MESNA and in TNFKO models on ABCA1 
and TTP involvement in CICI following Dox administration would further 
elucidate the mechanism of CICI. 
2. HNE preferentially binds certain amino acids (Cys, Lys, and His), thereby 
altering protein structure and function.  ApoA-I contains several such sites 
where HNE has been shown to bind in vitro. Examination of HNE binding 
sites on ApoA-I following Dox administration in vivo would provide specific 
insights into the inability of oxidized ApoA-I to inhibit TNF-α related 
consequences. 
3. More insights into definitive diagnosis, progression, and prevention of CICI 
may be elucidated using MRS and neuroimaging techniques. Gray and 
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white matter status should be examined following Dox treatment in 
TNFKO model and with co-administration of MESNA. These techniques 
non-invasively provide information of the CNS status in living systems. 
Ultimately, the author of this dissertation would like to see all 
chemotherapy patients examined for gray and white matter changes and 
MRS-indexed neurochemical profile status at every phase of treatment. Of 
course, such an appeal would be ridiculously expensive. 
4. H1-MRS does not currently allow resolution of the choline cluster of peaks 
to allow identification of individual choline-containing compounds that are 
changing following Dox administration to be identified.  More precise 
methods do exist. P31-MRS may allow these peaks to be resolved and 
individual neurochemical species to be identified. 
5. Based on MESNA protection of PC-PLC activity and protection of PLD 
activity in TNFKO in mouse brain, further examination of the impact of 
chemotherapy on choline metabolism including ACh production and 
ceramide and sphingomyelin levels is warranted. Perhaps, a combination 
of MESNA and anti-TNF antibody, administered during chemotherapy may 
completely preserve choline metabolism. 
6. VitD deficits are common, especially with advanced age. As people age, 
they tend to become more sedentary spending less time outside and 
nutritional status declines further exacerbating VitD deficiency. More 
studies are necessary to determine the effects VitD deficiency has on 
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cognition and the biochemical consequences of such deficiency. Further 
protein activity and gene studies may provide more insight. 
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APPENDIX A 
Dietary Vitamin D Deficiency in Rats from Middle- to Old-age 
Leads to Elevated Tyrosine Nitration and Proteomics Changes in 
Levels of Key Proteins in Brain: Implications for Low Vitamin D-
dependent Age-Related Cognitive Decline 
 
 
A.1 Overview of study 
 
In addition to the well-known effects of vitamin D (VitD) in maintaining bone 
health, there is increasing appreciation that this vitamin may serve important 
roles in other organs and tissues, including the brain.  Given that VitD deficiency 
is especially widespread among the elderly, it is important to understand how the 
range of serum VitD levels that mimic those found in humans (from low to high) 
affects the brain during aging from middle-age to old-age. To address this issue, 
twenty-seven male F344 rats were split into three groups and fed isocaloric diets 
containing low (100 IU/kg food), control (1000 IU/kg food), or high (10000 IU/kg 
food) VitD beginning at middle-age (12 months) and continued for a period of 4-
5months.We compared the effects of these dietary VitD manipulations on 
oxidative and nitrosative stress measures in posterior brain cortices.  The low 
VitD group showed global elevation of 3-nitrotyrosine (3-NT) compared to control 
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and high VitD treated groups. Further investigation showed that this elevation 
may involve dysregulation of the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) pathway and NF-κB mediated transcription of inducible 
nitric oxide synthase (iNOS) as indicated by translocation of NF-κB to the 
nucleus and elevation of iNOS levels. Proteomic techniques were used to 
provide insights into potential mechanisms underlying these effects. Several 
brain proteins were found at significantly elevated levels in low VitD group 
compared to the control and high VitD groups. Three of these proteins, 6-
phosphofructokinase, triosephosphate isomerase, and pyruvate kinase, are 
involved directly in glycolysis. Two others, peroxiredoxin-3 and DJ-1/PARK7, 
have peroxidase activity and are found in mitochondria. Peptidyl-prolylcis-trans 
isomerase A (PPIA or cyclophilin A) has been shown to have multiple roles 
including protein folding, regulation of protein kinases and phosphatases, 
immunoregulation, cell signaling, and redox status. Together, these results 
suggest that dietary VitD deficiency contributes to significant nitrosative stress in 
brain and may promote cognitive decline in middle-aged and elderly adults. 
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Figure A.1. Graphical Abstract, Vitamin D deficiency study. Used by 
permission from Elsevier Scientific Publishers, Inc.  
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A.2 Introduction 
 
The steroid hormone Vitamin D (VitD) can be produced by the body or obtained 
through the diet. VitD is synthesized in the skin from the cholesterol precursor, 7-
dehydrocholesterol and is converted to cholecalciferol (VitD3) upon exposure to 
sunlight (Holick 2004). VitD3 can also be obtained through several dietary 
sources and is transported in the blood via vitamin D-binding protein. In the liver, 
VitD3 is converted to calcidiol, 25-hydroxy vitamin D (25-OH VitD) followed by 
further conversion to calcitriol, 1α, 25-dihydroxy vitamin D (1α, 25-(OH)2VitD) 
primarily in the kidneys where it helps to regulate calcium 
homeostasis(Nezbedova et al. 2004; Brewer et al. 2006). VitD also plays roles in 
autoimmunity (Cantorna et al. 2004), mental health (Brewer et al. 2001; Brewer 
et al. 2006; Fernandes de Abreu et al. 2009; Farid et al. 2012; Mizwicki et al. 
2013), and inhibition of tumor growth through reductions in proliferation and 
angiogenesis(Deeb et al. 2007; Holick 2008; Holick et al. 2008; Holick 2012). 
 
VitD deficiency has long been associated with osteoporosis, brittle bones, and 
muscle weakness, but recently low levels of VitD have been linked to increased 
overall mortality (Semba et al. 2009; Zittermann et al. 2009). VitD status is 
typically assessed using serum concentration of 25-OH VitD because it is longer 
lived than the biologically active 1α, 25-(OH)2VitD (Weaver et al. 2004; Ginter et 
al. 2009; Zittermann et al. 2009). VitD deficiency is highly prevalent in Europe 
and North America (Holick 2004; Vieth et al. 2007) with the elderly particularly at 
risk (Holick 2006; Holick et al. 2008; Zittermann et al. 2009; Holick 2010; 
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Llewellyn et al. 2011). Current estimates suggest that as many as 40-100% of 
the elderly populations in these areas are VitD deficient (Holick 2007). Poor diet 
and lower exposure to UV-B from the sun limits VitD synthesis in the skin and an 
age-related decrease in the VitD synthesis machinery may contribute to the 
observed lower VitD levels (Ginter et al. 2009). 
 
The elderly represent those at greatest risk of age-related cognitive decline and 
neurodegenerative disorders (Poon et al. 2006). Recent retrospective studies on 
elderly human subjects provide correlative evidence that those with VitD 
deficiency have a much higher incidence of cognitive impairment than those with 
normal VitD levels (Przybelski et al. 2007; Llewellyn et al. 2009). Thus, it appears 
that VitD deficiency may accelerate cognitive decline in aging (Llewellyn et al. 
2010).  A recent meta-analysis also shows that patients with Alzheimer disease 
(AD)typically have lower serum concentrations of VitD (Annweiler et al. 2013). 
AD is associated with defects in amyloid-β (Aβ) processing and an upregulation 
of inflammatory cytokines and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) (Mizwicki et al. 2013).  Interestingly, 1α,25(OH)2VitD 
helped to reverse soluble Aβ and inflammatory issues (Mizwicki et al. 2013).In 
addition to these actions, VitD is neuroprotective against Ca2+-mediated 
excitotoxicity, reduces biomarkers of brain aging associated with 
Ca2+dyshomeostasis(Brewer et al. 2001; Brewer et al. 2006), and helps to 
regulate glutathione levels, a primary antioxidant in the brain, by modulating γ-
glutamyltranspeptidase activity(Garcion et al. 1999). VitD also prevents onset of 
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autoimmune demyelination in animal models of multiple sclerosis (Lemire et al. 
1991; Garcion et al. 2002). 
 
Here, we manipulated serum VitD status by dietary supplementation with low, 
moderate/control or high levels of VitD in order to identify changes in the VitD-
dependent proteome in the brains of rats from middle- to old-age. Prior studies 
have shown that cognitively impaired subjects have significant levels of 
mitochondrial dysfunction and oxidative protein damage.  In particular, nitration of 
protein resident tyrosine residues is a common marker observed in brain of 
cognitively impaired subjects (Beckman 1996; Souza et al. 2001; Castegna et al. 
2003; Butterfield et al. 2007; Feeney et al. 2012). Therefore, we tested the 
hypothesis that manipulating serum VitD levels would alter protein nitration and 
key protein markers of mitochondrial function.  Our results identify several 
possible targets of VitD action that may mechanistically link circulating VitD levels 
with risk forage-related cognitive decline. 
 
A.3 Methods and Materials 
 
A.3.1 Chemicals 
 
Criterion precast polyacrylamide gels, tris-glycine-SDS (TGS) and MES 
electrophoresis running buffers, ReadyStrip™ IPG strips, mineral oil, Precision 
Plus Protein™ All Blue Standards, SYPRO Ruby® Protein Stain, nitrocellulose 
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membranes, dithiothreitol (DTT), iodoacetamide (IA), Biolytes, and urea were 
purchased from Bio-RAD (Hercules, CA, USA). Chemicals, proteases, protease 
inhibitors, and antibodies used in this study were purchased from Sigma-Aldrich 
(St. Louis, MO, USA) unless otherwise noted.  
 
A.3.2 Animals 
 
All animal studies were approved by the University of Kentucky Institutional 
Animal Care and Use Committee and followed NIH Guidelines for the Care and 
Use of Laboratory Animals. Middle-aged (12 month old) male F344 rats, a 
standard model for studies of brain aging, were obtained from the National 
Institutes on Aging rodent colony. Four-to five-month dietary manipulation of VitD 
was carried outusing cholecalciferol (VitD3) added to an isocaloric diet in the 
following amounts (based on pilot studies intended to mimic the range of human 
levels): control VitD = 1000 IU/kg food, low VitD = 100 IU/kg food, and high VitD 
= 10,000 IU/kg food with nine animals in each group (Table A.1). Animals were 
weighed and food intake measured 2-3 times per week. Serum 25-OH VitD 
levels were monitored as a measure of circulating VitD. Dietary manipulation of 
VitD resulted in different serum levels of VitD.  Upon conclusion of the long-term 
treatment, animals were euthanatized and samples isolated from the right 
posterior corticalarea.  Samples were then stored at −80°C until needed for 
oxidative stress and expression proteomics determinations (Robinson et al. 
2011; Butterfield et al. 2012). 
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Table A.1. VitD dietary manipulation [*p < 0.0001 (one-way ANOVA)]. 
 
 Control Low High 
Weight at 12 months  480g  485g  475g  
Weight at 18 months  538g  565g  548g  
Daily Food Intake  16.5 g/day  16.4 g/day  15.9 g/day  
Daily intake of Cholecalciferol 16.5 IU/day  1.64 IU/day  159 IU/day  
*Serum levels of 25(OH)VitD 12.7 ng/mL  5.8 ng/mL  31.7 ng/mL  
 
 
A.3.3 Sample preparation 
 
Protein estimation was performed using the bicinchoninic acid (BCA, Pierce) 
assay. Homogenized cortex samples were diluted according to initial protein 
estimation results 20 µg sample in 140 µL of media-I buffer [0.32 M sucrose, 
0.6 mM MgCl2, and 0.125 M Tris pH 8.0 with protease inhibitors, 4 μg/ml 
leupeptin, 4 μg/ml pepstatin A, and 5 μg/ml aprotinin]. 
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A.3.4 Slot blot assay 
 
The slot-blot method was used to determine levels of protein 3-nitrotyrosine (3-
NT) in brain as previously described (Sultana et al. 2008; Aluise et al. 2011). For 
3-NT determination, samples were solubilized in Laemmli buffer. Protein (250 ng) 
from each sample was loaded onto a nitrocellulose membrane in respective wells 
in a slot-blot apparatus (Bio-Rad) under vacuum. Membranes were blocked in 
3% bovine serum albumin (BSA) in PBS with 0.2% (v/v) Tween-20 for 1.5 h and 
then incubated in primary antibody (anti-nitrotyrosine produced in rabbit, Sigma-
Aldrich) for 2 h, washed three times in PBS with 0.2% (v/v) Tween-20 and then 
incubated for 1 h with secondary antibody (goat anti-rabbit secondary linked to 
alkaline phosphatase). Membranes were developed with 5-bromo-4-chloro-3-
indolyl-phosphate (BCIP) dipotassium and nitro blue tetrazolium (NBT) chloride 
in alkaline phosphatase activity (ALP) buffer, dried, and scanned for analysis. 
Image analysis was performed using Scion Image (Scion Corporation, Frederick, 
MD). A negative control for nitration was performed by reducing nitrotyrosine to 
aminotyrosine according to the method of Miyagi and Crabb et al. (Miyagi et al. 
2002) as follows. One replicate membrane was treated with 10 mM sodium 
dithionite in 50 mM pyridine-acetate buffer (pH=5.0) for 1h at room temperature, 
rinsed thoroughly with nanopure water, and developed as above.  No staining of 
the membrane was observed (data not shown), indicating that the anti-3NT 
antibody was specific for this specific posttranslational modification. 
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A.3.5 Proteomics (Butterfield et al. 2012) 
 
A.3.5.1 Isoelectric focusing (IEF) 
 
Aliquots (containing 150ug of protein) of the homogenized cortical samples 
prepared above were precipitated using cold 100% trichloroacetic acid (TCA) to 
obtain a concentration of 15% (v/v) TCA in solution and incubated on ice for 15 
minutes. Samples were centrifuged at 14,000 rpm for 10 min at 4 °C. The 
resulting pellets were resuspended and rinsed four times in a cold ethanol: ethyl 
acetate (1:1 v/v) mixture. After allowing the final pellets to dry completely at room 
temperature, the pellets were rehydrated for 2 h in rehydration buffer [8 M urea, 2 
M thiourea, 50 mM DTT, 2.0% (w/v) CHAPS, 0.2% Biolytes, Bromophenol Blue] 
then sonicated for 10 s at 20% power. Each entire sample was added to an 11 
cm pH 3-10 ReadyStrip™ IPG strip in a lane of the IEF tray. After 45 min of run 
time, 2 mL of mineral oil were added to each lane to prevent evaporation. Strips 
were actively rehydrated at 20 °C for 18 h at 50 V, focused at a constant 
temperature of 20 °C beginning at 300 V for 2 h, 500 V for 2 h, 1000 V for 2 h, 
8000 V for 8 h, and finishing at 8000 V for 10 h rapidly. IPG strips were stored at 
−80 °C until needed for the second dimension of analysis.  
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A.3.5.2 Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) 
 
IEF strips were allowed to come to room temperature (~30 min) and equilibrated 
for 10 min in the dark in 4 mL equilibration buffer A [50 mM Tris–HCl, pH 6.8, 6 M 
urea, 1% (w/v) SDS, 30% v/v glycerol, 0.5% DTT] and then re-equilibrated for 10 
min in the dark in equilibration buffer B [50 mM Tris–HCl, pH 6.8, 6 M urea, 1% 
(w/v) SDS, 30% v/v glycerol, 4.5% IA]. All strips were rinsed in TGS running 
buffer to remove residual equilibration buffers before being placed onto Criterion 
precast linear gradient (8–16%) Tris–HCl polyacrylamide gels. Precision Plus 
Protein™ All Blue Standards and samples were run at a constant voltage of 200 
V for 65 min. 
 
A.3.5.3 SYPRO Ruby® staining 
 
Following 2D-PAGE, gels were incubated in 50 mL fixing solution [7% (v/v) acetic 
acid, 10% (v/v) methanol] for 20 min at room temperature. SYPRO Ruby® Protein 
Gel Stain (50-55 mL) was added to gels and allowed to stain overnight at room 
temperature on a gently rocking platform. The stain was then removed and gels 
were rinsed with deionized (DI) water and stored in 50 mL DI water in the 
refrigerator until scanning. Gels were scanned into Adobe Photoshop 6.0 with a 
Molecular Dynamics STORM phosphoimager (λex/λem: 470/618 nm) and stored in 
DI water at 4 °C. 
 
154 
 
A.3.5.4 Image analysis: differential expression 
 
Spot intensities from SYPRO Ruby®-stained 2D-gel images of cortex samples 
were quantified according to total spot density using PDQuest software (Bio-
RAD, Hercules, CA, USA). Intensities were normalized to total gel densities. Only 
low or high VitD samples with normalized spot densities that were significantly 
increased or decreased by at least 1.4-fold from control were considered for 
mass spectrometry (MS) analysis. This is a conservative cut-off criterion, but 
does greatly minimize false positives. 
 
A.3.5.5 In-gel trypsin digestion 
 
Protein spots identified as significantly altered in VitD deficient rat brain relative 
to normal VitD controls were excised from 2D-gels with new, sterilized 
micropipette tips and transferred to Eppendorf microcentrifuge tubes. Gel plugs 
were then washed with 0.1 M ammonium bicarbonate (NH4HCO3) at room 
temperature for 15 min, followed by incubation with 100% acetonitrile at room 
temperature for 15 min. Solvent was removed, and gel plugs were dried in their 
respective tubes in a biosafety cabinet at room temperature. Gel plugs were 
incubated for 45 min in 20 μl of 20 mM DTT in 0.1 M NH4HCO3 at 56 °C. The 
DTT solution was then removed and replaced with 20 μl of 55 mM IA in 0.1 M 
NH4HCO3 and incubated with gentle agitation at room temperature in the dark for 
30 min. Excess IA solution was removed, and the gel plugs were incubated for 
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15 min with 200 μl of 50 mM NH4HCO3 at room temperature. 200 μL of 100% 
acetonitrile was added to this solution in each tube and incubated for 15 min at 
room temperature. All solvent was removed, and gel plugs were allowed to dry 
for 30 min at room temperature in a biosafety cabinet. Gel plugs were rehydrated 
with 20 ng/μL of modified trypsin (Promega, Madison, WI, USA) in 50 mM 
NH4HCO3 in a shaking incubator overnight at 37 °C. Enough trypsin solution was 
added in order to completely submerge the gel plugs (approximately 10uL). 
 
A.3.5.6 Mass spectrometry 
 
Salts and other contaminants were removed from tryptic digest solutions using 
C18 ZipTips (Sigma-Aldrich, St. Louis, MO, USA), reconstituted to a volume of 
approximately15 μl in a 50:50 DI water:acetonitrile solution containing 0.1% 
formic acid. Tryptic peptides were analyzed with an automated Nanomate 
electrospray ionization (ESI) [Advion Biosciences, Ithaca, NY, USA] Orbitrap XL 
MS (ThermoScientific, Waltham, MA, USA) platform. The Orbitrap MS was 
operated in a data-dependent mode whereby the eight most intense parent ions 
measured in the Fourier Transform (FT) at 60,000 resolution were selected for 
ion trap fragmentation with the following conditions: injection time 50 ms, 35% 
collision energy, MS/MS spectra were measured in the FT at 7500 resolution, 
and dynamic exclusion was set for 120 s. Each sample was acquired for a total 
of approximately 2.5 min. MS/MS spectra were searched against the 
International Protein Index (IPI) database using SEQUEST and the following 
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parameters: two trypsin miscleavages, fixed carbamidomethyl modification, 
variable Methionine oxidation, parent tolerance 10 ppm, and fragment tolerance 
of 25 mmu or 0.01 Da. Results were filtered with the following criteria: Xcorr>1.5, 
2.0, 2.5, 3.0 for +1, +2, +3, and +4 charge states, respectively, Delta CN>0.1, 
and P-value (protein and peptide) <0.01. IPI accession numbers were cross-
correlated with SwissProt accession numbers for final protein identification 
(Robinson et al. 2011).  
 
A.3.5.7 One-dimensional polyacrylamide gel electrophoresis 
 
Sample homogenates were incubated in sample buffer (0.5 M Tris (pH 6.8), 40% 
glycerol, 8% sodium dodecyl sulfate (SDS), 20% β-mercaptoethanol, and 0.01% 
bromophenol) for 5 min in a water bath at 95°C and loaded onto precast Criterion 
TGX (4-15%) or Criterion XT (12% Bis-Tris) Precast Gels as appropriate for the 
molecular weight of the protein of interest. Precision Plus Protein™ All Blue 
Standards and samples were run at 80 V for 15 min, increasing the voltage to 
120 V and run for 90 min in TGS or MES running buffer as appropriate for the 
gel. 
 
A.3.5.8 Western Blotting 
 
In-gel proteins were transferred to a nitrocellulose membrane (0.45 μm) using a 
Trans-Blot® TurboTM Blotting system at 25 V for 30 min (BioRAD, Hercules, CA, 
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USA). After transfer, membranes were incubated in blocking solution [3% BSA in 
phosphate buffer (PBS) solution with 0.2% (v/v) Tween 20] at room temperature 
for 1.5 h. Membranes were then incubated with rabbit anti-inducible nitric oxide 
synthase (iNOS) antibody (Calbiochem/Millipore, Billerica, MA) or rabbit anti-NF-
κB antibody (Enzo, Farmingdale, NY) for 2 h on a gentle rocking platform, 
followed by three rinses for 5 min each with PBS solution with 0.2% (v/v) Tween 
20. Blots were then incubated for 1 h with ECL anti-rabbit IgG, horseradish 
peroxidase-linked whole antibody. The resulting blots were rinsed three times for 
5, 10, and 10 min each in PBS solution with 0.2% (v/v) Tween 20 and signals 
were detected using ClarityTM Western ECL Substrate (BioRAD) and the 
ChemiDocTMMP Imaging System (BioRAD).Blots were stripped using Re-blot 
Plus Strong Solution (Millipore, Billerica, MA, USA) according to package 
instructions and re-probed with mouse anti-actin antibody (Sigma-Aldrich, St. 
Louis, MO) or mouse anti-histone H2B antibody (Chemicon, Temecula, CA) for 
normalization. Analysis was performed using the ImageLab software (BioRAD). 
 
A.3.5.9 Validation 
 
Proteomics results were validated by IEF and 2D-PAGE as described above 
followed by Western blot (Robinson et al. 2011) for peroxiredoxin 3 (PrxIII) and 
1D-gel electrophoresis followed by Western blot for peptidyl-prolylcis-trans 
isomerase A (PPIA or cyclophilin A). PrxIII blots were probed for PrxIII as 
described above using rabbit polyclonal to PrxIII primary antibody (Abcam, 
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Cambridge, MA, USA), mouse anti-actin primary antibody and anti-rabbit whole 
molecule IgG alkaline phosphatase oranti-mouse whole molecule IgG alkaline 
phosphatase secondary antibody respectively. The resulting blots were 
developed colorimetrically with a solution of BCIP combined with NBT in ALP 
buffer [0.1 M Tris, 0.1 M NaCl, 5 mM MgCl2 · 6 H2O (pH 9.5)]. Developed blots 
were allowed to dry overnight at room temperature and scanned into Adobe 
Photoshop 6.0 using a Canon CanoScan 8800F scanner. The resulting images 
were analyzed using Image Quant software. PPIA blots were probed for PPIA by 
incubation with anti-cyclophilin A rabbit antiserum (Upstate/Millipore, Billerica, 
MA, USA, ) primary antibody  and ECL anti-rabbit IgG, horseradish peroxidase-
linked whole antibody and developed chemiluminescently as described above. 
PPIA blots were stripped and re-probed for the actin. Analysis was performed 
using the ImageLab software (BioRAD). 
 
A.3.6 Statistical analysis 
 
All data are presented as mean±SD or mean±SEM, and statistical analyses were 
performed using a two-tailed Student's t-test or ANOVA where indicated, with 
p<0.05 considered significant for spot comparison. A Mann–Whitney U statistical 
analysis was performed to determine the significance of differential expression 
fold-change values, where a p<0.05 was considered significant. Significance was 
also confirmed using a Student's t-test. Only spots that were significant by both 
tests were further evaluated. Protein and peptide identifications obtained with the 
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SEQUEST search algorithm with a p< 0.01 were considered as statistically 
significant. To further validate PD-Quest analysis, identities of protein spots were 
verified matching calculated molecular weight (MW) and isoelectric point (pI) 
values from MS results and SwissProt database information to spot locations on 
the gels (Table A.2 and Figure A.2). 
 
Table A.2. Brain protein identifications in VitD deficiency based on MS/MS 
results and in-gel spot locations. 
 
SSP Protein Identification Score Coverage Unique 
Peptides 
MW 
[kDa] 
CalcpI 
5201 Triosephosphate isomerase 67.52 48.59 10 26.8 7.24 
8103 Pyruvate kinase isozymes 
M1/M2 
241.21 50.85 21 57.8 7.06 
6701 6-phosphofructokinase type 
C 
69.17 19.54 11 85.7 7.28 
3207 Peroxiredoxin 3 154.94 33.85 6 28.3 7.55 
4201 DJ-1/PARK7 61.73 58.20 11 20.0 6.77 
8104 Peptidyl-prolyl cis-trans 
isomerase A(cyclophilin A) 
56.18 28.66 7 17.9 8.16 
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Figure A.2. Representative 2D gels used for proteomics identification of 
differentially expressed proteins. Brain samples of rats fed a control, low-VitD, 
or high-VitD diet from middle age to old age were separated by IEF using IPG 
strips pH 3–10 followed by SDS–PAGE using 8–16% Tris–HCl gels. Separated 
proteins were visualized with SYPRO Ruby protein gel stain. Acquired images 
were analyzed using PDQuest software and spots showing different intensities 
were chosen for further analysis. A comparison of the PrxIII spot as a 
representative of those found with significant expression differences in low vs 
control VitD groups as identified by PDQuest analysis is shown. Below are 
expansions of the spot images showing clearly that the PrxIII level is elevated in 
brain of rats on a chronic low-VitD diet. Used by permission from Elsevier 
Scientific Publishers, Inc. 
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A.4 Results 
 
A.4.1 Vitamin D deficiency leads to increased nitrosative protein damage in 
brain. 
 
Tyrosine nitration is a common indicator/biomarker of the aging brain and of age-
related neurodegenerative disorders (Souza et al. 2001; Castegna et al. 2003), 
both of which typically are accompanied by different extents of cognitive deficit.  
Here, we tested for indicators of oxidative and nitrosative stress in brain tissue 
samples from rats in which we manipulated serum VitD levels from middle-age to 
old-age. Significantly increased global 3-NT (Figure A.3) in the brains of rats on a 
low VitD diet compared to rats on control or high VitD diets was observed.3-NT 
measures of brain samples from rats fed high VitD diets were similar to the 
control group. No significant differences were observed for the other oxidative 
stress parameters measured. 
 
A.4.2 VitD deficiency elevation of peroxidases, glycolytic enzymes, and 
PPIA. 
 
In order to determine changes, possible causes, consequences, or mechanisms 
for the elevated nitrosative stress, expression proteomics experiments 
(Butterfield et al. 2012) were performed on brain of rats fed a low VitD, control, or 
high VitD diet to determine which proteins were altered. PDQuest analysis was 
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performed on all groups as well. Only spots that were found to be statistically 
different in relative intensity by statistical tests were further evaluated. Compared 
to control, the high VitD group was similar to control in terms of protein levels for 
easily discernible protein spots. In contrast, a number of protein spots with 
significant differences in intensity were found between the control and low VitD 
groups. Table A.3 shows the PDQuest software generated I.D. numbers (SSP) of 
these protein spots. Spot intensities between control and low VitD groups were 
used to calculate fold changes reflecting significant increases in protein amounts. 
These proteins were identified by MS/MS and database interrogation as 6-
phosphofructokinase (6-PFK) type C, PPIA, triosephosphate isomerase (TPI), 
PrxIII, DJ-1/PARK7, and pyruvate kinase (PK) isozymes M1/M2 (Table A.3). 
 
 
 
Figure A.3. Slot-blot analysis of 3-NT levels in rat brain homogenates. Slot-
blot analyses were performed using brain samples of rats fed a control, low-VitD, 
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or high-VitD diet from middle age to old age (n=9). Data show a significant 
increase in 3-NT levels in rat brains between control and low-VitD diet (*p<0.01). 
No difference was observed in high-VitD diet compared to control. High-VitD diet 
decreased 3-NT levels compared to low-VitD diet (**p<0.05). Used by permission 
from Elsevier Scientific Publishers, Inc. 
 
Table A.3. VitD 2D-Gel Comparison PDQuest Data: spot matching Low VitD 
(L) vs. Control (C), Levels. (SSP=PDQuest software-generated ID numbers). 
 
SSP Fold Change  Direction of  change L vs C  p-value L vs C 
6701 1.41 Increased  0.0114 
8104 2.49  Increased  0.0130 
5201 60.3  Increased  0.0291 
3207 1.53  Increased  0.0347 
8103 1.48  Increased  0.0373 
4201 1.53  Increased  0.0473 
 
 
To validate protein identity from proteomics, 2D and 1D Western blots were 
performed, selecting PrxIII and PPIA as representative proteins. 2D Western 
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blots showed a 1.5-fold increase in PrxIII levels confirming the 1.5-fold increase 
suggested by 2D-PAGE. Further, the position of the PrxIII spot appears at 
approximately 26 kDa and 7.2 pI on 2D Western blot (Figure A.4). 1D Western 
blot showed a 2.24-fold increase in PPIA levels, further validating the 2.49-fold 
increase seen in the proteomics results (Figure 4). These validation results 
provide confidence in the proteomics identification of other proteins reported in 
this study. 
 
 
 
Figure A.4. Validation of expression proteomics results for PrxIII by 2D 
Western blot analysis. Depicted are representative blots showing a 1.5-fold 
increase in PrxIII in brain samples of rats fed the low-VitD diet from middle age to 
old age compared to those fed the control diet. Circled spots are PrxIII from 
control-VitD brain samples shown on the left and low-VitD brain samples on the 
right. Used by permission from Elsevier Scientific Publishers, Inc.  
165 
 
A  
B  
 
Figure A.5. Validation of expression proteomics results by 1D Western blot 
analysis of PPIA levels. 1D Western blot analysis was used to determine PPIA 
levels of brain samples of rats fed a control or low-VitD diet from middle age to 
old age (n=9). (A) Analysis using a specific antibody against PPIA showed a 
2.24-fold increase in PPIA levels in brain of the low-VitD group compared to 
control (*p<0.01). This result confirms the increase in PPIA levels found by 
expression proteomics. (B) Representative lanes from 1D Western blot showing 
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probes for PPIA and the actin loading control. Used by permission from Elsevier 
Scientific Publishers, Inc. 
 
A.4.3 VitD deficiency leads to NF-κB activation and increased iNOS levels 
in brain. 
 
Preliminary results of this study coupled with previous studies in our laboratory 
and existing literature led us to propose a model to connect the observed 
increases in nitrosative protein damage and expression proteomics results 
showing elevated levels of the above mentioned peroxidases, glycolytic 
enzymes, and PPIA to VitD deficiency (Figure A.6). Based on this proposed 
model, we examined the hypothesis that VitD deficiency would lead to increased 
NF-κB activation and iNOS levels, resulting in the observed increase in protein 
tyrosine nitration seen in the low-VitD group compared to control.   
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Figure A.6. Potential mechanism for the biochemical consequences of VitD 
deficiency. Circled areas indicate data collected in this study. Increased tyrosine 
nitration was found by slot-blot analysis, increased iNOS levels were found by 1D 
Western blot analysis, and elevation of glycolytic enzymes and peroxidases was 
found by expression proteomics using brain samples of rats fed a control or low-
VitD diet from middle age to old age. Items in large type are the most potentially 
damaging agents in this diagram. Used by permission from Elsevier Scientific 
Publishers, Inc.  
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NF-κB is a redox-sensitive nuclear transcription factor that can be activated by 
oxidizing agents such as H2O2 (Schreck et al. 1992). Hypoxic activation of NF-κB 
and gene transcription has been found to require mitochondrial ROS (Chandel et 
al. 2000).  Among downstream products of NF-κB pathway activation are tumor 
necrosis factor-α (TNFα) and iNOS (Griscavage et al. 1996; Chandel et al. 2000; 
Feo et al. 2009). Using 1D Western blotting, we investigated whether NF-κB 
activation of iNOS expression may be a plausible reason for the nitration of 
tyrosine residues through overproduction of NO. (Kim et al. 1999; Akama et al. 
2000; Fitzgerald et al. 2007; Tangpong et al. 2007; Tangpong et al. 2008) seen in 
these samples. 
 
Under normal conditions, NF-κB exists in an inactive form bound to inhibitor of 
kB-α (IkB-α). Upon activation of a Toll-like receptor by a variety of substrates 
including lipopolysaccharide (LPS) and TNFα (Chagas et al. 2012), 
phosphorylation of IkB-α occurs through IkB kinase (IKK) allowing IkB-α 
proteasomal degradation and NF-κB activation. NF-κB is translocated to the 
nucleus leading to bursts of iNOS activation, subsequent NO. elevation (Akama 
et al. 2000; Feo et al. 2009), and further transcriptional activation of the TNFα 
gene(Kim et al. 1999; Baker et al. 2011). Pro-inflammatory cytokines such as 
TNFα lead to further and rapid phosphorylation of IkBs (Pomerantz et al. 2002). 
Overproduction of NO. as a consequence of iNOS activation results in protein 
nitration events and further stimulation of IKK  (Mendes et al. 2002; Feo et al. 
2009). 1α, 25-(OH)2VitD has been shown to interfere with these processes 
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through decreasing TNFα levels and TNFα-induced inflammatory cytokines 
(Furman et al. 1996; Giulietti et al. 2007; Diaz et al. 2009), down-regulating Toll-
like receptors (Sadeghi et al. 2006), up-regulating IkB-α, decreasing IkB-α 
phosphorylation, and decreasing translocation of NF-κB (Chagas et al. 2012), 
thereby reducing many downstream consequences. Further decrease of NF-κB 
action may occur through the suppression of NF-κB-directed expression by the 
VitD responsive element (Haussler et al. 2008). Thus, VitD can inhibit protein 
nitration in the brain via its suppressive effects on the NF-κB pathway. VitD 
deprivation may exacerbate NF-κB-directed nitrosative damage and subsequent 
neurodegenerative consequences. As an estimate of NF-κB activity, subcellular 
fractionation was done on control and low VitD brain samples. NF-κB levels were 
found to be significantly decreased in the cytosolic fraction and significantly 
increased in the nuclear fraction of the low VitD group compared to control 
(Figure A.7) indicating NF-κB translocation to the nucleus.  
 
Our analysis further revealed a significant increase in iNOS levels in the low VitD 
samples compared to control (Figure A.8). These NF-κB and iNOS results 
provide evidence to support the proposed mechanism of protein nitration due to 
VitD deficiency. TNFα is one of several initiators of the NF-κB activation cascade. 
1D Western blot analysis of these samples for TNFα showed a trend toward 
increase (data not shown) in the low VitD group compared to control consistent 
with NF-κB activation and iNOS elevation. Figure A.9 depicts a suggested 
mechanism for the protein nitration regulatory effects of VitD in brain. 
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A 
 
B 
 
 
Figure A.7. Effect of VitD deficiency on NF-κB subcellular localization in rat 
brain. 1D Western blots were used to determine the NF-κB (p65) levels in the 
cytosolic and nuclear fractions of brain samples of rats fed a control or a low-VitD 
diet from middle age to old age (n=9). The NF-κB (p65) subunit is common in the 
NF-κB signaling pathway. NF-κB (p65) levels in the cytosolic fraction were 
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normalized to β-actin, and NF-κB (p65) levels in the nuclear fraction were 
normalized to histone H2B. (A) A decrease in NF-κB (p65) in the cytosolic 
fraction (*p<0.05) and increase in the nuclear fraction (**p<0.05) in brain samples 
from the low-VitD group compared to control is observed, indicative of NF-κB 
activation and translocation. (B) Representative bands from 1D Western blot are 
shown here side by side for comparison. Nuclear and cytosolic fractions were 
alternated across all gels. Blots were probed for NF-κB (p65), stripped, probed 
for β-actin, and then stripped and probed for histone H2B. Used by permission 
from Elsevier Scientific Publishers, Inc. 
 
A 
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Figure A.8. Effect of VitD deficiency on iNOS levels in rat brain. 1D Western 
blot was performed to compare iNOS levels between brain samples of rats fed a 
control or a low-VitD diet from middle age to old age (n=9). iNOS signals were 
normalized to β-actin. (A) iNOS levels were significantly higher in brain samples 
from the low-VitD group compared to control (*p<0.01). (B) Representative lanes 
from 1D Western blot. Used by permission from Elsevier Scientific Publishers, 
Inc. 
 
A.5 Discussion 
 
We have previously shown that tyrosine nitration occurs early in 
neurodegenerative processes, i.e., in mild cognitive impairment (MCI), arguably 
the earliest form of AD (Butterfield et al. 2007).  Nitration of tyrosine occurs from 
the reaction NO.  with the O2-.through the reactive intermediate ONOO-in the 
presence of CO2 (Beckman 1996; Labetoulle et al. 2001) leading to tyrosine 
nitration by NO2. radical. Nitrosative stress measures on these cortical samples 
showed approximately a 25% elevation of 3-NT globally in brain protein in the 
low VitD group versus the control and high VitD-treated groups. 
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Figure A.9. Proposed mechanism for the protein nitration regulatory effects 
of VitD in brain based on recent literature and results from the current 
study. Results obtained from this study are marked with dark green arrows. The 
deficient serum levels of VitD in the low-VitD group in brain led to decreased NF-
κB in the cytosolic fraction, increased NF-κB in the nuclear fraction, iNOS 
elevation, increased protein tyrosine nitration, and elevations in mitochondrial 
and regulatory proteins. Used by permission from Elsevier Scientific Publishers, 
Inc. 
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A.5.1 Glycolytic enzymes targeted by low VitD 
 
The brain proteins identified by proteomics in the present study to be at 
increased levels (Table A.2) fall primarily in the following functional categories: 
glycolysis, mitochondrial peroxidase activity, and protein folding. Three of these 
proteins, 6-PFK, TPI, and PK, are enzymes involved in the production of ATP in 
the cell during glycolysis in response to the need for energy. PK catalyzes the 
conversion of phosphoenolpyruvate (PEP) to pyruvate transferring a phosphate 
group from PEP to ADP to produce ATP. Pyruvate, NADH, and H+ from 
glycolysis continue onto the tricarboxylic acid (TCA) cycle for further ATP 
production. PK has been identified by redox proteomics as oxidatively modified in 
brain regions, such as cortex and hippocampus, during brain aging (Poon et al. 
2006; Perluigi et al. 2010) and neurodegeneration resulting in reduced enzymatic 
activity (Reed et al. 2008). 6-PFK catalyzes a key regulatory step, the conversion 
of fructose-6-phosphate to fructose-1,6-bisphosphate at the expense of ATP, 
committing the path of glucose through glycolysis. This rate-limiting glycolytic 
enzyme was found by Tang and colleagues to be upregulated in several 
biological systems as part of the oxidative stress response including the 
response to H2O2 induced oxidative stress (Tang et al. 2012). TPI catalyzes the 
interconversion of the trioses, glyceraldehyde-3-phosphate (G3P) and 
dihydroxyacetone phosphate (DHAP). Significant increases of TPI have been 
found by our group using proteomic analysis in the Alzheimer’s disease 
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hippocampus (Sultana et al. 2007).  Further studies identified TPI as significantly 
nitrated in the inferior parietal lobe (IPL) in early AD brain (Reed et al. 2009) and 
in both AD hippocampus and IPL (Sultana et al. 2006). Dysfunction of this 
enzyme leads to the buildup of a toxic species, methylglyoxal, leading to 
neurodegenerative consequences (Sultana et al. 2009; Pun et al. 2012).Thus, 
metabolic effects in brain are evident from the effect of a low-VitD diet. 
 
A.5.2 Other identified targets of VitD deficiency (DJ-1, PPIA, PRXIII) 
 
Mutations of the DJ-1 gene are believed to be one possibility that leads to 
Parkinson disease (PD) (van Duijn et al. 2001).  DJ-1 is thought to be involved in 
cell cycle regulation, gene transcription, spermatogenesis, and the cellular stress 
response (Bonifati et al. 2004) among other functions. Evidence exists that DJ-1, 
in response to oxidative stress, may have roles as an anti-oxidant (Mitsumoto et 
al. 2001; Mitsumoto et al. 2001) and a redox sensitive chaperone (Zucchelli et al. 
2009; Foti et al. 2010).  Accordingly, elevation of DJ-1 in brain could be a 
consequent cell-stress response to elevated protein nitration. 
 
PPIases regulate activity of target proteins to which they bind by catalyzing the 
cis-trans isomerization of proline of these target proteins(Andreotti 2003; Sarkar 
et al. 2007), typically a rate limiting step in protein folding. PPIA, or cyclophilin A, 
is also known to play a variety of roles from immunoregulation to cellular 
signaling and proliferation, but more recently has been identified as a potential 
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marker of inflammation in a variety of disease states (Zhang et al. 2001; Satoh et 
al. 2008; Satoh et al. 2010; Bannon et al. 2012; Ramachandran et al. 2012) and 
may play a regulatory role in the NF-κB pathway in some cell types (Sanchez-
Tillo et al. 2006; Bahmed et al. 2012). In addition, PPIA treatment was shown to 
reduce reactive oxygen species (ROS) and alleviate some forms of Aβ-induced 
neurotoxicity in PC12 cell culture while maintaining activities of certain key anti-
oxidant enzymes including SOD (Ge et al. 2009). PPIA binds Prxs and activates 
their peroxidase activity acting as an immediate electron donor (Lee et al. 2001). 
PPIA may also indirectly stimulate PrxIII, a downstream consequence of tumor 
necrosis factor-α (TNFα) (Regent et al. 2011).   
 
PrxIII is a mitochondria resident,  thioredoxin-dependent peroxide reductase that 
acts to scavenge as much as 90% of H2O2in mitochondria, with GPx 1 and 4 and 
PrxV thought to account for the rest (Netto et al. 1996; Kang et al. 1998; Rhee et 
al. 1999; Bentley et al. 2008; Jones 2008; Cox et al. 2010). Rhee and colleagues 
elegantly showed that peroxiredoxin over expression inhibited NF-κB (Rhee et al. 
1999), and over expression of PrxIII has been shown to protect against H2O2-
dependent apoptosis in cancer cells (Nonn et al. 2003). Further, PrxIII was 
shown to be essential in maintaining normal mitochondrial homeostasis (Wonsey 
et al. 2002). Dysfunctional PrxIII leads to increased ROS and subsequent DNA 
damage and apoptosis linked to loss of peroxidase activity in mitochondria 
(Mukhopadhyay et al. 2006). Prxs have been shown to detoxify peroxynitrite, 
thereby decreasing biomolecule damage caused by more reactive products of 
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ONOO- and protecting human cells in culture from iNOS-related cell death (Bryk 
et al. 2000). 
 
Tyrosine nitration can and does have functional consequences on the affected 
proteins (Labetoulle et al. 2001; Ischiropoulos 2009; Feeney et al. 2012). Steric 
hindrance by the NO2 groupin the 3-position of tyrosine may prevent 
phosphorylation at the 4-position thereby causing dysregulation of 
activation/deactivation processes in the affected proteins (MacMillan-Crow et al. 
1998; Tangpong et al. 2008; Ischiropoulos 2009; Surmeli et al. 2010; Feeney et 
al. 2012; Frau et al. 2012). Such considerations have implications for cognitive 
dysfunction following low dietary VitD.   
 
A.5.3 Consequences of low dietary VitD 
 
Based on this experimental evidence, the biochemical consequences of low 
dietary VitD include increased 3-NT in the brain as well as increases in certain 
proteins with peroxidase activity. A likely link between these two pathways is O2-. 
(Figure A.6). The high O2 usage in energy metabolism coupled with age-related 
decreases in the efficiency of these reactions results in the production and 
leakage of O2-. from the electron transport chain. MnSOD in the mitochondria 
react with O2-. producing H2O2. NO. reacts with O2-. by radical-radical 
recombination producing the potentially more reactive species, ONOO-, that 
leads to the nitration of tyrosine (Beckman 1996; Squadrito et al. 1998; Koppal et 
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al. 1999; Butterfield et al. 2011) residues, hindering protein activity regulation by 
sterically blocking the phosphorylation site. The findings of this study are 
consistent with current literature hypothesizing that oxidative damage during the 
aging process leads to mitochondrial dysfunction (Perluigi et al. 2010; Tang et al. 
2012). Increased glycolytic enzymes could be a compensatory mechanism 
reflecting changes in energy production, changes in mitochondrial redox status, 
and oxidative stress (Tang et al. 2012) reminiscent of the Warburg effect in 
cancer (Warburg et al. 1924; Warburg 1930; Vander Heiden et al. 2009; Sotgia et 
al. 2012). 
 
Collectively, these results reflect a change in mitochondrial redox potential, 
glucose metabolism, and structural changes in proteins. Data from the current 
study are consistent with recent findings that VitD: a) increases SOD activity, b) 
decreases levels of endogenous oxidants, c) attenuates H2O2 induced changes, 
d) decreases release of inflammatory cytokines, and e) may have natural anti-
oxidant and anti-inflammatory properties (Halicka et al. 2012; Tukaj et al. 2012). 
In contrast, VitD deficiency contributes to inflammation through increased 
production of inflammatory cytokines, effects that are attenuated by 
1,25(OH)2VitD supplementation (Muller et al. 1992; Zhu et al. 2005; Zittermann et 
al. 2009; Farid et al. 2012).  
 
More recently, VitD has been shown to play potential roles in CNS homeostasis 
(Lefebvre d'Hellencourt et al. 2003). The VitD receptor (VDR) is expressed in 
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microglia, and 1α-hydroxylase, the enzyme that converts 25-OH VitD to 1α, 25-
(OH)2VitD, is present in activated but not resting microglia  (Neveu et al. 1994; 
Garcion et al. 1998; Garcion et al. 2002; McCarty 2006). In activated microglia, 
1α,25(OH)2VitD suppresses the production of NO. and the inflammatory 
mediators, TNFα and interleukin-6 (IL-6), in a dose-dependent manner 
suggesting direct anti-inflammatory roles for VitD in the brain (Lefebvre 
d'Hellencourt et al. 2003). Local conversion of VitD to the active 1α,25(OH)2VitD 
in the brain may be a direct neuroprotective response to CNS inflammation 
followed by inhibition of NF-κB related iNOS induction (Garcion et al. 1998).NF-
κB leads to mitochondrial dysfunction inhibition of MnSOD through nitration via 
activation of iNOS, an effect that is absent in iNOS knockout animal models 
(Tangpong et al. 2007). 
 
Our data are consistent with existing evidence that sufficient VitD is known to be 
anti-inflammatory and to suppress the NF-κB cellular stress response pathway 
(Yu et al. 1995; Cohen-Lahav et al. 2006; Haussler et al. 2008; Chagas et al. 
2012; Minelli et al. 2012). Hydrogen peroxide (H2O2) has been shown to 
modulate NF-κB activity thereby helping to regulate NF-κB-dependent processes 
including inflammation (Schreck et al. 1992; Li et al. 2001; Wang et al. 2002; 
Oliveira-Marques et al. 2009).  During inflammatory events in the CNS, iNOS 
generates excessive amounts of NO.. This increased activity of iNOS and 
resulting overproduction of NO. may occur in brief bursts. In rat models with 
experimental allergic encephalomyelitis (EAE), Garcion and colleagues showed 
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that 1α,25(OH)2VitD inhibited the iNOS increases (Garcion et al. 1997). VitD 
restriction led to slight worsening of clinical symptoms (Garcion et al. 2003).  
Nitration of protein resident tyrosine residues also occurs during brain aging 
leading to mitochondrial dysfunction and neurodegeneration (MacMillan-Crow et 
al. 1998; Anantharaman et al. 2006; Tangpong et al. 2008). 
 
A.6 Conclusions 
 
This study is the first to demonstrate that a chronic low-VitD diet and 
consequential low levels of VitD in the bloodstream result in significant increases 
in tyrosine nitration in brain proteins, alterations in glucose metabolism and 
mitochondrial changes in brain of elderly rats, an animal model of brain in older 
human subjects (Figure A.1). A shift from the TCA cycle to glycolysis may be 
indicative of metabolic dysfunction. Further, ATP generated from glycolysis is 
important for maintaining a proper resting membrane potential in neurons (e.g., 
via NA+/K+ATPase), which is, in turn, important for neurotransmission.  The 
results of this study are consistent with the notion that nitration of brain proteins 
occurs via NF-κB activation of iNOS. These results provide biochemical evidence 
to support the conclusions, consistent with other studies, that suggest that higher 
serum VitD levels may have direct and indirect anti-oxidant properties and be 
beneficial to modulate damaging effects of brain aging. Based on evidence from 
the present study and the literature as noted above, it is our opinion that current 
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daily VitD intake in the general adult population is too low and should be 
increased. 
 
The present study used brain tissue from animals as part of a larger study 
examining the effects of serum VitD status and brain aging.  A component of 
these larger studies examined learning and memory and a preliminary report 
indicated that low VitD animals displayed poorer performance, but that 
performance improved with high VitD (Latimer CS, et al., personal 
communication, 2011). Hence, these data support the present findings and 
conclusions. 
 
As people age, their lifestyles become more sedentary, physically and mentally. 
Perhaps due to limited access, physical or financial limitations, or lack of 
motivation, nutritional status often declines. Concurrently, time spent outside 
decreases. Less sun exposure further decreases circulating VitD levels.  Our 
studies, together with those of others, indicate that higher VitD may be beneficial 
for older individuals and, thus, it would appear that further studies are warranted 
to determine whether VitD supplementation can offset some of the changes 
associated with unhealthy brain aging. Further studies to address this issue are 
ongoing in our laboratory. 
 
 
Copyright © Jeriel T. R. Keeney 2013 
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Appendix B 
Insights into the mechanism of chemotherapy-induced cognitive 
impairment caused by the anti-cancer drug doxorubicin: 
Perspectives from a human clinical pilot study. In progress. 
 
B.1 Overview of study 
 
Our preliminary results are consistent with a novel hypothesis involving 
Doxorubicin(Dox)-induced, ROS-mediated plasma protein oxidation leading to 
peripheral TNF-α elevation which crosses the blood-brain barrier leading to CNS 
oxidative stress, mitochondrial damage, and cognitive impairment. The data 
presented here is from a human pilot study based on this hypothesis. Patients 
who entered the trial were randomly assigned into one of two treatment groups. 
For the first two cycles of chemotherapy, patients agreed to receive only Dox with 
or without MESNA, each combination for one of the first two cycles. A naïve 
blood sample was obtained prior to any treatment. Treatment then followed the 
schedule presented in figure B.1. Preliminary oxidative stress data as assessed 
by protein carbonyl levels is presented in figure B.2. The project is ongoing. 
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Figure B.1. Experimental Design: Dox/MESNA Human Clinical Pilot Study. 
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Model Estimates for % individual change of protein carbonyl depending 
on an individuals baseline level of PC
Saline: 75% quantile baseline PC
Mesna: 25% quantile baseline PC
Saline: 25% quantile baseline PC
Saline: 50% quantile baseline PC
Mesna: 75% quantile baseline PC
Mesna: 50% quantile baseline PC
p-values
For overall interaction: p=0.0568
Trt differences- 25%ile baseline PC (SOLID LINES): p=0.0705
Trt differences- 50%ile baseline PC (DOTTED LINES): p=0.4754
Trt differences- 75%ile baseline PC (LONG DASH LINES): p =0.2803
184 
 
Figure B.2. Model estimates for percent change of protein carbonyl (PC) 
depending on an individual’s baseline PC level.  
Preliminary protein carbonyl (PC) data from our human pilot study show those 
patients who would potentially get the most PC prevention benefit from co-
administration of MESNA with Dox. 
 
B.2 Raw data from ongoing human trials 
plasma HNE-modified ApoA1, Human trial random 10 Ratio of 
     
change 
Sample 
# HNE ApoA1 
HNE+ 
ApoA1 
HNE/(HNE+ 
ApoA1) post/pre 
AC4 1A 2347434 876672 3224106 0.728088344 0.914474405 
AC4 1B 1485680 745680 2231360 0.665818156   
AC5 1A 3872838 696174 4569012 0.847631392 0.932328001 
AC5 1B 3374240 895488 4269728 0.790270481 
 CH2 1A 2756149 1115608 3871757 0.711860016 0.642612825 
CH2 1B 1910020 2265340 4175360 0.457450376   
CH4 1A 3347280 1656256 5003536 0.668982895 1.162201598 
CH4 1B 2091848 598656 2690504 0.77749299 
 CH7 1A 2870784 1785434 4656218 0.616548452 0.6844679 
CH7 1B 1825659 2500469 4326128 0.422007624   
CH8 1A 2263653 1533042 3796695 0.59621671 0.751527042 
CH8 1B 972520 1197930 2170450 0.44807298 
 CH10 1A 5246010 3124914 8370924 0.626694257 1.090927401 
CH10 1B 4575129 2116807 6691936 0.683677937   
CH14 1A 1418877 44720 1463597 0.969445141 0.928934405 
CH14 1B 1911124 211048 2122172 0.900550945 
 CH18 1A 497670 9854 507524 0.980584169 0.891939481 
CH18 1B 3670030 526104 4196134 0.874621735   
TA2 1A 2214449 1610648 3825097 0.578926234 0.48807523 
TA2 1B 473246 1201608 1674854 0.282559554 
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Collection Sample Collection Approx vol # of vials Sample Notes 
Date Number Code collected (uL) aliquoted Collector 
10/22/10 CH1 C1A 3300 7 R 
10/22/10 CH1 C1B 3300 7 J 
11/12/10 CH1 C2A 3300 7 R 
11/12/10 CH1 C2B 3300 7 J 
12/16/10 CH2 C1A 3300 7 J 
12/16/10 CH2 C1B 4000 7 J 
12/21/10 CH3 C1A 3200 10 T 
12/21/10 CH3 C1B 3200 10 T 
1/11/11 CH4 C1A 2000 5 J 
1/11/11 CH4 C1B 2700 7 J 
1/12/11 CH3 C2A 3600 7 J 
1/12/11 CH3 C2B 4000 7 J 
1/14/11 AC2 C1A 3100 7 J 
1/14/11 AC2 C1B 2800 7 J 
1/14/11 CH2 C2A 4000 7 J 
1/14/11 CH2 C2B 4000 7 J 
1/27/11 AC2 C2A 3300 7 J 
1/27/11 AC2 C2B 3300 7 J 
2/2/11 CH4 C2A 2800 7 J 
2/2/11 CH5 C1A 4000 7 J 
2/2/11 CH4 C2B 3200 7 J 
2/2/11 CH5 C1B 3200 7 J 
2/10/11 CH6 C1A 3600 7 J 
2/10/11 CH6 C1B 3600 7 J 
2/22/11 AC4 C1A 3200 6 T 
2/22/11 AC4 C1B 3200 7 J 
2/22/11 AC5 C1A 3600 7 J 
2/22/11 AC5 C1B 3200 7 J 
2/23/11 CH5 C2A 3600 7 J 
2/23/11 CH5 C2B 3200 7 J 
2/25/11 TA1 C1A 3600 7 J 
2/25/11 TA1 C1B 3600 7 J 
3/1/11 CH7 C1A 3600 7 J 
3/1/11 CH7 C1B 3600 7 J 
3/3/11 CH6 C2A 3300 7 J 
3/3/11 CH8 C1A 3300 7 J 
3/3/11 CH6 C2B 3300 7 J 
3/3/11 CH8 C1B 3100 7 J 
3/7/11 CH9 C1A 4000 7 J 
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3/7/11 CH9 C1B 4000 7 J 
3/15/11 AC4 C2A 3200 7 J 
3/15/11 CH7 C2A 3600 7 J 
3/15/11 AC4 C2B 2800 7 J 
3/15/11 CH7 C2B 4000 7 J 
3/17/11 TA1 C2A 3200 7 J 
3/17/11 TA1 C2B 3600 7 J 
3/22/11 AC5 C2A 3600 7 J 
3/22/11 AC5 C2B 3600 7 J 
3/24/11 CH8 C2A 4000 7 J 
3/24/11 CH8 C2B 3600 7 J 
3/28/11 CH9 C2A 3600 7 J 
3/28/11 CH9 C2B 3200 7 J 
4/15/11 AC6 C1A 4000 7 J 
4/15/11 AC6 C1B 4000 7 J 
4/25/11 AC7 C1A 3200 7 J 
4/25/11 AC7 C1B 2900 7 J 
5/6/11 AC6 C2A 3300 7 J 
5/6/11 AC6 C2B 3600 7 G 
5/13/11 CH10 C1A 3500 7 G 
5/13/11 CH10 C1B 3500 7 G 
5/16/11 AC7 C2A 3500 7 J 
5/16/11 AC7 C2B 3600 7 J 
5/19/11 CH11 C1A 2900 7 J 
5/19/11 CH11 C1B 3300 7 J 
6/2/11 CH10 C2A 3200 7 J 
6/2/11 CH10 C2B 3300 7 J 
6/9/11 CH11 C2A 3200 7 J 
6/9/11 CH11 C2B 3100 7 J 
6/28/11 AC8 C1A 3600 7 J 
6/28/11 AC8 C1B 3300 7 J 
7/26/11 AC8 C2A 2800 7 J 
7/26/11 AC8 C2B 2800 7 J 
8/25/11 CH14 C1A 2900 7 J 
8/25/11 CH13 C1A 3300 7 J 
8/25/11 CH14 C1B 2900 7 J 
8/25/11 CH13 C1B 3300 7 J 
9/15/11 CH15 C1A 3300 7 J 
9/15/11 CH13 C2A 3300 7 J 
9/15/11 CH13 C2B 3300 7 J 
9/15/11 CH15 C1B 3500 7 J 
187 
 
9/16/11 AC9 C1A 2900 6(+1) T 
9/16/11 AC9 C1B 2800 7 T 
9/20/11 CH14 C2A 2800 7 J 
9/20/11 CH14 C2B 2700 7 J 
9/23/11 AC10 C1A 3700 7 J 
9/23/11 AC10 C1B 3600 7 J 
9/29/11 AC9 C2A 3100 7 J 
9/29/11 AC9 C2B 3200 7 J 
10/6/11 CH15 C2A 3100 7 J 
10/6/11 CH15 C2B 3100 7 J 
10/24/11 AC10 C2A 3700 7 J 
10/24/11 AC10 C2B 3500 7 J 
12/29/11 CH16 C1A 4000 8 T 
12/29/11 CH16 C1B 4000 8 T 
1/6/12 CH17 C1A 4000 7 J 
1/6/12 CH17 C1B 4000 7 J 
1/17/12 CH18 C1A 3400 7 J 
1/17/12 CH18 C1B 3400 7 J 
1/19/11 CH16 C2A 3600 7 J 
1/19/11 CH16 C2B 3500 7 J 
1/20/11 TA2 C1A 3300 7 J 
1/20/11 TA2 C1B 3400 7 J 
1/25/12 AC11 C1A 3400 7 J 
1/25/12 AC11 C1B 3400 7 J 
1/27/12 CH17 C2A 3500 7 T 
1/27/12 CH17 C2B 3500 7 T 
1/30/12 AC12 C1A 3400 7 J 
1/30/12 AC12 C1B 3600 7 J 
2/7/12 CH18 C2A 3300 7 J 
2/7/12 CH18 C2B 3400 7 J 
2/8/12 TA2 C2A 3500 7 J 
2/8/12 TA2 C2B 3500 7 J 
2/8/12 AC11 C2A 3500 7 J 
2/8/12 AC11 C2B 3500 7 J 
3/27/12 CH19 C1A 3400 7 J 
3/27/12 CH19 C1B 3600 7 J 
4/17/12 CH19 C2A 3400 7 J 
4/17/12 CH19 C2B 3800 7 J 
4/24/12 CH20 C1A 3700 7 J 
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4/24/12 CH20 C1B 3800 7 J 
5/15/12 CH20 C2A 3800 7 J 
5/15/12 CH20 C2B 3800 7 J 
5/25/12 AC13 C1A 3500 7 J 
5/25/12 AC13 C1B 3500 7 J 
6/15/12 AC13 C2A 3500 7 T 
6/15/12 AC13 C2B 3500 7 T 
 
Eureka Grant Human Trial Graphs 
  PC slotblot set1 avg%control 5Jun2012 
  
      
 
Blot 1 Blot 2 Avg trend trend 
 
% naïve % naïve % from from 
 
control control control naïve 
pre to 
post 
CH1 
C1A 100 100 100 
  CH1 
C1B 30.48887 47.21279 38.85083 DOWN DOWN 
CH1 
C2A 53.19467 59.98822 56.59145 DOWN 
 CH1 
C2B 4.831667 20.9032 12.86743 DOWN DOWN 
CH2 
C1A 100 100 100 
  CH2 
C1B 104.5881 91.70973 98.14891 same same 
CH2 
C2A 56.10178 36.1957 46.14874 DOWN 
 CH2 
C2B 33.33926 15.5469 24.44308 DOWN DOWN 
CH3 
C1A 100 100 100 
  CH3 
C1B 344.2072 129.3153 236.7612 UP UP 
CH3 
C2A 176.1221 141.4497 158.7859 UP 
 CH3 
C2B 330.952 213.7081 272.3301 UP UP 
CH4 
C1A 100 100 100 
  CH4 
C1B 5.106001 16.05881 10.5824 DOWN DOWN 
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CH4 
C2A 91.37903 87.67585 89.52744 down 
 CH4 
C2B 81.37535 70.52749 75.95142 down same 
 
Eureka Grant Human Trial 
     PC slotblot set2 blot1 5Jun2012 
   
Blot 1 
       
% naïve 
  Rep1 Rep2 Rep3 RepAvg RepStdDev %CV control 
AC2 C1A 42.38 62.07 73.14 59.19667 15.580001 26.31905 100 
AC2 C1B 45.34 53.14 55.85 51.44333 5.4565587 10.60693 86.90242 
AC2 C2A 133.15 136.58 127.37 132.3667 4.6547001 3.51652 223.6049 
AC2 C2B 94.96 96.46 89.75 93.72333 3.5217941 3.757649 158.3254 
CH5 C1A 127.32 126.77 123.71 125.9333 1.9450021 1.54447 100 
CH5 C1B 124.25 125.18 118.26 122.5633 3.7556935 3.064288 97.32398 
CH5 C2A 101.08 116.42 117.06 111.52 9.0469663 8.112416 88.55479 
CH5 C2B 88.64 103.92 104.22 98.92667 8.9097774 9.006447 78.55479 
CH6 C1A 117.37 105.65 102.16 108.3933 7.9674609 7.350508 100 
CH6 C1B 74.71 78.25 77.5 76.82 1.8653954 2.428268 70.87152 
CH6 C2A 155.85 157.11 151.55 154.8367 2.9152244 1.882774 142.847 
CH6 C2B 144.15 142.56 146.35 144.3533 1.903164 1.318407 133.1755 
AC4 C1A 87.87 84.84 80.31 84.34 3.8047208 4.51117 100 
AC4 C1B 86.68 83.15 76.14 81.99 5.3648952 6.543353 97.21366 
AC4 C2A 87.5 87.78 77.73 84.33667 5.7232537 6.786199 99.99605 
AC4 C2B 73.45 68.7 65.6 69.25 3.9537956 5.709452 82.10813 
                
 
Eureka Grant Human Trial 
     PC slotblot set2 blot2 5Jun2012 
   
Blot 2 
       
% naïve 
  Rep1 Rep2 Rep3 RepAvg RepStdDev %CV control 
AC2 C1A 63.98 94.15 103.49 87.20667 20.649877 23.67924 100 
AC2 C1B 50.51 70.38 77.31 66.06667 13.910918 21.05588 75.75873 
AC2 C2A 109.05 136.98 139.39 128.4733 16.864206 13.12662 147.3205 
AC2 C2B 77.46 95.52 100.5 91.16 12.123019 13.29862 104.5333 
CH5 C1A 88.27 98.81 81.94 89.67333 8.5221026 9.503497 100 
CH5 C1B 79.11 92.47 81.4 84.32667 7.1446787 8.472621 94.03762 
190 
 
CH5 C2A 74.9 85.66 77.9 79.48667 5.552705 6.985706 88.64025 
CH5 C2B 63.52 70.19 70.45 68.05333 3.9281336 5.77214 75.89027 
CH6 C1A 118.27 115.87 129.37 121.17 7.202083 5.943784 100 
CH6 C1B 80.11 79.83 77.46 79.13333 1.4558961 1.839801 65.30769 
CH6 C2A 170 176.06 164.57 170.21 5.7478779 3.376933 140.4721 
CH6 C2B 171.82 167.45 158.8 166.0233 6.6262081 3.991131 137.0169 
AC4 C1A 81.31 94.29 101.33 92.31 10.155806 11.00185 100 
AC4 C1B 73.93 90.4 85.74 83.35667 8.4897252 10.18482 90.3008 
AC4 C2A 98.16 114.2 113.4 108.5867 9.0386135 8.32387 117.6326 
AC4 C2B 76.66 88.49 89.13 84.76 7.0221008 8.284687 91.82104 
 
Eureka Grant Human Trial Graphs 
  PC slotblot set2 blot1 5Jun2012 
  
      
 
Blot 1 Blot 2 Avg trend trend 
 
% naïve % naïve % naïve from from 
 
control control control naïve pre to post 
AC2 C1A 100 100 100 
  AC2 C1B 86.90242 75.75873 81.330575 down down 
AC2 C2A 223.6049 147.3205 185.46274 UP 
 AC2 C2B 158.3254 104.5333 131.42932 up down 
CH5 C1A 100 100 100 
  CH5 C1B 97.32398 94.03762 95.680799 same same 
CH5 C2A 88.55479 88.64025 88.59752 down 
 CH5 C2B 78.55479 75.89027 77.22253 down down 
CH6 C1A 100 100 100 
  CH6 C1B 70.87152 65.30769 68.089606 DOWN DOWN 
CH6 C2A 142.847 140.4721 141.65955 up 
 CH6 C2B 133.1755 137.0169 135.09617 up same 
AC4 C1A 100 100 100 
  AC4 C1B 97.21366 90.3008 93.757229 same same 
AC4 C2A 99.99605 117.6326 108.81433 up 
 AC4 C2B 82.10813 91.82104 86.964586 down down 
Set 3 PC 
Set 3 PC 
        rep1 rep2 rep3 repAvg RepStdDev %CV 
AC5 C1A 217.69 215.7 219.61 217.6667 1.9551044 0.89821 
191 
 
AC5 C1B 245.61 248.61 236.37 243.53 6.3795925 2.619633 
AC5 C2A 305.02 278.61 290.83 291.4867 13.21724 4.534424 
AC5 C2B 262.19 216.78 210.81 229.9267 28.099862 12.22123 
TA1 C1A 253.25 230.52 218.62 234.13 17.594979 7.515047 
TA1 C1B 303.42 246.53 258.53 269.4933 29.987731 11.12745 
TA1 C2A 286.4 252.64 264.05 267.6967 17.172887 6.415054 
TA1 C2B 251.54 261.39 271.46 261.4633 9.9602025 3.809407 
CH7 C1A 234.05 225.31 237.27 232.21 6.1886671 2.665117 
CH7 C1B 316.97 260.14 233.5 270.2033 42.635235 15.77894 
CH7 C2A 282.18 253.9 228.54 254.8733 26.833243 10.52807 
CH7 C2B 281.89 243.5 220.92 248.77 30.824745 12.39086 
CH8 C1A 239.87 236.52 239.22 238.5367 1.7764665 0.744735 
CH8 C1B 246.98 249.84 267.78 254.8667 11.274331 4.423619 
CH8 C2A 238.86 236.13 234.33 236.44 2.2808551 0.964665 
CH8 C2B 250.55 254.05 241.55 248.7167 6.448514 2.592715 
     
avg%cv 6.201824 
       
 
rep1 rep2 rep3 repAvg RepStdDev %CV 
AC5 C1A 188.49 230.94 206.42 208.6167 21.310083 10.21495 
AC5 C1B 121.79 150.35 145.68 139.2733 15.320001 10.99995 
AC5 C2A 312.3 319.79 349.39 327.16 19.612616 5.994809 
AC5 C2B 258.75 246.61 248.7 251.3533 6.4903801 2.582174 
TA1 C1A 255.35 248.21 236.71 246.7567 9.4046017 3.811286 
TA1 C1B 160.43 173.62 163.03 165.6933 6.986704 4.216648 
TA1 C2A 251.3 273.52 289.14 271.32 19.015688 7.008583 
TA1 C2B 249.66 261.02 278.07 262.9167 14.299652 5.438853 
CH7 C1A 295.45 256.45 275.54 275.8133 19.501437 7.07052 
CH7 C1B 193.83 156.21 144.22 164.7533 25.884927 15.71132 
CH7 C2A 266.86 282.42 255.06 268.1133 13.722993 5.118355 
CH7 C2B 267.75 228.2 220.37 238.7733 25.398083 10.6369 
CH8 C1A 238.48 222.74 220.89 227.37 9.665904 4.251178 
CH8 C1B 373.33 333.28 324.04 343.55 26.200777 7.626481 
CH8 C2A 304.81 261.67 239.47 268.65 33.224527 12.36722 
CH8 C2B 353.29 335.03 331.34 339.8867 11.753341 3.458018 
     
avg%cv 7.281703 
       
   
Avg%Con 
   AC5 C1A 100 100 100 
   AC5 C1B 111.8821 66.76041 89.32124 
   AC5 C2A 133.9142 156.8235 145.3689 
   AC5 C2B 105.6325 120.4857 113.0591 
   TA1 C1A 100 100 100 
   TA1 C1B 115.1041 67.14847 91.12631 
   
192 
 
TA1 C2A 114.3368 109.9545 112.1456 
   TA1 C2B 111.6744 106.549 109.1117 
   CH7 C1A 100 100 100 
   CH7 C1B 116.3616 59.73364 88.04763 
   CH7 C2A 109.7598 97.20826 103.4841 
   CH7 C2B 107.1315 86.57063 96.85105 
   CH8 C1A 100 100 100 
   CH8 C1B 106.8459 151.0973 128.9716 
   CH8 C2A 99.12103 118.1554 108.6382 
   CH8 C2B 104.2677 149.4862 126.8769 
    
PC Set4 CH9, AC6, AC7, CH10 
    Blot 1 
      Sample Rep1 Rep2 Rep3 RepAvg RepStdDev %CV 
CH9 C1A 218.87 258.06 284.92 253.95 33.216257 13.07984 
CH9 C1B 264.74 284.32 315.32 288.126667 25.503963 8.85165 
CH9 C2A 168.19 187.83 202.4 186.14 17.167501 9.222897 
CH9 C2B 210.59 218.69 248.53 225.936667 19.981154 8.843697 
AC6 C1A 166.88 175.28 202.67 181.61 18.715841 10.30551 
AC6 C1B 274.96 307.59 318.78 300.443333 22.767394 7.577933 
AC6 C2A 248.5 301.67 343.66 297.943333 47.689332 16.00618 
AC6 C2B 231.76 261.15 289.25 260.72 28.747412 11.02616 
AC7 C1A 201.62 186.26 179.91 189.263333 11.162259 5.89774 
AC7 C1B 271 249.6 230.66 250.42 20.182497 8.059459 
AC7 C2A 295.05 269.85 254.69 273.196667 20.387068 7.462415 
AC7 C2B 239.18 239.78 222.65 233.87 9.7214351 4.156769 
CH10 C1A 288.3 267.33 249.42 268.35 19.460059 7.251746 
CH10 C1B 305.6 279.75 251.47 278.94 27.074089 9.706062 
CH10 C2A 278.54 253.18 239.36 257.026667 19.871229 7.731193 
CH10 C2B 248.21 241.87 272.15 254.076667 15.969751 6.285406 
Blot 2 Rep1 Rep2 Rep3 RepAvg RepStdDev %CV 
CH9 C1A 93.19 99.77 97.94 96.9666667 3.3962676 3.50251 
CH9 C1B 118.9 144.25 155.12 139.423333 18.586141 13.33072 
CH9 C2A 100.76 126.51 138.2 121.823333 19.154948 15.72355 
CH9 C2B 80.8 79.13 83.09 81.0066667 1.9880728 2.454209 
AC6 C1A 147.79 148.37 148.98 148.38 0.595063 0.40104 
AC6 C1B 140.83 162.35 156.39 153.19 11.111148 7.253181 
AC6 C2A 171.85 184.11 181.99 179.316667 6.552628 3.654221 
AC6 C2B 194.8 184.97 178.22 185.996667 8.3375436 4.482631 
AC7 C1A 111.79 113.3 113.39 112.826667 0.8989067 0.796715 
AC7 C1B 155.13 140.34 139.95 145.14 8.6537911 5.962375 
AC7 C2A 164.51 153.9 130.09 149.5 17.626801 11.7905 
193 
 
AC7 C2B 144.91 127.77 113.32 128.666667 15.814077 12.29073 
CH10 C1A 246.33 234.63 208.47 229.81 19.384767 8.435128 
CH10 C1B 239.98 234.57 205.88 226.81 18.326639 8.080172 
CH10 C2A 106.5 109.96 106.12 107.526667 2.1158765 1.967769 
CH10 C2B 250.27 247.2 250 249.156667 1.6998922 0.682258 
      
Graph 
comparison 
Blot1 %Con Blot2 %Con Blot Avg Blot StdDev Blot%CV Lanes 
CH9 C1A 100 100 100 0 0 1 
CH9 C1B 113.45803 143.784806 128.6214 21.4442689 16.672394 2 
CH9 C2A 73.2978933 125.634239 99.46607 37.0073847 37.20604 3 
CH9 C2B 88.9689571 83.5407356 86.25485 3.83833223 4.4499902 4 
AC6 C1A 100 100 100 0 0 5 
AC6 C1B 165.433254 103.241677 134.3375 43.9760863 32.735534 6 
AC6 C2A 164.056678 120.84962 142.4531 30.5520036 21.447054 7 
AC6 C2B 143.560377 125.351575 134.456 12.8755673 9.5760469 8 
AC7 C1A 100 100 100 0 0 9 
AC7 C1B 132.313003 128.639801 130.4764 2.59734575 1.9906632 10 
AC7 C2A 144.347382 132.504136 138.4258 8.37443943 6.0497696 11 
AC7 C2B 123.568573 114.039234 118.8039 6.73825999 5.6717497 12 
CH10 C1A 100 100 100 0 0 13 
CH10 C1B 103.946339 98.6945738 101.3205 3.71355862 3.6651618 14 
CH10 C2A 95.7803863 46.7893767 71.28488 34.6418751 48.596384 15 
CH10 C2B 94.6810757 108.418549 101.5498 9.71386028 9.5656113 16 
 
Set 5 
    
%contro
l 
%contro
l 
%contro
l 
%contro
l 
Blot 1 Rep1 Rep2 Rep3 Rep Avg Rep1 Rep2 Rep3 Rep Avg 
CH11 
C1A 174.9 155.34 164.12 
164.786
7 
106.137
2 
94.2673
4 
99.5954
4 100 
CH11 
C1B 186.39 172.15 161.38 
173.306
7 
113.109
9 
104.468
4 
97.9326
8 
105.170
3 
CH11 
C2A 152.91 190.54 152.31 
165.253
3 92.7927 
115.628
3 
92.4285
9 
100.283
2 
CH11 
C2B 126.57 127.26 134.52 129.45 76.8084 
77.2271
2 
81.6328
2 
78.5561
1 
AC8 
C1A 221.12 250.99 246.96 239.69 
92.2524
9 
104.714
4 
103.033
1 100 
AC8 
C1B 137.11 203.33 222.18 187.54 
57.2030
5 
84.8304
1 
92.6947
3 
78.2427
3 
AC8 
C2A 104.67 112.63 110.08 
109.126
7 
43.6689
1 
46.9898
6 
45.9259
9 
45.5282
5 
AC8 
C2B 174.77 183.74 180.32 179.61 
72.9150
2 
76.6573
5 
75.2305
1 
74.9342
9 
194 
 
CH13 
C1A 219.86 223.24 184.89 209.33 
105.030
3 106.645 
88.3246
5 100 
CH13 
C1B 277 305.54 257.87 
280.136
7 
132.326
9 
145.960
9 
123.188
3 
133.825
4 
CH13 
C2A 217.08 243.29 200.3 
220.223
3 
103.702
3 
116.223
2 
95.6862
4 
105.203
9 
CH13 
C2B 279.2 289.15 292.41 286.92 
133.377
9 
138.131
2 
139.688
5 
137.065
9 
CH14 
C1A 534.29 527.76 494.42 
518.823
3 
102.981
1 
101.722
5 
95.2964
1 100 
CH14 
C1B 472.96 475.02 458.03 468.67 
91.1601
3 
91.5571
8 
88.2824
6 
90.3332
5 
CH14 
C2A 435.37 442.27 422.49 
433.376
7 
83.9148
8 
85.2448
2 
81.4323
4 
83.5306
8 
CH14 
C2B 256.14 260.39 184.74 
233.756
7 
49.3694
1 
50.1885
7 35.6075 
45.0551
6 
Blot 2 Rep1 Rep2 Rep3 Rep Avg 
    CH11 
C1A 147.11 177.89 197.08 
174.026
7 
84.5330
2 102.22 113.247 100 
CH11 
C1B 127.47 141.73 146.6 138.6 73.2474 
81.4415
4 
84.2399
6 
79.6429
7 
CH11 
C2A 210.59 260.23 249.34 
240.053
3 
121.010
2 
149.534
6 
143.276
9 
137.940
5 
CH11 
C2B 565.63 672.26 704.3 
647.396
7 
325.024
9 
386.297
1 
404.708
1 372.01 
AC8 
C1A 208.67 258.12 280.07 
248.953
3 
83.8189
2 
103.682
1 112.499 100 
AC8 
C1B 227.76 317.83 331.16 292.25 
91.4870
3 
127.666
5 
133.020
9 
117.391
5 
AC8 
C2A 204.49 273.45 277.23 
251.723
3 
82.1398
9 
109.839
9 
111.358
2 
101.112
7 
AC8 
C2B 142.4 184.83 176.27 
167.833
3 
57.1994
8 
74.2428
3 
70.8044
3 
67.4155
8 
CH13 
C1A 233.98 230.42 206.03 
223.476
7 104.7 103.107 
92.1930
7 100 
CH13 
C1B 175.37 175.52 162.03 
170.973
3 
78.4735
2 
78.5406
4 
72.5042
1 
76.5061
2 
CH13 
C2A 299.53 285.59 239.42 
274.846
7 
134.031
9 
127.794
1 
107.134
2 
122.986
7 
CH13 
C2B 217.79 233.43 206.24 
219.153
3 
97.4553
6 
104.453
9 
92.2870
4 
98.0654
2 
CH14 
C1A 401.63 359.32 318.85 
359.933
3 
111.584
6 99.8296 
88.5858
5 100 
CH14 
C1B 288.92 228.6 247.88 
255.133
3 
80.2704
2 
63.5117
6 
68.8683
1 70.8835 
CH14 
C2A 172.81 176.05 176.56 175.14 
48.0116
7 
48.9118
4 
49.0535
3 
48.6590
1 
CH14 153.53 167.15 160.83 160.503 42.6551 46.4391 44.6832
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C2B 3 2 6 7 
 
Set 6 
    
%contro
l 
%contro
l 
%contro
l 
%contro
l 
Blot 1 Rep1 Rep2 Rep3 Rep Avg Rep1 Rep2 Rep3 Rep Avg 
CH15 
C1A 965.87 988.29 1027.3 993.82 
97.1876
2 
99.4435
6 
103.368
8 100 
CH15 
C1B 864.36 886.32 894.67 
881.783
3 86.9735 
89.1831
5 
90.0233
4 
88.7266
6 
CH15 
C2A 627.54 663.48 567.61 
619.543
3 
63.1442
3 
66.7605
8 
57.1139
6 
62.3395
9 
CH15 
C2B 583.47 632.45 542.21 
586.043
3 
58.7098
3 
63.6382
8 
54.5581
7 
58.9687
6 
AC9 
C1A 360.39 415.34 325.26 
366.996
7 98.1998 
113.172
7 
88.6275
1 100 
AC9 
C1B 594.49 593.44 563.25 
583.726
7 
161.987
8 
161.701
7 
153.475
5 159.055 
AC9 
C2A 258.14 241.15 216.01 
238.433
3 
70.3385
1 
65.7090
4 
58.8588
5 64.9688 
AC9 
C2B 272.71 254.68 260.78 
262.723
3 
74.3085
8 
69.3957
3 
71.0578
7 
71.5873
9 
AC10 
C1A 297.92 304.68 250 284.2 
104.827
6 
107.206
2 
87.9662
2 100 
AC10 
C1B 472.56 465.41 393.37 443.78 
166.277
3 
163.761
4 
138.413
1 
156.150
6 
AC10 
C2A 893.39 814.33 713.12 
806.946
7 
314.352
6 
286.534
1 
250.921
9 
283.936
2 
AC10 
C2B 506.37 429.38 341.09 
425.613
3 
178.173
8 
151.083
7 
120.017
6 
149.758
4 
CH16 
C1A 812.43 713.28 628.03 
717.913
3 
113.165
5 
99.3546
1 
87.4799
2 100 
CH16 
C1B 464.96 405.41 348.01 
406.126
7 
64.7654
8 56.4706 
48.4752
1 
56.5704
3 
CH16 
C2A 564.06 542.57 443.9 
516.843
3 
78.5693
7 
75.5759
7 
61.8319
8 
71.9924
4 
CH16 
C2B 661.26 578.35 533.76 
591.123
3 
92.1086
1 
80.5598
6 
74.3488
1 
82.3390
9 
Blot 2 Rep1 Rep2 Rep3 Rep Avg 
    CH15 
C1A 364.42 380.43 404.48 383.11 
95.1215
1 
99.3004
6 105.578 100 
CH15 
C1B 175.95 216.11 203.99 
198.683
3 
45.9267
6 
56.4093
9 53.2458 
51.8606
5 
CH15 
C2A 204.2 237.97 230.14 
224.103
3 
53.3006
2 
62.1153
2 
60.0715
2 
58.4958
2 
CH15 
C2B 252.08 289.14 278.28 
273.166
7 
65.7983
3 75.4718 72.6371 
71.3024
1 
196 
 
AC9 
C1A 164.04 150.69 138.03 150.92 
108.693
3 99.8476 
91.4590
5 100 
AC9 
C1B 273.06 276.41 258.05 
269.173
3 
180.930
3 183.15 
170.984
6 178.355 
AC9 
C2A 269.83 268.21 259.86 
265.966
7 
178.790
1 
177.716
7 
172.183
9 
176.230
2 
AC9 
C2B 263.16 277.77 272.62 
271.183
3 
174.370
5 
184.051
2 
180.638
7 
179.686
8 
AC10 
C1A 212.86 188.76 189.2 196.94 
108.083
7 
95.8464
5 
96.0698
7 100 
AC10 
C1B 267.29 261.55 229.19 
252.676
7 
135.721
5 
132.806
9 
116.375
5 
128.301
3 
AC10 
C2A 230.78 212.28 204.59 
215.883
3 
117.182
9 
107.789
2 
103.884
4 
109.618
8 
AC10 
C2B 237.74 231.33 201.22 223.43 120.717 
117.462
2 
102.173
3 
113.450
8 
CH16 
C1A 290.02 288.16 284.58 
287.586
7 
100.846
1 
100.199
4 
98.9545
2 100 
CH16 
C1B 306.4 275.65 262.17 
281.406
7 
106.541
8 
95.8493
7 
91.1620
8 
97.8510
8 
CH16 
C2A 287.18 282.6 253.11 
274.296
7 
99.8585
9 
98.2660
3 
88.0117
3 
95.3787
8 
CH16 
C2B 237.93 221.27 235.23 
231.476
7 
82.7333
2 
76.9402
8 
81.7944
7 
80.4893
6 
 
Set 7 
    
%contro
l 
%contro
l 
%contro
l 
%contro
l 
Blot 1 Rep1 Rep2 Rep3 Rep Avg Rep1 Rep2 Rep3 Rep Avg 
CH17 
C1A 228.35 309.37 338.81 
292.176
7 
78.1547
7 
105.884
6 
115.960
7 100 
CH17 
C1B 369.84 493.85 505.2 
456.296
7 
126.580
9 
169.024
4 
172.909
1 
156.171
5 
CH17 
C2A 261.38 409.34 543.15 
404.623
3 
89.4595
7 
140.100
2 
185.897
8 
138.485
8 
CH17 
C2B 217.85 251.61 315.62 
261.693
3 
74.5610
5 
86.1157
1 
108.023
7 
89.5668
1 
CH18 
C1A 343.27 331.38 322.75 
332.466
7 
103.249
4 
99.6731
5 97.0774 100 
CH18 
C1B 311.31 326.42 314.78 
317.503
3 
93.6364
5 
98.1812
7 
94.6801
7 95.4993 
CH18 
C2A 371.56 450.89 462.73 
428.393
3 
111.758
6 
135.619
6 
139.180
9 128.853 
CH18 
C2B 250 263.81 253.95 255.92 
75.1955
1 
79.3493
1 76.3836 
76.9761
4 
TA2 
C1A 286.17 276.8 299.37 
287.446
7 
99.5558
6 
96.2961
2 104.148 100 
TA2 277.06 300.47 245.2 274.243 96.3865 104.530 85.3027 95.4066
197 
 
C1B 3 8 7 8 8 
TA2 
C2A 345.43 342.67 296.19 
328.096
7 
120.171
9 
119.211
7 
103.041
7 
114.141
8 
TA2 
C2B 271.68 288.07 211.04 256.93 
94.5149
2 
100.216
9 
73.4188
4 
89.3835
4 
AC11 
C1A 292.87 320.13 251.01 
288.003
3 
101.689
8 111.155 
87.1552
4 100 
AC11 
C1B 311.44 352.5 235.39 
299.776
7 
108.137
6 
122.394
4 
81.7316
9 
104.087
9 
AC11 
C2A 333.89 380.88 270.65 
328.473
3 
115.932
7 
132.248
5 
93.9746
1 
114.051
9 
AC11 
C2B 270.77 310.84 261.49 
281.033
3 
94.0162
7 
107.929
3 
90.7940
9 
97.5798
9 
Blot 2 Rep1 Rep2 Rep3 Rep Avg 
    CH17 
C1A 208.5 245.93 279.01 244.48 
85.2830
5 
100.593
1 
114.123
9 100 
CH17 
C1B 174.67 212.03 237.59 
208.096
7 
71.4455
2 
86.7269
3 
97.1817
7 
85.1180
7 
CH17 
C2A 210.99 278.66 294.76 261.47 
86.3015
4 
113.980
7 
120.566
1 
106.949
4 
CH17 
C2B 183.47 170.12 189.21 
180.933
3 
75.0449
9 
69.5844
2 
77.3928
3 
74.0074
2 
CH18 
C1A 380.45 428.27 387.11 398.61 
95.4441
7 
107.440
9 
97.1149
7 100 
CH18 
C1B 191.43 241.1 245.17 225.9 
48.0243
8 
60.4851
9 
61.5062
3 
56.6719
3 
CH18 
C2A 351.09 420.53 405.95 
392.523
3 
88.0785
7 
105.499
1 
101.841
4 
98.4730
3 
CH18 
C2B 217.98 284.8 289.75 
264.176
7 
54.6850
3 
71.4482
8 72.6901 
66.2744
7 
TA2 
C1A 195.55 227.56 208.4 
210.503
3 
92.8963
9 
108.102
8 
99.0008
1 100 
TA2 
C1B 298.4 321.9 300.43 306.91 
141.755
5 
152.919
2 
142.719
8 
145.798
2 
TA2 
C2A 237.22 267.73 243.16 249.37 
112.691
8 
127.185
6 
115.513
6 
118.463
7 
TA2 
C2B 112.62 125.61 140.56 
126.263
3 
53.5003
4 
59.6712
6 
66.7732
9 
59.9816
3 
AC11 
C1A 233.68 242.5 207.65 
227.943
3 
102.516
7 
106.386
1 91.0972 100 
AC11 
C1B 240.24 250.99 210.81 
234.013
3 
105.394
6 
110.110
7 
92.4835
1 
102.662
9 
AC11 
C2A 259.37 244.71 217.42 240.5 
113.787
1 
107.355
6 
95.3833
6 
105.508
7 
AC11 
C2B 251.24 227.68 206.03 
228.316
7 
110.220
4 
99.8844
7 90.3865 
100.163
8 
 
198 
 
Set 8 
    
%contro
l 
%contro
l 
%contro
l 
%contro
l 
Blot 1 Rep1 Rep2 Rep3 Rep Avg Rep1 Rep2 Rep3 Rep Avg 
AC12 
C1A 249.52 247.51 310.13 
269.053
3 
92.7399
8 
91.9929
1 
115.267
1 100 
AC12 
C1B 173.59 198.52 216.37 196.16 
64.5188
1 
73.7846
3 80.419 
72.9074
8 
AC12 
C2A 182.47 190.8 196.23 
189.833
3 
67.8192
7 
70.9153
1 72.9335 
70.5560
2 
AC12 
C2B 203.74 209.67 219.11 210.84 
75.7247
6 
77.9287
9 
81.4373
9 
78.3636
5 
CH19 
C1A 218.65 275.27 293.43 262.45 
83.3111
1 
104.884
7 
111.804
2 100 
CH19 
C1B 245.94 279.53 302.41 275.96 
93.7092
8 
106.507
9 
115.225
8 
105.147
6 
CH19 
C2A 264.86 276.66 297.75 
279.756
7 
100.918
3 
105.414
4 
113.450
2 
106.594
3 
CH19 
C2B 177.13 190.89 215.14 
194.386
7 
67.4909
5 
72.7338
5 
81.9737
1 
74.0661
7 
CH20 
C1A 293.78 294.27 320.29 302.78 
97.0275
4 
97.1893
8 
105.783
1 100 
CH20 
C1B 360.05 375.56 408.46 
381.356
7 
118.914
7 
124.037
3 
134.903
2 
125.951
7 
CH20 
C2A 292.05 279.57 319.35 296.99 
96.4561
7 
92.3343
7 
105.472
6 
98.0877
2 
CH20 
C2B 221.85 223.4 264.04 236.43 
73.2710
2 
73.7829
4 
87.2052
3 78.0864 
AC13 
C1A 265.95 255.55 276.37 
265.956
7 
99.9974
9 
96.0870
8 
103.915
4 100 
AC13 
C1B 223.37 213.15 238.12 224.88 
83.9873
7 
80.1446
4 
89.5333
8 
84.5551
3 
AC13 
C2A 208.64 219.51 241.24 223.13 
78.4488
7 82.536 
90.7065
1 
83.8971
3 
AC13 
C2B 180.09 188.88 201.12 190.03 
67.7140
4 
71.0190
9 
75.6213
4 
71.4514
9 
Blot 2 Rep1 Rep2 Rep3 Rep Avg 
    AC12 
C1A 106.02 127.3 132.18 
121.833
3 
87.0205
2 104.487 
108.492
5 100 
AC12 
C1B 157.2 169.92 169.64 
165.586
7 
129.028
7 
139.469
2 
139.239
4 
135.912
4 
AC12 
C2A 152.07 203.04 194.45 
183.186
7 
124.818
1 
166.653
9 
159.603
3 
150.358
4 
AC12 
C2B 143.61 145.9 153.07 
147.526
7 
117.874
1 
119.753
8 
125.638
9 
121.088
9 
CH19 
C1A 305.91 301.1 263.15 
290.053
3 
105.466
8 
103.808
5 
90.7246
9 100 
CH19 
C1B 307.92 379.68 364.32 350.64 
106.159
8 
130.900
1 
125.604
5 
120.888
1 
199 
 
CH19 
C2A 313.48 377.77 382.72 357.99 
108.076
7 
130.241
6 
131.948
1 
123.422
1 
CH19 
C2B 267.7 311.41 305.91 
295.006
7 
92.2933
7 107.363 
105.466
8 
101.707
7 
CH20 
C1A 434.8 402.79 394.5 
410.696
7 
105.868
9 
98.0748
2 
96.0562
9 100 
CH20 
C1B 436.35 420.98 419.16 
425.496
7 
106.246
3 
102.503
9 
102.060
7 
103.603
6 
CH20 
C2A 307.37 320.08 323.19 316.88 
74.8411
2 
77.9358
7 
78.6931
1 77.1567 
CH20 
C2B 312.41 305.98 332.68 
317.023
3 
76.0683
1 
74.5026
7 
81.0038
2 77.1916 
AC13 
C1A 219.6 236.41 279.38 245.13 
89.5851
2 96.4427 
113.972
2 100 
AC13 
C1B 243.29 220.28 237.59 233.72 
99.2493
8 
89.8625
2 
96.9240
8 
95.3453
3 
AC13 
C2A 331.11 303.3 316.46 
316.956
7 
135.075
3 
123.730
3 
129.098
8 
129.301
5 
AC13 
C2B 253.46 258.06 250 253.84 
103.398
2 
105.274
8 
101.986
7 
103.553
2 
 
Dox/MESNA human clinical trial  HNE Set 6 blot 1 
 
       Sample Rep1 Rep2 Rep3 RepAvg RepStdDev Rep%CV 
  2,494,029 2,563,026 3,741,861 2,932,972 701367.38 23.9132 
  2,947,251 2,659,164 2,813,835 2,806,750 144174.12 5.136693 
  2,356,362 2,325,297 2,668,102 2,449,920 189588.21 7.738546 
  2,724,891 2,879,671 2,933,953 2,846,172 108482.18 3.811512 
  2,508,635 3,406,904 3,414,643 3,110,061 520864.28 16.74772 
  2,315,269 2,474,518 3,453,011 2,747,599 616071.65 22.42218 
  2,923,925 2,891,770 3,532,363 3,116,019 360922.46 11.58281 
  2,664,505 2,724,019 2,708,977 2,699,167 30946.02 1.146503 
  6,547,957 7,026,031 6,859,915 6,811,301 242716.25 3.563435 
  4,457,119 4,420,822 5,395,064 4,757,668 552299.1 11.60861 
  3,864,159 3,855,875 3,630,899 3,783,644 132346.17 3.497849 
200 
 
  4,130,991 4,164,454 4,109,627 4,135,024 27635.101 0.668318 
  4,630,102 3,983,623 3,769,002 4,127,576 448235.52 10.85953 
  3,805,190 5,005,498 4,170,558 4,327,082 615272.01 14.2191 
  3,477,536 3,632,752 3,740,553 3,616,947 132218.89 3.655538 
  3,288,966 3,313,600 4,242,062 3,614,876 543298.64 15.02952 
      
9.725066 
       Sample Rep1 Rep2 Rep3 RepAvg RepStdDev Rep%CV 
  3,280,464 4,887,560 5,462,099 4,543,374 1130809.7 24.8892 
  2,971,885 3,412,790 3,788,077 3,390,917 408535.38 12.04793 
  2,633,876 2,311,127 2,408,573 2,451,192 165541.58 6.753513 
  2,960,113 2,714,536 3,729,762 3,134,804 529677.81 16.89668 
  2,780,699 2,780,045 3,362,977 2,974,574 336367.31 11.30808 
  2,486,726 2,883,377 3,433,500 2,934,534 475455.63 16.20208 
  3,165,687 3,103,557 3,214,192 3,161,145 55457.153 1.754337 
  5,568,156 3,805,844 4,332,096 4,568,699 904666.52 19.8014 
  5,218,484 4,755,997 3,519,610 4,498,030 878324.15 19.52686 
  4,088,481 3,859,690 4,490,691 4,146,287 319447.56 7.704424 
  4,442,513 4,131,863 4,320,215 4,298,197 156491.05 3.640853 
  3,512,852 3,237,409 3,519,828 3,423,363 161078.66 4.705275 
  4,024,498 4,078,453 3,887,921 3,996,957 98206.298 2.457026 
  6,179,755 6,027,700 4,767,878 5,658,444 774991.27 13.69619 
  4,210,997 4,223,750 4,337,001 4,257,249 69360.695 1.629237 
  4,716,757 5,026,208 3,591,223 4,444,729 755178.64 16.99043 
      
11.25022 
201 
 
 
HNE set1 blot1 analysis 
6/12/201
2 
 
Dox Mesna Human Trial 
        
        
        
Sample Rep1 Rep2 Rep3 RepAvg 
RepStdDe
v %CV 
%naïve 
control 
CH1 C1A 74.4 85.66 90.48 83.51333 8.2521351 9.881219 100 
CH1 C1B 74.61 90.2 85.59 83.46667 8.0089596 9.595399 99.9441207 
CH1 C2A 75.87 82.82 81.71 80.13333 3.7336354 4.659279 
95.9527420
8 
CH1 C2B 71.02 70.61 66.95 69.52667 2.2408555 3.223016 83.2521753 
CH2 C1A 71.34 70.71 61.01 67.68667 5.7907369 8.555211 100 
CH2 C1B 66.55 70.66 61.16 66.12333 4.7643503 7.205248 
97.6903378
3 
CH2 C2A 75.67 81.63 73.3 76.86667 4.2919964 5.58369 
113.562493
8 
CH2 C2B 86.11 87.06 73.79 82.32 7.4024523 8.992289 
121.619225
8 
CH3 C1A 92.16 82.1 100 91.42 8.9729148 9.815046 100 
CH3 C1B 113.31 93.43 107.93 104.89 10.282743 9.803359 
114.734193
8 
CH3 C2A 82.9 81.75 79 81.21667 2.0039544 2.467418 
88.8390578
3 
CH3 C2B 71.59 73.62 81.7 75.63667 5.3481991 7.070908 
82.7353606
1 
CH4 C1A 62.83 65.45 66.52 64.93333 1.8984818 2.92374 100 
CH4 C1B 68.68 63.14 60.42 64.08 4.2094655 6.569079 
98.6858316
2 
CH4 C2A 70.13 70.75 66.88 69.25333 2.0786133 3.001463 
106.652977
4 
CH4 C2B 75.18 72.06 72.81 73.35 1.6285883 2.220298 
112.962012
3 
      
6.347916 
 
 
HNE set1 blot2 analysis 6/12/2012 
 
Dox Mesna Human Trial 
        
        
        
 
Rep1 Rep2 Rep3 RepAvg RepStdDev %CV 
%naïve 
control 
202 
 
CH1 C1A 86 89.93 80.42 85.45 4.7787969 5.592507 100 
CH1 C1B 96.07 105.29 84.83 95.39667 10.246606 10.74105 111.6403355 
CH1 C2A 91.68 91.93 88.83 90.81333 1.7221595 1.896373 106.276575 
CH1 C2B 101.85 101.99 96.79 100.21 2.962634 2.956425 117.2732592 
CH2 C1A 77.16 61.41 63.46 67.34333 8.5630505 12.71551 100 
CH2 C1B 103.3 101.8 94.35 99.81667 4.7933113 4.802115 148.2205613 
CH2 C2A 105.73 
 
87.93 96.83 12.586501 12.99855 143.7855764 
CH2 C2B 100 92.44 83.64 92.02667 8.1878284 8.897235 136.6529723 
CH3 C1A 108.83 104.32 96.64 103.2633 6.1633135 5.96854 100 
CH3 C1B 109.02 113.14 108.91 110.3567 2.4110648 2.184793 106.8691694 
CH3 C2A 102.76 98.04 99.21 100.0033 2.4579734 2.457891 96.84302269 
CH3 C2B 96.78 91.94 85.95 91.55667 5.4251667 5.925474 88.66328803 
CH4 C1A 70.37 66.3 67.63 68.1 2.0753072 3.047441 100 
CH4 C1B 65.9 61.94 72.32 66.72 5.2383585 7.851257 97.97356828 
CH4 C2A 70.05 73.98 75.47 73.16667 2.8000417 3.826936 107.4400392 
CH4 C2B 72.57 84.06 81.03 79.22 5.9550063 7.517049 116.328928 
      
6.211197 
 HNE set2 blot1 analysis ######## 
 
Dox Mesna Human Trial 
        
                    
  Rep1 Rep2 Rep3 RepAvg RepStdDev %CV %naïve control 
AC2 C1A 100 91.51 88.46 93.32333 5.9798857 6.407707 100 
AC2 C1B 78.55 78.49 71.43 76.15667 4.0935233 5.375135 81.60517198 
AC2 C2A 78.32 87.91 83.63 83.28667 4.80421 5.768282 89.24527628 
AC2 C2B 87 84.67 78 83.22333 4.671149 5.612788 89.17741187 
CH5 C1A 121.84 118.95 121.93 120.9067 1.6951204 1.402007 100 
CH5 C1B 111.45 125.85 122.45 119.9167 7.5268409 6.276726 99.18118659 
CH5 C2A 94.48 98.17 102.65 98.43333 4.0913608 4.156479 81.4126599 
CH5 C2B 115.66 109.39 95.16 106.7367 10.50441 9.841426 88.28021614 
CH6 C1A 110.4 110.15 113.53 111.36 1.8834277 1.691296 100 
CH6 C1B 92.25 91.01 86.63 89.96333 2.9525808 3.281982 80.78603927 
CH6 C2A 108.09 100.85 97.33 102.09 5.486128 5.373815 91.67564655 
CH6 C2B 102.26 90.23 91.1 94.53 6.7084946 7.096683 84.88685345 
AC4 C1A 103.44 90.84 85.1 93.12667 9.3813929 10.0738 100 
AC4 C1B 112.93 95.91 93.84 100.8933 10.475315 10.38256 108.3398955 
AC4 C2A 113.14 96.36 83.57 97.69 14.829798 15.18047 104.900136 
AC4 C2B 112.05 98.45 103.87 104.79 6.8465174 6.53356 112.5241606 
                
            6.52842   
HNE Set 2 blot 2             
  Rep1 Rep2 Rep3 RepAvg RepStdDev %CV %naïve control 
AC2 C1A 77.55 95.34 87.19 86.69333 8.9053935 10.2723 100 
AC2 C1B 62.5 75.58 67.47 68.51667 6.6025172 9.63637 79.03337435 
AC2 C2A 59.15 64.07 59.4 60.87333 2.77121514 4.55243 70.21685635 
AC2 C2B 53.16 50.32 44.64 49.37333 4.33817166 8.78647 56.95170717 
203 
 
CH5 C1A 93.98 89.86 96.1 93.31333 3.17296917 3.40034 100 
CH5 C1B 89.18 87.45 99.89 92.17333 6.73857799 7.31077 98.77830964 
CH5 C2A 81.13 91.23 90.17 87.51 5.55060357 6.34282 93.78081017 
CH5 C2B 84.65 98.83 77.99 87.15667 10.6437274 12.2122 93.40215761 
CH6 C1A 88.53 93.26 102.9 94.89667 7.3234714 7.71731 100 
CH6 C1B 85.27 81.82 81.73 82.94 2.0183409 2.4335 87.40033018 
CH6 C2A 100.03 94.27 111.5 101.9333 8.77127319 8.60491 107.4150831 
CH6 C2B 84.94 84.79 106.28 92.00333 12.3641835 13.4388 96.95106958 
AC4 C1A 80.35 79.24 93.9 84.49667 8.1624159 9.66004 100 
AC4 C1B 95.12 98.66 98.48 97.42 1.99389067 2.0467 115.2944889 
AC4 C2A 106.06 117.77 110.83 111.5533 5.88841518 5.27856 132.020987 
AC4 C2B 110.92 113.59 100 108.17 7.20027083 6.65644 128.0168843 
            7.39687   
 
 
HNE set 3 blot 1 
     
       Sample Rep1 Rep2 Rep3 RepAvg RepStdDev %CV 
AC5 C1A 138.36 126.21 102.92 122.4967 18.00944 14.70199 
AC5 C1B 191.38 180.64 149.8 173.94 21.58452 12.40918 
AC5 C2A 178.53 190.93 146.43 171.9633 22.96526 13.35474 
AC5 C2B 238.21 257.12 189.7 228.3433 34.7761 15.22974 
TA1 C1A 262.18 249.81 177.73 229.9067 45.60765 19.83746 
TA1 C1B 291.19 263.76 180.29 245.08 57.76166 23.56849 
TA1 C2A 143.02 153.81 109.21 135.3467 23.26908 17.19221 
TA1 C2B 137.63 117.02 125.26 126.6367 10.37374 8.191733 
CH7 C1A 286 323.62   304.81 26.60136 8.727193 
CH7 C1B 209.18 253.08 234.13 232.13 22.01823 9.485302 
CH7 C2A 215.2 248.12 218.37 227.23 18.16057 7.992153 
CH7 C2B 269.54 321.67 337.73 309.6467 35.64954 11.51297 
CH8 C1A 358.69 339.72 328.92 342.4433 15.07069 4.400929 
CH8 C1B 299.07 304.91 296.19 300.0567 4.442942 1.480701 
CH8 C2A 382.63 382.37 381.98 382.3267 0.327159 0.085571 
CH8 C2B 323.97 358.83 241.62 308.14 60.18711 19.53239 
       
       783.31 Blot abnormality 
     
 
 
    
204 
 
 
3NT set 3 blot1 
      rep1 rep2 rep3 rep avg rep stddev %cv 
276.44 271.67 274.61 274.24 2.406429 0.8774901 
298.1 280.32 282.05 286.8233 9.804113 3.4181714 
284.01 295.82 277.4 285.7433 9.331529 3.2657031 
261.06 252 230.34 247.8 15.78479 6.3699718 
277.23 280.47 247.86 268.52 17.96527 6.6904792 
274 266.2 238.39 259.53 18.71857 7.2124863 
257.57 239.36 220.09 239.0067 18.7425 7.8418307 
250 263.06 239.04 250.7 12.02529 4.7966853 
422.02 446.75 467.73 445.5 22.88062 5.1359423 
366.75 409.41 420.57 398.91 28.40485 7.1206166 
351.89 404.51 470.37 408.9233 59.36317 14.516943 
310.9 379.04 393.37 361.1033 44.0638 12.202545 
291.96 321.62 341.58 318.3867 24.96752 7.8418854 
299.93 321.46 332.14 317.8433 16.40674 5.1618964 
336.96 337.91 368.94 347.9367 18.19562 5.2295785 
279.5 301.53 342.67 307.9 32.06314 10.413491 
     
6.7559823 
3NT set 3 blot2 
    
      rep1 rep2 rep3 rep avg rep stddev %cv 
147.95 152.75 151.28 150.66 2.459329 1.6323704 
157.82 175.83 175.83 169.8267 10.39808 6.1227595 
175.97 178.59 173.5 176.02 2.545368 1.4460677 
173.01 185.97 177.96 178.98 6.539931 3.6540011 
179.51 198.82 188.48 188.9367 9.663096 5.1144633 
179.48 182.2 176.96 179.5467 2.620636 1.4595849 
186.85 174.07 168.93 176.6167 9.227445 5.2245605 
277.29 266.96 248.01 264.0867 14.84997 5.623143 
230.22 233.65 250 237.9567 10.56989 4.4419402 
235.55 269.33 298.49 267.79 31.49825 11.762294 
246.56 275.17 297.71 273.1467 25.63496 9.3850522 
236.42 246.65 259.76 247.61 11.69958 4.7250018 
211.34 226.55 248.67 228.8533 18.77129 8.2023221 
222.17 234.71 263.87 240.25 21.39489 8.90526 
245.03 267.66 322.51 278.4 39.84091 14.310673 
216.53 262.29 286.76 255.1933 35.64878 13.969321 
     
6.6236759 
3NT set 4 blot1 
    
      
205 
 
rep1 rep2 rep3 rep avg rep stddev %cv 
141.02 161.38 173.51 158.6367 16.41781 10.34932 
153.54 149.59 159.4 154.1767 4.935892 3.201452 
134.59 132.51 142.14 136.4133 5.06731 3.714674 
156.63 139.76 151.01 149.1333 8.590147 5.760045 
162.47 148.37 163.83 158.2233 8.560288 5.410256 
189.93 174.66 194.35 186.3133 10.33123 5.545081 
164.26 151.92 170.32 162.1667 9.376915 5.78227 
173.94 185.53 200.56 186.6767 13.34699 7.149792 
169.16 147.79 163.43 160.1267 11.06134 6.907869 
188.41 180.37 174.85 181.21 6.818915 3.76299 
180.86 170.72 172.23 174.6033 5.47078 3.133262 
197.38 178.21 200.99 192.1933 12.2437 6.370513 
214.78 250 218.69 227.8233 19.3048 8.473585 
244.34 217.09 229.21 230.2133 13.65268 5.930447 
230.15 220.56 246.62 232.4433 13.18049 5.670412 
220.45 226.06 241.36 229.29 10.82274 4.72011 
     
5.74263 
3NT set4 blot2 
    
      rep1 rep2 rep3 rep avg rep stddev %cv 
253.45 228.02 239.94 240.47 12.72328 5.291006 
228.25 208.16 241.64 226.0167 16.85136 7.455805 
221.33 194.17 222.68 212.7267 16.08471 7.561212 
259.53 233.79 229.51 240.9433 16.23816 6.739409 
295 268.44 264.41 275.95 16.62038 6.022969 
291.63 278.42 275.05 281.7 8.763156 3.110811 
264.93 245.87 251.78 254.1933 9.756487 3.838215 
261.86 275.02 264.18 267.02 7.024642 2.630755 
242.31 231.42 250 241.2433 9.335815 3.869875 
250.72 238.35 276.23 255.1 19.3161 7.571974 
303.95 198.57 239.42 247.3133 53.13158 21.48351 
237.32 221.93 253.91 237.72 15.99375 6.727979 
254.69 274.16 280.48 269.7767 13.44214 4.982693 
301.41 283.02 327.84 304.09 22.52987 7.408947 
269.23 248.03 269.91 262.39 12.44077 4.741328 
271.82 235.39 258.93 255.38 18.47263 7.23339 
     
6.666867 
 
Copyright © Jeriel T. R. Keeney 2013 
206 
 
APPENDIX C 
DATA TO SUPPLEMENT TABLES AND FIGURES 
 
Table A.3 
           
ttest 
L1u L9u L4m L4u L5m L5u L8m L8u L9m LowGrpAvg 
rel 
avgs C vs L 
908.7 1596.1 964.8 2.6 2365.8 0.7 2171.6 1433.8 877.6 1146.86 1474.06 0.0114 
233.2 1392.7 518.8 2.6 1844.6 0.7 1083 716 158.4 661.11 849.53 0.013 
5.9 192.5 10.1 2.6 256.9 0.7 289.1 132.9 5.4 99.57 217.85 0.0291 
596 439.4 284.7 402.7 565.9 0.7 560.8 554.2 198.8 400.37 450.33 0.0347 
654.2 1192 648.5 2.6 861.2 0.7 668.9 1039 812.1 653.23 839.40 0.0374 
527.2 569.2 10.1 2.6 442.9 0.7 345.8 387.6 5.4 254.61 454.54 0.0428 
1279 968.1 286.3 1397 811.5 0.7 943 931.5 499.3 790.72 889.48 0.0473 
            
c2u C5m c5u c7m c7u c8m c8u c10m c10u ConGrpAvg 
rel 
avgs SSP 
1.9 2.8 1 1230 2.4 2.1 855.8 0.7 7 233.78 1043.05 6701 
1.9 2.8 1 5.3 2.4 341 9.3 0.7 7 41.22 340.60 8104 
1.9 2.8 1 5.3 2.4 2.1 9.3 0.7 7 3.61 3.61 5201 
1.9 2.8 439 337.8 2.4 272 291.9 98.4 321.6 196.43 293.47 3207 
1.9 2.8 1 722 2.4 381 746.8 0.7 454.8 257.00 576.05 8103 
1.9 2.8 1 409.8 2.4 2.1 9.3 0.7 7 48.56 409.80 6203 
1.9 393.1 826.4 699.2 2.4 367 430 0 770.7 387.86 581.07 4201 
 
Figure 4.1a 
Saline Dox Dox/Mesna Mesna 
114.211100 144.368400 114.845500 111.258800 
115.865400 121.518800 79.936560 114.057500 
76.136580 116.023500 85.624480 79.725110 
93.786930 136.252300 124.420100 102.165800 
105.439300 130.082700 117.864300 82.058710 
78.108630 140.650000 92.583140 119.199000 
104.720800 154.927900 104.017500 107.208900 
95.797170 96.394610 86.593690 124.123900 
111.349300 120.250300 97.355030 112.744600 
104.584700 123.812200 98.228500 103.544900 
  100.107800 103.246200 98.028090 
  129.208000 102.713000 100.787600 
  93.456600   110.975000 
207 
 
 
Figure 4.1b 
Saline Dox Dox/Mesna Mesna 
100.91140 176.76120 137.7715 135.9275 
96.48774 244.86560 187.7915 113.0395 
105.06910 183.87210 192.7291 150.1657 
65.85894 183.63090 179.1203 156.4663 
131.67280 194.70600 137.5846 145.0312 
109.58880 113.53540 121.9427 133.9293 
104.78480 191.96110 149.6186 147.6161 
114.10410 265.92170 133.9399 122.7599 
71.52222 199.68350 139.3021 143.0786 
  199.42160 144.5231 129.9210 
  211.44900 129.4157 137.5026 
 
Figure 4.1c 
Saline Dox Dox/Mesna Mesna 
81.251690 146.112900 83.237210 90.048170 
110.488300 99.782270 96.098500 104.642400 
  124.289200 98.182530 105.289600 
101.049300   96.464420 126.252600 
84.680970 100.498700 102.083900 76.547280 
92.671120 112.701400 112.828000 108.201200 
83.158990 115.561900 94.730650 103.397200 
91.005530 98.692420 100.249100 123.983400 
93.320320 110.675800 110.800100 75.171490 
79.791340 143.486800 81.741170 88.429730 
108.502500 97.988870 94.371310 102.761700 
99.233120 122.055300 96.417880 106.256500 
 
Figure 4.1d 
Saline Dox Dox/Mesna Mesna 
104.90500 127.349600 127.981800 129.492300 
109.59960 183.059100 110.467300 114.426900 
95.15001 236.767600 109.689600 101.863400 
92.96438 142.945200 120.337100 126.933000 
109.23120 137.152600 143.589200 103.220500 
88.14976 139.096100 135.459700 137.841700 
114.77500 101.369100 101.872300 103.074600 
99.95960 145.713300 87.930920 91.082730 
115.50100 188.464800 87.311880 81.082310 
102.83960 113.783000 146.135300 132.877100 
89.56430 209.172200 131.704400 82.162540 
88.98714 110.719200 127.094800 109.720700 
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Figure 4.2a 
Saline: 24h post Mesna: 24h post Dox: 24h post Dox+Mesna: 24h post 
71.3 94.0 58.3 63.6 
80.4 71.4 48.1 75.4 
82.9 69.1 80.2 70.6 
79.6 74.2 53.1 72.4 
75.3 66.5 53.3 64.3 
66.8 81.5 79.5 46.3 
66.5 62.1 66.3 67.3 
  64.1   75.6 
 
Saline: 72h post 
Mesna: 72h 
post Dox: 72h post 
Dox+Mesna: 72h 
post 
81.6 72.4 35.8 67.8 
70.2 73.3 23.0 60.3 
70.6 53.6 49.1 48.6 
81.9 53.5 7.8 51.9 
67.4 64.2 34.3 62.7 
67.5 57.0 45.7 38.8 
67.8 70.3 66.9 65.1 
  73.5   62.7 
 
 
Figure 4.2b 
Saline: 24h post 
Mesna: 24h 
post 
Dox: 24h 
post 
Dox+Mesna: 24h 
post 
90. 56. 52. 61. 
62. 82. 63. 92. 
47. 115. 59. 74. 
77. 90. 71. 67. 
81. 98. 65. 92. 
108. 91. 61. 74. 
103. 80. 71. 83. 
  114.   65. 
 
Saline: 72h post Mesna: 72h post 
Dox: 72h 
post 
Dox+Mesna: 72h 
post 
64. 49. 24. 34. 
75. 117. 35. 68. 
24. 86. 28. 10. 
34. 52. 5. 23. 
54. 62. 8. 19. 
97. 80. 42. 6. 
92. 55. 44. 44. 
  82.   26. 
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Figure 4.3b 
Saline-NAA/Cr Dox-NAA/Cr 
0.916 0.908 
1.01 0.836 
0.897 0.761 
0.828 0.877 
0.888 0.844 
0.983 0.870 
1.01 0.879 
0.853 0.926 
0.858 0.860 
0.974 0.837 
0.966 0.857 
 
Figure 4.3c 
Saline Dox Dox/Mesna Mesna 
1.07 0.722 0.775 1.09 
1.01 0.769 0.693 1.05 
1.10 0.709 0.735   
1.22 0.870 0.840   
1.11 0.728 0.662   
1.17 0.764     
1.05 0.757     
1.14 0.723     
1.08 0.727     
1.13 0.650     
  0.624     
  0.532     
  0.581     
  0.624     
 
Figure 4.4a 
Dox WT Mesna + Dox Mesna 
50.973450 103.008900 101.946900 
64.778760 96.637170 94.513280 
61.592920 93.982300   
 
Figure 4.4b 
Saline Dox WT Mesna + Dox Mesna 
89.484500 73.930950 80.608760 103.454400 
103.401300 66.001410 77.968190 101.144700 
210 
 
107.114200 74.922520 70.264420   
  
Figure 5.1a 
WT Saline WT Dox TNFKO Saline TNFKO Dox 
86.63986 111.1058 109.53350 116.42410 
95.34743 112.8020 110.51390 123.68740 
97.86980 122.5462 93.32509 136.13900 
107.12850 119.1486 72.68974 115.04000 
105.95090 136.4738 91.81253 125.36520 
107.06360 131.4830 84.97487 84.38054* 
 
 
Figure 5.1b 
WT Saline WT Dox TNFKO Saline TNFKO Dox 
88.15740 118.98880 100.01450 100.42200 
94.39760 102.92840 106.30080 105.59410 
99.28319 111.69250 101.44710 99.18892 
105.59560 123.30750 95.95238 103.48660 
105.83720 115.52690 93.36102 98.48431 
106.72900 120.73220 102.92420 90.31973 
 
Figure 5.1c 
WT Saline WT Dox TNFKO Saline TNFKO Dox 
71.095600 218.330700 92.911650 84.438200 
87.822320 210.183900 87.490140 153.609500 
114.774100 225.073300 101.581500 207.733600 
87.949420 176.257200 137.170200 148.166000 
127.240000 230.395600 76.334820 177.535500 
111.118600 242.003600 84.357960 136.842200 
 
Figure 5.1d 
WT Saline WT Dox TNFKO Saline TNFKO Dox 
95.800510 139.883900 98.885800 108.506900 
98.048670 142.535200 118.339000 121.187200 
89.461560 168.325000 129.850200 153.977600 
80.535320 103.493600 122.408500 129.876200 
115.744600 128.140300 117.537500 143.801600 
120.409300 134.465100 84.208740 100.349000 
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Figure 5.2 mitochOCR 
  TNFα +/+_ Saline TNFα +/+_ DOX TNFα -/-_ Saline TNFα -/-_ DOX 
Basal 360.82 204.34 380.46 345.20 
Oligomycin 74.20 55.38 76.10 76.37 
FCCP 585.29 228.55 584.15 558.16 
Antimycin A 33.79 42.98 55.95 55.17 
     
     Mean         
  TNFα +/+_ Saline TNFα +/+_ DOX TNFα -/-_ Saline TNFα -/-_ DOX 
Basal 360.82 204.34 380.46 345.20 
ATP-Linked 286.62 148.96 304.35 268.83 
Maximal Capacity 585.29 228.55 584.15 558.16 
Reserve Capacity 224.47 24.21 203.69 212.97 
          
          
SEM         
  TNFα +/+_ Saline TNFα +/+_ DOX TNFα -/-_ Saline TNFα -/-_ DOX 
Basal 20.00 25.00 20.00 30.00 
ATP-Linked 15.00 18.00 17.00 19.00 
Maximal Capacity 12.00 14.00 12.00 15.00 
Reserve Capacity 12.00 14.00 16.00 17.00 
 
Figure 5.3 
Saline Dox WT Dox TNFKO 
1.08 0.650 0.789 
1.13 0.624 0.772 
  0.532 0.783 
  0.581 0.882 
  0.624   
 
Figure 5.4a 
Saline Dox WT Dox TNFKO 
98.230090 50.973450 58.407080 
96.637170 64.778760 54.690270 
105.132700 61.592920 46.194690 
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Figure 5.4b 
Saline Dox WT Dox TNFKO 
89.484500 73.930950 83.728570 
103.401300 66.001410 86.060370 
107.114200 74.922520 94.679360 
 
Figure 6.2a 
Solvent 
Only 15min 10µM 30min 10µM 90min 10µM 
103.855400 164.209800 190.819800 316.414800 
99.705090 151.931100 188.336700 315.159300 
96.439480 129.959800 200.688300 330.723500 
 
Figure 6.2b 
Solvent Only 15min 0.1µM 15min 1µM 15min 10µM  
103.855400 114.004000 139.111400 164.209800 
99.705090 117.545900 138.877900 151.931100 
96.439480 116.706300 153.318800 129.959800 
 
Figure 6.2c 
Solvent Only 15min 10µM 30min 10µM 90min 10µM 
101.301300 100.008200 129.288600 148.036400 
95.601140 106.499500 113.216000 167.626000 
103.097500 121.054800 136.601600 159.441000 
 
Figure 6.3 
Media  DMSO+Crown ether KO2_0.1µM KO2_1µM KO2_10µM LPS 
58.276 60.254000 54.213 1535.877 8535.877 5065.467 
55.711 61.248000 57.263 1589.112 9891.112 6598.405 
54.236 63.548000 55.897 1600.780 8934.589 7023.548 
 
 
Figure A.4 
1 18499 
 
2D validation Original 2D gel PDQuest analysis 
2 56270 
 
fold change Ovr fold change Rel fold change 
  
2 1.29115 
 
2.038697 
 
1.534242 
 1 23389 1 1.264339 
 
increase in low VitD compared to control 
2 72653 
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Figure A.5 
Control Diet Low VitD Diet 
0.1552208 0.450910 
0.192403 0.346070 
0.154096 0.417273 
 
Figure A.7 
NFkB ControlCyt 
NFkB 
LowVitDCyt 
NFkB 
ControlNuc NFkB LowVitDNuc 
0.349778 0.193625 0.124206 0.264936 
0.385451 0.212839 0.048534 0.075577 
0.250173 0.220648 0.044043 0.091913 
0.151604 0.182924 0.037732 0.086837 
0.190344 0.224332 0.102414 0.204766 
0.327843 0.189652 0.050578 0.095727 
0.391415 0.202379 0.038098 0.092418 
0.272194 0.230036 0.036522 0.076946 
0.191043 0.190335 0.042182 0.114980 
 
Figure A.8  
Control Diet Low VitD Diet 
0.025247 0.043433 
0.021871 0.035006 
0.038149 0.060472 
0.025479 0.058023 
0.020323 0.045006 
0.039095 0.063172 
0.026288 0.033450 
0.022176 0.037236 
0.037210 0.040988 
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